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Preface  
Writing a PhD thesis can make your life difficult. Just google for PhD 
pictures and you will find lots of cartoons in which a PhD student is being 
frustrated, puzzled, tired, nervous, angry, isolated, or sad. I probably 
repressed all these feelings, since to my mind I mainly felt positive while 
working on my thesis. This was most certainly not because there were no 
stressful moments, but probably because I was surrounded by nice 
colleagues, fellow researchers and friends during the past years. Therefore, I 
would like to thank all of them, although I am aware that I can only highlight 
a few names at this point.  
 
First of all I would like to thank my promotor Prof. Dr. Karel Brookhuis. 
Dear Karel, thank you for your pleasant guidance during the past years. I 
admire your patience, your intelligence and your ability to stay relaxed no 
matter what pressure comes your way. I always looked forward to meeting 
you, since each time you gave me a confidence boost and stimulated me in 
continuing with the process. I appreciated this very much. 
 
I would also like to express my gratitude to the members of the exam 
committee and especially to those who were also a member the reading 
committee: Prof. Dr. Han de Gier, Prof. Dr. Jan Ramaekers, and Prof. Dr. 
Alain Verstraete. I am very thankful that you agreed to read my thesis and 
decided to approve it. I enjoyed working with you in the European DRUID 
project (Driving Under the Influence of Drugs, Alcohol and Medicines) and 
the dissemination activities after the DRUID project had finished.  
Alain, you were a co-author of a number of my papers and I envy your 
knowledge and your dedication. No matter how busy you were, or whether 
you were in Belgium or near the North or South Pole, you always made time 
to help me with your comments on an article or on other issues. I can hardly 
express how much this meant to me.  
 
Aught for naught, and a penny change (voor niets komt de zon op). This 
thesis was possible thanks to the funding sources of my PhD project. A large 
share of the project was funded by the European Commission, under the 
DRUID Project 6th Framework Program.  
Furthermore, I would also like to thank the management team of SWOV, and 
especially the two department heads Rob Eenink and Henk Stipdonk, and 
managing director Fred Wegman, who gave me the opportunity to work on 
my thesis. Furthermore, I would also like to thank the Ministry of 
Infrastructure and Environment, who agreed to fund my PhD project.  
 
During the work on my thesis I had two great colleagues at SWOV who 
supported me and who formed me professionally level over the past years: 
René Mathijssen and Marjan Hagenzieker.  
Dear René, you were the one who introduced me into the world of driving 
under the influence of psychoactive substances. You took me with you to 
Tilburg where we collected blood and urine samples from randomly selected 
drivers (mostly at times of the day when normal people were still asleep or 
just getting out of bed). I learned a lot from working with you in both the 
IMMORTAL and DRUID project. As the years went by I got more 
experienced and you gave me more and more responsibility. You have 
taught me many things and gave me room to make my own choices (and 
mistakes) to learn from. And in case of mistakes, you always patiently 
explained to me how to prevent these mistakes in future. I surely miss the 
discussions that we had at SWOV.  
Dear Marjan, initially you were only involved in your role as coordinator of 
all PhD students at SWOV. In this role you always gave very bright and 
constructive comments in a friendly way. When you took over René’s role in 
the DRUID project, out contact became much closer and I learned a lot from 
you. I admire your analytical abilities and your style of communication. 
These abilities enabled you to overcome all scientific and non-scientific 
difficulties that came on our path during the last years of the DRUID project. 
I believe that you and René both had your share in the success of the DRUID 
project.  
 
I met so many nice and bright colleagues during the DRUID project, both 
from the Netherlands and abroad. I would like to mention a few of them at 
this point. Cor Kuijten, thank you for the friendship that we started within 
the DRUID project. It was always both fun and educational to spend time 
with you during the DRUID meetings. The trip to the PhD defence of Sara-
Ann is also memorable to me. I hope that you enjoy your after-police life 
together with your wife and hopefully we will run into each other once in a 
while. Sara-Ann Legrand: you are such a wonderful young woman with a 
kindness, spirit and perseverance that you should cherish. I hope the coming 
years will be totally without worries and that you will enjoy your new house 
this summer.  
All other members of WP 2 and WP3 of DRUID are thanked, among which 
the proud grandfather Laszlo, my Finnish friends from THL and ex-THL 
such as Pirjo, Anna, Charlotta, Tom and Kaarina, and Hallvard Gjerde and 
Asborg Christoffersen from Norway. Furthermore, I would like to thank 
Ilona, Marija, Peter, Frau Lottner, Anja, Stephan, Javier, Juan Carlos, Monica, 
Kerstin, Michael, Martina, Raschid, Guido, Eva, Volker, Silvia, Susana, 
Simone, Elke, Kristof, Trudy, Kim, Tim, Annemiek, Wendy, Asa, Dick, Janet, 
Charles, Terje, Knut, Kirsten, Heike, Sofie, Liane, Tibor, Mario, Colette, 
Suzana, Anni, Cristina, Uta, and many, many others. 
Dimitri Margaritis, my Greek friend, it was nice seeing you again at the 
DRUID meetings. Horst: If you happen to see a nice coffin (), don’t hesitate 
to buy it for me. Jan: How do you say cheap in a French bar? Han: Thank you 
for the insights in the discussion on medicine use in traffic. I hope that I can 
continue to learn from you on the issue of medicinal drugs in traffic. 
Inger Marie and Tove: many thanks for working with you in WP2 of DRUID. 
I will miss the meetings with you and the discussions on guidelines, odds 
ratios and logistic regression. But I am also very happy that we have become 
friends and I look forward to seeing you again. 
Beitske Smink: thank you for the fun times we had at the meetings and the 
nice discussions on toxicological and non-toxicological issues. May there be 
many meetings to come. Many thanks as well to your colleagues at NFI: Bart, 
Peter, Albert, Veronique and Sandra. Thank you for your efforts and 
cooperation during all hours of the day and days of the week when we were 
collecting oral fluid and blood samples from drivers and visitors of 
‘coffeeshops’. We survived broken down mobile homes, rain, wind, heat, 
cold, snowball fights and so on. Thanks also to all interviewers (about 30). 
Just to mention a few of them: Tiny, Vincent, Eric, Joyce, Yvonne, Linda, Tim, 
Philippe, Emma, Marjolein, Gerard, Ymte, Hans, Ellen, Marrit, and Marieke.  
I also wish to express my gratitude to the team leaders and team members of 
the regional traffic enforcement teams of Amsterdam-Amstelland, 
Groningen, Hollands Midden, Gelderland-Zuid, Twente, and the police of 
Tilburg. I am very happy that you were willing to cooperate with us, as 
without your help we couldn’t have conducted this research. Your work is 
very important for traffic safety in the Netherlands and it is my pleasure to 
have worked alongside you in the 70+ roadside survey sessions. Your work 
cannot be appreciated enough. 
 
I would also like to thank my colleagues at SWOV for working together with 
me in a setting that breathes research. I have worked at SWOV for more than 
10 years now, and one of the major benefits of SWOV is working with such 
nice colleagues. 
In addition to Marjan, René, and my management team, I have also benefited 
from the work of Ineke and Dennis who provided me with many articles and 
reports. Dennis, you are still continuing to do so and I want to thank you 
very much for your active search for publications that may fit my needs. 
Marijke and Hansje, many thanks for all the editing of my reports and 
helping me with the layout of this thesis. I am happy that you are always so 
patient with me. Patrick: thank you for the times we went on roadside 
surveys together and for guiding me through questions of the press. And of 
course, many thanks for teaching me some nice magic tricks. Niels, thank 
you for helping me in preparing tables and output during my thesis. 
To the closer friends among my colleagues: Thank you for your friendship, 
and for talking about other things than road safety once in a while. Jolieke, it 
is so nice to see you and Ramon as proud parents of Clarijn and I am already 
looking forward to your wedding. Maura and Saskia, good luck with the last 
weeks of your pregnancies. Thank you for the fun times we had, especially 
for the road trip to Germany. I hope that we can do this again. Saskia, thank 
you very much for agreeing to be my paranymph, although your belly will 
probably be nearly exploding by the beginning of May. I appreciate it very 
much; you are a very good friend/colleague. Frits, mon frère, thank you for 
the years that we were roommates at SWOV. It has always been very nice to 
work with you in our projects. Your advice, both work and non-work 
related, has always been very valuable to me. Marjan, thank you for our 
conversations and for supporting me along the way. I hope that we can 
continue like this in future.  
 
Dear friends from my childhood until the present time. My life in Raerd, at 
the football club, at high school, at university, in the city of Groningen and 
now in The Hague has always been so good. Thank you very much for being 
part of this: Harmen, Paul (Pol), André, Giacomo, Menze, Henri, Marcel, JJ, 
Merijn, all team members and old team members of HBS 9, Anno and 
Nathalie, my family-in-law, and many others.  
 
Saving the best for last, I would like to thank my parents and my sister for 
their support throughout the years and for giving me my nice childhood 
memories. Roel and Emi, you are the best parents that a child could wish. 
You have created a safe and warm environment and formed me into the 
person I am now (In case someone thinks of me as a terrible person, my 
parents shouldn’t be blamed of course). I look forward to spending some 
time together again. Saskia, little sister, thanks for everything. We have such 
different characters and I have always envied your sense of adventure. I am 
happy that you agreed to be my paranymph.  
Sanneke, my dear wife and best friend, thank you for the wonderful years in 
which we have moved from a small student room to our own house in The 
Hague. Thank you for being there for me when I need you, and for just being 
you. Together, we make a great team. I love you. You gave birth to our two 
precious children: Lucas and Lisette. The three of you are the reason why I 
always want to rush back home when I am away.  
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1. General introduction1 
1.1. European road safety policy and the DRUID project 
In 2001, approximately 54,000 road users were killed in traffic accidents 
within the European Union. To decrease the number of traffic fatalities the 
European Commission formulated road safety targets (Commission of the 
European Communities, 2001). The target for 2010 was set at 27,000: a 50% 
decrease of the number of fatalities in European traffic as compared to 2001. 
By the end of 2010, the total number of road fatalities was nearly 31,000 
which comes down to a 43% reduction (ETSC, 2011). Despite the fact that the 
decrease of road fatalities did not meet the 50% target reduction, a new 
ambitious road safety target was formulated for the period 2011-2020 which 
again included a 50% decrease of the number of traffic fatalities in a period of 
ten year. The aim of the 2020 road safety target was set at a maximum 
number of 15,500 traffic fatalities (European Commission, 2010).  
It is generally known that using psychoactive substances (such as alcohol 
and drugs) impairs driving skills resulting in higher relative risks of being 
involved in a road crash (Beirness et al., 2006; Brault et al., 2004; Compton et 
al., 2002; Drummer et al., 2004; Hels et al., 2011; Kelly et al., 2004; Krüger and 
Vollrath, 2004; Mathijssen and Houwing, 2005; Mura et al., 2003; Ramaekers 
et al., 2004; Walsh et al., 2004). The European Commission acknowledged the 
negative effect of substance use on traffic safety and granted a proposal of 
the DRUID consortium (DRiving Under the Influence of Drugs, alcohol and 
medicines) within the 6th EU Framework Programme (2002-2006) for 
conducting research into the prevalence and effects of driving under the 
influence and its countermeasures with the ultimate aim to decrease the 
number of traffic fatalities as a result of driving under the influence. The 
main target of DRUID was to provide scientific support to the EU transport 
policy to reach the road safety targets by establishing guidelines and 
measures to combat impaired driving (DRUID, 2012). The DRUID project 
covered different topics such as impairment, prevalence, risk, enforcement, 
classification of medicines, countermeasures, dissemination and guidelines. 
By combining the knowledge from different scientific fields a new approach 
                                                 
 
1 This chapter is partly based on Houwing, S., Mathijssen, R. and Brookhuis, K.A. (2009). 
Case-control studies. This is published as a chapter in Drugs, Driving and Traffic Safety edited 
by Verster, J.C., Pandi-Perumal, S.R., Ramaekers, J.G. and De Gier, J.J.  
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could be developed to help reduce the number of alcohol and drug impaired 
traffic fatalities. More information on the DRUID project is available at the 
DRUID website: www.druid-project.eu. 
The present PhD thesis is the result of prevalence and risk studies that were 
conducted within the DRUID project. Furthermore, it is part of the PhD 
program of the SWOV. In this program, researchers from SWOV are 
supported to write their PhD thesis. 
1.2. Injury risk 
A study on the concepts and applications of risk and exposure in traffic 
safety research (Hakkert and Braimaister, 2002) found that several definitions 
of risk are being used in the field of road safety research. They stated that 
“Popular perception associates risk with both the probability of a hazardous 
event for someone involved in a certain activity and with the severity of the 
outcome.” In traffic safety studies hazardous events are generally described 
in terms of accidents or injuries.  
Several factors are known to contribute to the risk of getting serious or fatally 
injured in a car crash. Commonly mentioned driver related factors are 
psychoactive substance use, drowsiness, seatbelt use, and vehicle speed 
(Dissanayake and Lu, 2002; Kim et al., 1995; Peden et al., 2004; Tefft, 2010). 
The focus of this thesis is solely on the injury risk related to the use of 
psychoactive substances in traffic. 
 
The use of psychoactive substances can influence injury risk in several ways. 
Firstly, psychoactive substances may influence the state of mind of drivers. 
XTC users for example, show more impulsive and reckless behavior, 
resulting in speeding and red light negation (Brookhuis et al., 2004; Morgan, 
1998; Schifano, 1995). The effect of psychoactive substances on “the brain” 
can also cause a negative influence on driving performance tasks such as 
keeping the right track and reaction time which may result in a higher crash 
risk and therefore a higher injury risk (Hargutt et al., 2011; Ramaekers et al., 
2004). Furthermore, drivers under the influence of drugs and alcohol seem to 
be using seatbelts less frequently than sober drivers causing injuries with 
relatively higher severity (Andersen et al., 1990; Desapriya et al., 2006; 
Isalberti et al., 2011; Li et al., 1999). And finally, it is assumed that the bad 
health condition of heavy drug and alcohol users could increase the overall 
likelihood of severe injury relatively to healthy car drivers (Shepherd and 
Brickley, 1996). Although many studies have found an increase of injury risk 
due to substance use (EMCDDA, 2008; Kelly et al., 2004; Krüger et al., 2008; 
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OECD, 2010; Walsh et al., 2004), the direct relationship between injury 
severity and substance use is under discussion as reported in earlier studies 
(Dissanayake and Lu, 2002; Smink et al., 2005). However, a recent study 
among injured persons who were hospitalized did find an effect of substance 
use on injury severity in general and also specifically among those who were 
injured after a car crash (Socie et al., 2012). Furthermore, in a recent European 
study the risk of fatal injury after use of psychoactive substances was 
generally higher than the risk of serious injury for the majority of the 
substances (Hels et al., 2011). 
 
The crash risk of driving under the influence of psychoactive substances is 
usually estimated by determining the relative risk (Houwing et al., 2012). 
Relative risk describes the crash or injury risk in relation to the use of 
psychoactive substances. In this PhD research, we specifically focused on the 
risk of serious injury of drivers of cars and small vans. Serious injury is 
defined as an injury with at an injury severity of 2 or higher on the 
Maximum Abbreviated Injury Scale (MAIS). 
1.3. Case-control studies  
Epidemiological case-control studies are regarded as the optimal 
methodological approach to determine crash and injury risks associated with 
driving under the influence of psychoactive substances, including alcohol, 
illegal drugs and medicines (Berghaus et al., 2007). However, most case-
control studies have been conducted to determine the relative risk of driving 
under the influence of alcohol and no other substances. The most cited study 
in this field is the Grand Rapids study by Borkenstein (1974), conducted in 
1964, that estimated drivers' crash risk at various Blood Alcohol 
Concentration (BAC)-levels. 
Only few case-control studies of drug driving have been conducted to date 
(see Section 1.3.3), since these studies tend to be very expensive and time 
(and labour) consuming. Furthermore, case-control studies are exposed to 
various sources of potential bias and to ethical issues. 
1.3.1. The concept of case-control studies 
In a case-control study the association between a risk factor (e.g. recent 
cannabis use) and an outcome measure (e.g. injury resulting from a road 
accident) can be determined for a defined population. Cases and controls are 
selected from the same source population with two subpopulations: exposed 
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and unexposed to a risk factor. Based on this design, the odds ratio of an 
outcome can be computed.  
If the target population consists of car drivers, an odds ratio of 1 is assigned 
to drivers who are not exposed to the independent variable, i.e. who did not 
recently use cannabis. If the odds ratio of cannabis-exposed drivers is less 
than one, their risk is lower than the risk of unexposed drivers. If the odds 
ratio is more than one, the risk of exposed drivers is higher. 
 
Odds ratio versus relative risk 
The terms relative risk and odds ratio are often used as if they were 
synonyms. Technically this is not correct, since relative risk (or risk ratio) 
compares the probability of injury rather than the odds. 
Haworth et al. (1997) explained the difference between the odds and the 
probability of an event as follows: "The odds of an event occurring is equal to 
the probability of the event occurring divided by the probability of it not 
occurring. For example, the odds of drawing a diamond from a pack of cards 
is one-third (one quarter divided by three quarters), compared with the 
probability which is one quarter". (p. 18) 
Relative risk is a ratio of the probability of an event occurring in the exposed 
group versus the non-exposed group. It is frequently used in studies with 
low probabilities, where absolute risk measures will not provide significant 
differences between exposure and outcome variables. An odds ratio 
represents the ratio of the odds of an event occurring in one group to the 
odds of it occurring in another group. 
 
In Table 1.1, a fictitious example is given of the results of a study on the 
effects of cannabis use. Cases are injured car drivers and controls are 
randomly selected drivers from the same geographical area from which the 
cases arose. Both groups were tested for the presence of cannabis in blood, 
resulting in the following table:  
Table 1.1. Example of fictive case-control study. 
  Cases  Controls   Total  
Positive  10 20 30 
Negative  290 780 1070 




The relative injury risk of cannabis use is:  
RR = (positive cases / all positives) / (negative cases / all negatives)  
= (10/30) / (290/1070) = 1.23 
 
The odds ratio of a being injured after cannabis use is:  
OR = (positive cases * negative controls) / (positive controls * negative cases)  
= (10*780) / (290*20) = 1.34 
This formula can also be written as: 
OR = (positive cases/negative cases) / (positive controls/negative controls) 
= (10/290) / (20/780) = 1.34 
 
The relative risk concept is easier to explain, but relative risk cannot always 
be computed in case-control studies. This is due to the fact that cases are 
selected on the basis of their injury, rather than on the basis of their 
substance use. Therefore, the probability of injury for participants using 
psychoactive substances is unknown, which means that additional 
information is needed to calculate the relative risk. In some studies the 
relative risk actually could have been calculated. However, if logistic 
regression analysis is used the outcome measures will be odds ratios instead 
of relative risks. In the fictitious example on the previous page the data is not 
sampled on exposure or disease status, so that it is possible to calculate both 
relative risk and odds ratios. 
 
The odds ratio can be calculated in case-control studies, and under the “rare 
disease assumption” it can be used as an indicator for relative risk 
(Cornfield, 1951). This means that if an outcome is relatively rare, the odds 
ratio can be used as an approximation of the relative risk.  
Apart from the impossibility of calculating relative risk for case-control 
studies, a practical advantage of odds ratios is that they are easier to adjust 
for confounding variables, whereas this is quite difficult for relative risk. 
 
Matched versus population based case-control studies 
The literature on the theory of case-control studies (Jamrozik and English, 
1991; Rothman and Greenland, 1998; Shadis et al., 2002) suggests that the 
common method to conduct case-control studies is by selecting the controls 
to be representative for the population from which the cases arise. Based on 
Rothman and Greenland (1998) the probability of selecting a driver for the 
control group should be proportional to the amount of time that the driver is 
driving during the roadside survey. In practice, other exposure indicators are 
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used as well, e.g. traffic volume or trip distribution (Haworth et al., 1997; 
Mathijssen and Houwing, 2005).  
 
If random sampling is not feasible or if it is necessary to compensate for the 
effects of confounding factors (Jamrozik and English, 1991) it will be more 
efficient to match cases and controls. This is also the case if the outcome 
should include results for different subpopulations (Schlesselman, 1982). 
Matching is based on characteristics of the cases which are related to the 
outcome (confounding variables). The distribution of the confounding factors 
used for matching should be the same in both the control and the case 
groups. Common confounding factors that have been found in the literature 
on epidemiological studies to determine the risk of driving under the 
influence are: age, gender, time of day, day of week and road type.  
Matching all confounding variables is not efficient, though, and almost 
impossible in practice. Besides, it could lead to overmatching and thus to less 
precise estimates. Wacholder et al. (1992) state that "matching should be 
considered only for risk factors whose confounding effects need to be 
controlled for, but that are not of scientific interest as independent risk 
factors in the study". 
Matching for a subset of confounding factors is commonly applied in case-
control studies. It implies that controls are selected to match a selection of 
confounding variables. Several case-control studies that have assessed the 
relative risk of driving under the influence of alcohol, have matched their 
controls regarding location, day of week and time of day (Borkenstein et al., 
1974; Compton et al., 2002; Krüger and Vollrath, 2004). Matching for 
confounding factors like age and gender would lead to practical problems 
and less efficiency. Instead, in the studies mentioned above the adjustment 
for these confounding factors was performed afterwards in the statistical 
analysis.  
1.3.2. Weaknesses of case-control studies 
The main reason for conducting case-control studies is based on the 
methodological strength of this study type. The case-control design is very 
suitable when dealing with rare events such as substance use in traffic and 
when many factors for the psychoactive substances under study need to be 
evaluated. However, different practical and ethical issues regarding case-
control studies have been mentioned in the literature as well. Berghaus et al. 
(2007) mention high cost and difficulties with the design. The results can be 
biased in many ways: by the selection of cases and controls, by the choice of 
confounding factors, and by non-response and missing cases.  
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The non-response rate will increase when the sample collection gets more 
invasive. This problem arises particularly when blood samples are required 
from control subjects (Beirness et al., 2006). If a study faces a large proportion 
of refusers, information on gender and age, self-reported drug use and 
clinical signs of impairment can be useful for determining whether, and to 
what extent, the non-response group would differ from the response group. 
These characteristics should therefore be available for both groups.  
The need for ethical approval can also lead to difficulties when conducting 
case-control studies. In Norway, a case-control study suffered difficulties due 
to requirements of the Ethical Committee (Assum, 2005) and in the United 
Kingdom a case-control study was cancelled because no approval was given 
by the Ethical committee and additional case-samples did not meet the 
requirements for comparison with the roadside (control) samples (Buttress et 
al., 2004). 
Alternatives for case-control studies are "culpability" or case-crossover 
studies, pharmaco-epidemiological studies and experimental studies. These 
alternative study types are in general less difficult and expensive to conduct 
than case-control studies. However, some particular methodological issues 
are associated with these study types when used for calculating relative risk. 
(Baldock, 2007; Berghaus et al., 2007). 
1.3.3. Examples of case-control studies 
As mentioned before, only few case-control studies have been conducted to 
assess the relative risk of driving under the influence of psychoactive 
substances other than alcohol.  
 
Haworth et al. (1997) conducted a case-control study to estimate the risk of 
fatal single-vehicle accidents in Victoria, Australia during the year 1995. A 
total number of 100 control sites were selected in a structured way according 
to location type (based on the proportion of single vehicle fatal crashes on 
roads inside and outside built-up area), road class (based on the amount of 
travel on the type of road) and time of day (based on amount of travel during 
day and night and on weekends and weekdays) to match the expected 100 
crash sites as much as possible.  
At each location two drivers were stopped at random by the police, and were 
interviewed. Prevalence of cannabis among the control group was based on 
self-reporting, and prevalence among the cases was based on toxicology 
reports. Table 1.2 shows the calculated odds ratios of this study at a 95% 
confidence level. For each odds ratio, the confidence interval is given. An 
effect is not significant if the confidence interval includes “1”. 
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Table 1.2. Unadjusted and adjusted odds ratios Haworth et al. (1997). 
Psychoactive 
substance 






Adj. for BAC 
(≥0.5 g/L) 
and age 












The unadjusted odds ratio for cannabis was 38.2 (CI 13.8-105.8). Adjustment 
for both BAC and age group led to a much lower odds ratio of 6.4 (CI 1.5-
28.0), mainly because of the relationship between cannabis and BAC. The 
adjustment for gender or age lowered the odds ratio only little. A 
comparable study in the Netherlands showed particularly higher prevalence 
of THC in both hospital and general driving population for young male 
drivers (Mathijssen and Houwing, 2005). Unfortunately, in the Haworth et al. 
study the odds ratio was not published for the combination BAC, age and 
gender. 
 
Mura et al. (2003) conducted a case-control study in France between June 
2000 and September 2001 in order to determine the prevalence of 
psychoactive substances in blood samples of hospitalized car drivers 
involved in non-fatal accidents and to compare these outcomes with those of 
patients who attended the same emergency units for non-traumatic reasons. 
Cases and controls were matched by gender and age. Blood and urine 
samples were collected from all subjects; if case urine sampling was not 
possible, sweat samples were collected.  
Table 1.3. Odds ratios Mura et al. (2003). 
Psychoactive substance Odds ratio (95% CI) 
THC alone 2.5 (1.5-4.2) 
THC + alcohol (BAC> 0.5 g/l) 4.6 (2.0-10.7) 
Morphine (> 20 ng/ml) 8.2 (2.5-27.3) 
Benzodiazepines 1.7 (1.2-2.4) 
 
 
Table 1.3 shows the odds ratios of the Mura et al. study at a 95% confidence 
level. No additional adjustments for confounding factors were made, except 
for the initial matching for age and gender. For drivers aged 18-26, odds 
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ratios were calculated for THC and alcohol (BAC > 0.5 g/l). For the odds ratio 
calculations of morphine and benzodiazepines all age groups were included.  
The odds ratio of THC alone was 2.5 (CI 1.5-4.2), for the combination of 
alcohol and THC 4.6 (CI 2.0-10.7), for morphine 8.2 (CI 2.5-27.3) and for 
benzodiazepines 1.7 (1.2-2.4).  
The main flaw of this study is that the choice of the control sample is 
incorrect from a methodological point of view, since the control sample was 
not drawn from the same population the case sample arose from. Thus one of 
the fundamental principles of case-control studies was violated (Rothman 
and Greenland, 1998). The results are therefore of limited value, indicative at 
most. 
 
Brault et al. (2004) conducted a case-control study in Canada between April 
1999 and November 2001. Blood and urine samples of fatally injured drivers 
were collected, as well as breath, urine and saliva samples of a random 
sample of drivers which was distributed proportionally to the distribution of 
fatal crashes by time of day and day of week. The control sample was 
weighted to eliminate the over-sampling during the night-time period. An 
interesting aspect of this study is that it includes both a case-control and a 
culpability study. A culpability study is a type of case-crossover study where 
the culpability of causing an accident is assessed for a risk factor by 
comparing the odds of cannabis use by culpable injured drivers and non-
culpable injured drivers. 
Table 1.4. Adjusted and unadjusted odds ratios Brault et al. (2004). 
Psychoactive substance Unadjusted odds 
ratio (95% CI) 
Adjustment for age, 
gender, hour and day 
(95% CI) 
THC 2.0 (1.4-2.9) 1.6 (1.1-2.4) 
Cocaine 3.7 (1.1-13.1) 4.5 (1.2-16.3) 
Benzodiazepines 3.5 (2.3-5.4) 3.9 (1.5-6.5) 
 
 
Table 1.4 presents the adjusted and unadjusted odds ratios at a 95% 
confidence level. The results of the case-control study were adjusted for age, 
sex, hour and day. An odds ratio of 1.6 (CI 1.5-3.4) was calculated for 
cannabis alone; of 4.5 (CI 1.4-17.4) for cocaine alone and of 3.9 (CI 1.4-4.3) for 
benzodiazepines alone. The results of the culpability studies showed lower 
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odds ratios for cannabis and benzodiazepines. No sufficient data were 
available for calculating the culpability rate of cocaine. 
Main weaknesses of this study are the high non-response rate and the use of 
urine as the body fluid to be analyzed. Since only inactive metabolites of 
THC can be detected in urine, the relative risk of cannabis use is calculated 
rather than the relative risk of cannabis impairment (Baldock, 2007). 
 
Mathijssen and Houwing (2005) conducted a case-control study in the 
Netherlands, between May 2000 and March 2004, to assess the relative injury 
risk of psychoactive substance use by car drivers. The study was part of the 
European Union's IMMORTAL-project, which aimed at investigating the 
influence of chronic and acute impairment factors on driving performance 
and accident risk. Cases consisted of injured drivers admitted to a regional 
trauma centre. Controls were selected from the general driving population in 
the hospital's catchment area. Research locations were distributed along 
main rural and municipal roads, where almost 90% of all serious injury 
crashes occurred. Blood or urine samples were taken from both the injured 
and non-injured drivers. 
Before analysis, the case sample was weighted to match the official 
distribution of seriously injured car drivers by gender in the research region 
and the control sample was weighted to match the distribution of traffic flow 
by time of day and day of week. Odds ratios were calculated by using 
unconditional logistic regression. 
Table 1.5. Adjusted and unadjusted odds ratios Mathijssen and Houwing (2005). 
Psychoactive substance Unadj. odds ratio 
(95% CI) 
Adj. for day-and-time, 
age and gender (95% CI) 
THC alone 1.45 (0.64-3.29) NS 1.29 (0.57-2.95) NS 
Morphine/heroin alone 32.4 (1.78-592) NS 11.7 (0.63-219) NS 
Codeine alone 3.04 (0.65-14.2) NS 6.89 (1.23-38.6) 
Benzodiazepines alone 2.98 (1.31-6.75) 3.48 (1.29-9.35) 
Combination of drugs 24 (11.5-49.7) 10.2 (4.38-23.9) 
Alcohol (BAC< 0.8 g/l) + drug(s) 12.9 (3.78-44.2) 7.39 (1.99-27.4) 




Both adjusted and unadjusted odds ratios are presented in Table 1.5 at a 95% 
confidence level. After adjustment for year, quarter of the year, day- and-
time period, gender and age, the following odds ratios were computed at a 
95% confidence interval: of cannabis alone 1.29 (CI 0.57-2.95; not significant); 
of benzodiazepines alone 3.48 (CI 1.29-9.35); of morphine/heroine alone 11.7 
(CI 0.63-219; not significant); and of codeine alone 6.89 (CI 1.23-38.6). For 
amphetamines, ecstasy, cocaine, tricyclic antidepressants and methadone, no 
odds ratios were calculated due to their absence in the case group. 
The collection by two different sample techniques is a methodological 
weakness and could lead to biased results. Comparison of the positive test 
results of blood and urine samples with self-reported use and clinical signs of 
impairment, however, indicated that the biasing effect of uneven distribution 
of blood and urine samples over the hospital and road samples was probably 
minimal.  
 
In New Zealand, a case-control study was conducted to assess the 
relationship between recent cannabis use in the form of marijuana and car 
crash injury, and between habitual marijuana use and car crash injury (Blows 
et al., 2005). The case group consisted of drivers involved in injury crashes, 
including fatal crashes. The control group was sampled from drivers in 
traffic on random roads in the region. Marijuana use was based on self-
reporting from an in-depth interview.  









group I 2 
Adj. for variable group 
I plus BAC, seat-belt 
use and travelling 
speed 










Table 1.6 presents the adjusted and unadjusted odds ratios of recent cannabis 
use at a 95% confidence level. Adjusted odds ratios were calculated for three 
different sets of variables. The first adjustment included age and gender; the 
second one included age, gender, and a set of other confounding factors 
mentioned in relevant literature; and the third set included the previous 
                                                 
 
2 age, sex, ethnicity, driving exposure, age of vehicle, time-of-day and number of passengers. 
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variables plus a set of additional risky driving variables such as BAC level 
and seat-belt use. The authors reported adjusted odds ratios for these three 
sets of variables of respectively 6.0 (CI 1.8-20.3); 3.9 (1.2-12.9); and 0.8 (CI 0.2-
3.3 not significant).  
The use of interviews, instead of samples of body fluids, is a major weakness 
of this study design. Furthermore, the choice of confounding factors could be 
questioned, since some of the variables, like sleepiness, may be associated 
with marijuana use. The authors have acknowledged this problem but 
indicated that it is difficult to estimate the size and direction of this potential 
bias. Finally, non-response among controls was 21.2%, which is quite a large 
proportion, especially since only 0.5% of the remaining drivers in the control 
group reported recent marijuana use. In comparison, 7.2% of the accident-
involved drivers, refused to cooperate and 5.6% reported recent marijuana 
use. 
The comparison of the outcomes of the 5 case-control studies in this section 
shows that there is considerable variation between the results. This raises the 
question whether the designs of the studies were comparable or not. 
1.3.4. Comparability of case-control studies 
As stated earlier, the number of case-control studies that have been 
conducted to assess the risk of driving under the influence of psychoactive 
substances other than alcohol is very small. But even a limited number of 
studies can provide good estimates of the risk of drug driving. The outcomes 
are only comparable, however, when the selected studies both have 
comparable study designs, and no (or very limited) bias.  
 
The comparability of the study design and the presence of potential bias can 
be measured by several indicators. The effect of these indicators on the 
results may vary and some indicators might be related to each other. 
Therefore, it cannot be assumed that studies which differ on only one 
indicator are more comparable than studies with more variation between the 
indicators. To provide more insight in the comparability of the case-control 
studies that were discussed in the previous section, a list of nine indicators 
was used by Houwing et al. (2009): 
• Substances  
• Type of cases 
• Type of controls 
• Collection method cases 
• Collection method controls 
• Response rate cases 
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• Response rate controls 
• Lower limit of substance concentration 
• Confounding factors  
This list of indicators should be seen as a short-list to illustrate the differences 
and not as an exhaustive comparison between the studies. 
 
Table 1.7 provides an overview of main indicators for the five recently 
conducted case-control studies as summarized in the previous section. In this 
table only the results for THC have been used since, this was the only drug 
type that was analyzed in all five studies. 
The designs of four of these studies are quite comparable for the type of cases 
and controls. Only Mura et al. (2003), however, did not use randomly 
selected drivers as controls, but non-crash involved patients in possession of 
a driving license.  
The four remaining studies all vary in the way they collected data on cases 
and controls. Blows et al. (2004) used interviews for both cases and controls, 
Haworth et al. (1997) used toxicological reports for cases based on blood and 
urine samples and interviews for the subjects in the control group, 
Mathijssen and Houwing (2005) have used blood or urine for the cases and 
urine or blood for the controls, whereas Brault et al. (2004) used urine for 
both cases and controls. In order to estimate the relative risk of driving under 
the influence of psychoactive substances, urine is less useful than saliva and 
blood since the detection window is much larger which has definite 
consequences for its validity as body fluid sample.  
Furthermore, the response rate of the different studies varies between 63% 
and 96% for the cases and between 49.6% and 96% for the controls. This is 
mainly a validity issue: the higher the refusal rate, the higher the risk of bias.  
 
The cut-off levels of the analyzed body fluids differ from each other. A 
higher cut-off level will result in a smaller proportion of positive subjects. In 
the case of these five selected studies the differences between the cut-off 
levels were small and would probably hardly affect the comparability.  
 
 Table 1.7. Comparability indicators case-control studies. 
 Indicator 
















Drivers of fatal 
single vehicle 
crashes 








blood or urine 
Interview 
marijuana use 
within 12 hours 
prior to 
recruitment 
82% 95% Unknown BAC and age  
Mura et al. 
(2003) 
Non fatally injured 
car drivers aged 
18-26 
Non-traffic accident 
involved patients  
Blood  Blood 96% 96% THC 1 ng/ml Gender and age 
by matching 





Stratified sample of 
non-crash involved 
car drivers 
Urine  Urine  63% 49.6% 25 ng/ml THC-
COOH 
Age, gender, 







Stratified sample of 
non-crash involved 
car drivers 
Blood or urine  Urine or blood  89% 89% 5 ng/ml THC 
in blood and 
50 ng/ml THC-
COOH in urine 
Age, sex, day-
and-time period 
Blows et al. 
(2004) 
Car drivers 
involved in serious 
injury crashes 





within 3 hours 
prior to crash 
Interview acute 
marijuana use 
within 3 hours 
prior to 
recruitment 
92.8% 78.8% - Age, gender, 
ethnicity, driving 
exposure, vehicle 
age, time of day, 
BAC, seatbelt use 
and speed 
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Finally, adjustment for confounding factors also differs from study to study. 
The impact of confounding factors on the odds ratio can be substantial. 
Haworth et al. (1997) found an unadjusted odds ratio for cannabis of 38.2, 
adjusting for age and gender resulting in lower odds ratios of respectively 
35.1 and 35.6. Adjustment for alcohol use resulted in a much lower odds ratio 
of 9.3, and adjustment for both alcohol and age even to an odds ratio of 6.4.  
Most studies included at least age, gender and time of day as confounding 
variables or matched for these variables when selecting controls. Blows et al. 
(2004) included many more possible confounding factors in the analysis, 
which probably resulted in overmatching. Above that, not all factors that 
were used in this study can be regarded as confounding factors.  
 
In this PhD thesis a more elaborated study on the effect of random and 
systematic errors is presented in Chapter 6. In this chapter, six case-control 
studies with more or less uniform study designs were screened for the 
presence of potential sources of errors, which could cause bias in the results.  
1.3.5. Discussion 
Case-control studies have their strengths, but also their weaknesses. The 
methodology is hard to implement and there are many sources of potential 
bias that could affect the validity of the study results. On top of that, ethical 
issues may arise, especially in collecting samples of body fluids among 
controls. Case-control studies are therefore not commonly used as method 
for assessing the risk of driving under the influence of psychoactive 
substances other than alcohol. 
Another problem is the lack of comparability between the case-control 
studies that have been conducted. It is likely that this variation is at least 
partly caused by differences in the research design, causing incomparable 
results even if the odds ratios seem to be more or less the same.  
The lack of comparable case-control studies does not mean that there are no 
risk estimations for driving under the influence of psychoactive substances 
other than alcohol. Instead of difficult and expensive case-control studies, the 
risk of drug driving is also measured by culpability studies where no non-
crash-involved drivers are selected in the control-group. These studies are 
also known as case-crossover studies. 
Furthermore, pharmaco-epidemiological studies are used to determine risk 
factors of medicines on therapeutic base. In these studies persons who are 
using prescriptive medicines or who are known to have a disease are 
compared crash involved drivers. 
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Finally, results of experimental studies are used as well to estimate risk. For 
this purpose the dose-related impairment of drugs or medicines is compared 
with the impairment by alcohol at different BAC levels. If the impairment 
factor is comparable, then the risk factor is regarded to be the same as that of 
the corresponding BAC level.  
These three alternative study designs are in general less difficult and 
expensive to conduct than case-control studies. However, some 
methodological issues are imbedded in these study types when using them 
for calculating the risk of drug driving (Baldock, 2007; Berghaus et al., 2007). 
Chapter 2 of this thesis provides a more detailed overview of the four study 
designs that are used to assess the risk of driving under the influence. The 
specific strengths and limitations of case-control studies and the three 
alternative study designs are discussed in this chapter. 
 
In 2006, a consensus meeting was organized by the International Council on 
Alcohol, Drugs and Traffic Safety (ICADTS) to develop standards for future 
research. These recommendations for standardized research included 
legal/ethical issues, subject and study design issues and core data 
parameters. At this meeting cut-off levels were recommended for blood, 
saliva and urine. These cut-off levels were applied in the prevalence and risk 
studies of the European DRUID project. Furthermore, guidelines were 
prepared for the design of the DRUID case-control studies (Assum et al., 
2007).  
 
Six case-control studies were conducted in the DRUID project to assess the 
relative risk of serious injury due to driving under the influence. Although 
the design of the DRUID case-control studies was more or less comparable, 
differences were still present because of practical, ethical or legal limitations 
between these countries. In order to compare the outcome of these studies 
with each other and with previous studies, more insight is needed in the 
effects that study errors and differences in study design have on the study 
outcomes. With more knowledge on the effect of bias and survey errors it 
will be easier to interpret the odds ratios from formerly conducted case-
control studies. Therefore we investigated the six DRUID case-control studies 
for the presence of potential sources of random and systematic errors. 
Researchers that are planning to conduct case-control studies to determine 
the risk of driving under the influence could use the results from this thesis 
to optimize their study design.  
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1.4. Objectives of the thesis 
This thesis aims at contributing to the current knowledge on how to design 
case-control studies which are used to assess the relative risk of driving 
under the influence of psychoactive substances. The results of this thesis will 
give insight in how to provide the best estimate of the risk of driving under 
the influence of psychoactive substances (DUI).  
To accomplish this main objective, the following research questions are 
studied throughout the thesis: 
• Which are the possible methods to estimate the risk of driving under 
the influence of psychoactive substances? (Chapter 2) 
• What is the most preferred case-control design and which design is 
most commonly used in practice? (Chapter 2) 
• What is the prevalence of psychoactive substances in general traffic? 
(Chapter 3) 
• What is the prevalence of psychoactive substances among seriously 
injured drivers? (Chapter 4) 
• Is there any difference between substance concentrations collected by 
means of spitting tubes and by a commercial oral fluid collection 
device? (Chapter 5) 
• What is the effect of random and systematic errors on the odds ratios of 
case-control studies? (Chapter 6) 
1.5. Outline of the thesis 
Chapter 2 focuses on the differences in study design between studies that 
assess the crash risk of driving under the influence of psychoactive 
substances. To this end, four types of study designs were discussed. 
Furthermore, this chapter provides an overview of the differences between 
the preferred study designs and the studies that were actually conducted in 
practice.  
The epidemiological case-control studies that were conducted within the 
European research project DRUID study the relative risk of serious injury by 
comparing the prevalence of psychoactive substances among injured car 
drivers (cases) and among non-injured drivers from daily traffic (controls). 
Chapter 3 compares the results of the Dutch and Belgian roadside surveys in 
which data on substance use were collected from non-injured drivers. These 
non-injured drivers also formed the control population for the case-control 
studies in Belgium and the Netherlands in which the relative risk of driving 
under the influence of psychoactive substances is estimated. In Chapter 4 the 
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results of the hospital studies on substance use among seriously injured 
drivers (cases) in both countries were compared. These seriously injured 
drivers formed the case population of the Dutch and Belgian case-control 
study. 
The methods of sample collection were comparable in the Netherlands and 
Belgium, except that oral fluid samples in the Netherlands were collected by 
spit tubes, whereas in Belgium a commercial oral fluid collection device was 
used. Chapter 5 discusses the differences in variability between these two 
oral fluid collection methods in determining the presence of THC. The results 
also provide information on the correlation between THC concentrations that 
were collected by both methods. 
Chapter 6 presents an overview of the effect of random and systematic errors 
on the results of case-control studies. The results of the six DRUID case-
control studies on the injury risk of driving under the influence of 
psychoactive substances were compared for eleven indicators of potential 
bias. 
In the final chapter the results of this thesis are discussed in the light of the 
research questions that were mentioned in Section 1.4. 
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2. In search of a standard for assessing the crash 
risk of driving under the influence of drugs 
other than alcohol; Results of a questionnaire 
survey among researchers3 
2.1. Introduction 
2.1.1. Relevance and previous research 
While numerous studies have assessed the crash risk of driving under the 
influence of alcohol, and the outcomes of the different studies are generally 
comparable, only a limited number of studies have assessed the risk of 
driving under the influence of drugs and medicines, and with quite 
divergent outcomes (EMCDDA, 2008; Kelly et al., 2004; Krüger et al., 2008; 
OECD, 2010; Walsh et al., 2004).  
The theoretically most sound study design mentioned in literature to assess 
risk is the case-control study (Howe and Choi, 1983; Shadis et al., 2002). The 
case-control study is an epidemiological study design that compares drug 
use between crash involved drivers and non-crash involved drivers on the 
roads. However, case-control studies are expensive and time-consuming and 
therefore not commonly conducted.  
A less expensive epidemiological study design is the culpability study. 
Culpability studies are nested case-control studies, which are used to 
compare culpability rates of drug-positive accident-involved drivers with 
culpability rates of drug-negative accident-involved drivers. The 
classification of culpability is based on a structured culpability analysis that 
is assessed without previous knowledge on the use of psychoactive 
substances by the driver. A second alternative study design is the pharmaco-
epidemiological study, which compares accident rates of medicine users with 
non-medicine users. For this purpose, information from pharmacy records or 
health insurance databases is linked with crash records.  
Other than epidemiological studies, experimental studies are used to 
determine the risk associated with driving under the influence of 
                                                 
 
3 This chapter is published as the following article: Houwing, S., Mathijssen, R. & Brookhuis, 
K.A. (2012). In search of a standard for assessing the crash risk of driving under the influence of 
drugs other than alcohol; Results of a questionnaire survey among researchers. This article is 
published in Traffic Injury Prevention (TIP) 2012; 13 (6) 554-565. 
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psychoactive substances. Experimental studies are applied to assess possible 
impairment of various skills and abilities that are related to driving 
(Brookhuis et al., 2003). At present, these experimental studies generally 
involve administering a drug to volunteer subjects and then measuring their 
performance in driving simulators, on closed courses, or in on-the-road 
situations in actual traffic (Ramaekers et al., 2004). For the additional 
assessment of the crash risk of licit and illicit drugs, the results are related to 
the results for alcohol at specific Blood Alcohol Concentration (Pelfrene et al.) 
levels, for which more or less standardized and accepted odds ratios have 
been derived from epidemiological research (Brookhuis et al., 2003; Krüger et 
al., 2008).  
Although in general the alternative study designs are less difficult and less 
expensive than case-control studies, they have some methodological 
limitations when they are used for calculating the risk of drug driving. An 
Australian literature review on cannabis and crash risk by Baldock (2007) 
states three limitations of culpability studies. The first limitation is that a 
non-culpable driver may still have contributed to the causation of the crash. 
Another limitation is the attribution of culpability. There may be a bias if the 
police are more likely to assign culpability to an impaired driver. The third 
problem of culpability studies is the (often small) sample size of the drug-
positive group, which may result in low statistical power. However, this 
problem is not particularly restricted to culpability studies and may also 
occur in case-control studies. 
The disadvantages of pharmaco-epidemiology studies are mentioned in 
Berghaus et al. (2007). The authors question the compliance of the driver to 
his medication and they state that it may not be known whether the driver 
was impaired by additional psychoactive substances or other influencing 
factors.  
The validity of risk assessment by means of experimental studies is also 
questioned by some authors. One reason being that dose-related risk rates for 
THC resulting from case-control and culpability studies are lower than risk 
rates derived from experimental studies (Grotenhermen et al., 2007; 
Ramaekers et al., 2004). For other drugs, dose-related risk factors from 
epidemiological studies are hardly available, which makes it impossible to 
compare between experimental and epidemiological studies.  
Despite the previously mentioned potential limitations on determining the 
risk by other methods than case-control studies, it is clear that present 
knowledge on the crash risk of driving under the influence would have been 
very limited without the additional results of experimental, pharmaco-
epidemiological and culpability studies. 
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The variety of study types on crash risk assessment with each different 
outcome measures makes it difficult though to compare the results for 
different substances. In addition to this, the comparison of results from 
studies within one and the same study type can also be difficult, since 
differences in study design may cause large differences in results as well. 
Design effects could directly influence the results, e.g. by differences in the 
applied adjustment for confounding factors. The relative risk of cannabis use 
for example varies in case-control studies from 0.8 to 35.6, depending on the 
confounding factors the odds ratio was adjusted for (Houwing et al., 2009).  
Differences in study design could also influence the results indirectly, e.g. by 
choosing a study design which could lead to a larger selective non-response 
bias, like gathering information by self-report.  
During the past 20 years, several meetings between researchers were 
organized to harmonize research designs. In 1991, a workshop was held in 
Padova, Italy, to address methodological issues of drug-driving research 
(Ferrara and Giorgetti, 1992). Guidelines and standards were proposed for 
both experimental and epidemiological studies.  
In the same year, a survey was conducted by Vermeeren et al. (1993) on 
expert opinions regarding the design and execution of experimental studies 
relevant to the effects of medicinal drugs and driving.  
One year later, in 1992, a follow-up meeting on the Padova workshop was 
organized during the ICADTS (International Council on Alcohol, Drugs and 
Traffic Safety) conference in Cologne. The results of Vermeeren’s survey 
were discussed and an agreement on six recommendations was reached.  
In 1994, a working group was established by ICADTS with the goal to 
"prepare a sound guide to an optimal methodology of experimental studies 
on drugs and driver fitness, publish these guidelines and attempt to get to 
acceptance by experts, institutions and authorities". Based on a review of the 
relevant literature this working group concluded in 1999 that the criteria of 
sound methodologies and comparable results are not met due to various 
differences in study design. Therefore, the guidelines on experimental 
research from the workshops in Padova and Cologne and the results of the 
expert survey by Vermeeren (1993) were compiled in a workshop report 
(ICADTS, 1999). 
Despite these efforts to harmonize results on drug driving, researchers still 
stated a lack of comparability at the beginning of the new millennium 
(Ramaekers et al., 2004; Walsh et al., 2004).  
In 2005, another ICADTS working group, the Working Group Illegal Drugs 
and Driving, identified the need for a set of standards and guidelines for 
drug-driving research and organized an expert meeting in September 2006, 
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in Talloires, France, to discuss the harmonisation of protocols for future 
drug-driving research. As a result, draft guidelines were developed for 
experimental research, epidemiological research and toxicological issues. 
Recommendations for standardized research include legal/ethical issues, 
subject selection issues, study design issues and core data parameters, such 
as demographic data and core drug groups. Furthermore, cut-off levels were 
recommended for blood, saliva and urine analysis. The draft "Talloires 
guidelines" were published on the ICADTS website during 45 days for 
comment and review by experts in the field of drug driving. The comments 
were integrated into a final document called "Guidelines for Drugged 
Driving Research” (Walsh et al., 2008). 
In the autumn of 2006, the European Research project DRUID (Driving 
Under the Influence of Drugs, Alcohol and Medicines) started. In this project 
several experimental and epidemiological studies on drug driving were 
conducted. In order to reach comparable results, a lot of effort was put into 
harmonization of study designs. For the case-control studies a working paper 
has been written containing guidelines for a uniform design and protocols 
for carrying out case-control and prevalence studies (Assum et al., 2007). This 
working paper was based on the Talloires guidelines and on past experience 
with case-control studies of the authors involved. It was agreed that any 
deviation from these guidelines should be reported by the partners. A similar 
protocol for study designs was prepared for the experimental studies within 
DRUID (Krüger et al., 2008). 
2.1.2. Knowledge gap 
A comparison of recent studies on the risk of driving under the influence of 
psychoactive substances including the case-control studies that were 
conducted within the DRUID project shows that design differences still exist 
(Houwing et al., 2009; Isalberti et al., 2011). Little is known about the reasons 
for these differences. Do they still occur because there is no consensus among 
researchers on standards to assess the risk of DUI, or is there actually a 
general consensus, but are researchers forced to deviate from their ’gold 
standard’ for more practical reasons?  
Furthermore, there is a knowledge gap with respect to the effect that design 
differences may have on the size and direction of differences between study 
results. Therefore, researchers have been requested to provide a rough 
indication of the size and direction of any bias that could arise from their 
deviations from the standard.  
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2.1.3. Study objective 
The present study uses questionnaires to find out if DUI researchers agree on 
a ’gold standard’ for study designs. Furthermore, it wants to provide more 
insight in the extent to which researchers deviate from their own standard, 
and for which reasons.  
2.2. Materials and methods 
2.2.1. Participants 
The questionnaire study was carried out among researchers who have 
conducted or are conducting studies to assess the crash risk of driving under 
the influence of psychoactive substances other than alcohol, and also among 
researchers who compiled reviews of these studies. 
2.2.2. Procedure 
First, an international literature search was conducted to generate a selection 
of authors of papers and studies involving the risk of driving under the 
influence of psychoactive substances. This search contained the combination 
of the keywords “driving” and “risk” plus one or more specified drugs or 
drug groups. From the resulting literature list, all corresponding authors 
were selected. If an author was mentioned more than once as a non-
corresponding author, the author’s name was added to the study frame as 
well. In some cases no contact details were available, even after an internet 
search by name and institute. In these cases, one of the co-authors, if present, 
was added to the study frame. 
Next, five recent review studies (EMCDDA, 2008; Kelly et al., 2004; Penning 
et al., 2010; TIRF and Palmer, 2007; Walsh et al., 2004) on the risk of driving 
under the influence of psychoactive substances were screened for any 
additional references. 
Finally, any additional researchers from the roadside prevalence studies in 
the European DRUID project were included in the study frame.  
Based on this literature search, 88 researchers were included in the study 
frame: 26 were linked to case-control studies, 18 to experimental studies, 28 
to review studies or DRUID roadside prevalence studies, 8 to pharmaco-
epidemiological studies, and 6 to culpability studies. For two researchers the 




In the next step, an internet survey questionnaire was sent out to all authors 
included in the study frame. The initial questionnaire was pre-tested by four 
different researchers with experience in different study types. Based on their 
remarks, some questions were simplified and answer options stating "I don't 
know" were added. Furthermore, a question on the respondent’s experience 
with drink and drug driving research was included in the questionnaire.  
The responses were collected within a three month period, between June and 
August 2010. After one and a half month a reminder was sent to non-
responders. The second and final reminder was sent one month after the first 
one. 
After completing the questionnaire, researchers who reported differences 
between their theoretical optimal study design and their design in practice, 
received a short follow-up questionnaire asking for the reasons why. The 
follow-up questionnaires were sent a week after the first responses arrived. 
A reminder was sent after two months and a second reminder was sent after 
three months. No incentives were used to encourage participation.  
 
When the questionnaire had been sent out, four e-mail addresses appeared to 
be invalid and no substitute e-mail address could be retrieved. Therefore, a 
total of 84 authors received an invitation to participate. 
2.2.3. Questionnaire 
The questionnaire consisted of several questions divided into three main 
categories. A general category contained a small number of questions on 
study types preference and research. This part contained questions such as 
whether the participant had conducted a study in the past or was conducting 
a study at present to assess the risk of driving under the influence of 
psychoactive substance. A second category contained questions on aspects of 
the theoretically optimal study design, such as which type of body fluid the 
participant would prefer to use to collect data on substance use among 
injured subjects if applicable. And a third category of questions regarded the 
study design in practice. This part contained questions such as which type of 
body fluid the participant used or was using in his study to collect data on 
substance use among injured subjects, if applicable. Researchers who had 
been conducting review studies and researchers who indicated that they had 
not been involved in the choice of study design, only needed to complete the 
general part of the questionnaire. The total number of questions depended 
both on the actually applied study design and on the answers that were 
given, since some answers would lead to additional questions.  
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Most questions throughout the questionnaire were closed questions. The 
majority of questions allowed only one answer option, but for a number of 
questions more than one answer could be given. In the part on the 
theoretically preferred design, these questions included a ranking of the 
answers, whereas the same questions on the design in practice included 
multiple choice questions. By using the ranking option, more detailed 
information became available regarding the preference of the respondent. 
2.2.4. Data collection and analysis 
All responses were collected through an online questionnaire application 
(LimeSurvey v1.85) and were exported into an Excel database for further 
analysis. Due to the small numbers and the explorative background of this 
survey, the results of the questionnaire were only analysed in a qualitative 
way, making use of SAS 9.2 statistical software (SAS Institute Inc., Cary, NC, 
USA). 
This study will discuss the extent to which researchers agree on the 
theoretical study design and the comparability of the different studies in 
practice. Comparability is defined in this study as the level of “similarity”.  
The similarity rate of the answers is calculated by dividing the largest 
number of identical answers by the total number of answers. The total 
number of answers equals the total number of respondents minus the 'no 
replies' and the number of 'I don't know' answers. 
Next, the average similarity rate of a study type is calculated by summing up 
all the similarity scores for a study type and dividing them by the number of 
questions.  
The similarity rate is regarded as 'good' if it is 75% or higher. The application 
of the 75% level is not based on a statistical ground rule, but we considered 
such a practical criterion very useful since it can be applied to make a 
statement on the similarity of study design items and different study designs. 
2.3. Results 
2.3.1. General results 
The overall response rate was 68% (n=57). The majority, 89% (n=51), 
completed all questions and 11% (n=6) of the respondents did not respond to 
part of the questionnaire. This response rate was satisfying, since the expert 
questionnaire sent in 1993 (Vermeeren et al., 1993) had a response rate of 47% 
and a recent questionnaire (De Gier et al., 2009) among experts in the field of 
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developing medical guidelines for assessing fitness-to-drive was returned by 
62% of the respondents.  
After a comparison between the answers of the theoretical part and the part 
with the questions on the actual situation, a customized follow-up 
questionnaire was sent to 31 respondents who reported differences between 
their theoretically preferred study design and their actual study design. 87% 
(n=27) replied to this follow-up questionnaire. 
 
When the questionnaire was returned, some authors of review studies were 
actually found to have been conducting some research on risk assessment by 
themselves. Furthermore, some other researchers appeared to draw their 
conclusions upon a different study type than they had been selected for in 
the literature search. However, the distribution of the respondents by study 
background reflected the expected distribution based on the literature search. 






Case-control study 30% 33% 
Culpability study 7% 9% 
Pharmaco-epidemiological study 9% 7% 
Experimental study 20% 26% 
Review study/DRUID prevalence study 32% 25% 
 
 
Out of the total number of 57 respondents, 33% (n=19) researchers conducted 
a case-control study, 26% (n=15) conducted an experimental study, 9% (n=5) 
a culpability study, 7% (n=4) a pharmaco-epidemiological study and 25% 
(n=14) did not conduct any study to assess the risk of DUI of psychoactive 
substances other than alcohol.  
 
Out of the 57 respondents, 43 researchers indicated that they were 
conducting or had conducted a study to determine the risk of driving under 
the influence of psychoactive substances. Just more than half of them (52%) 
had ten or more years of experience in the field of alcohol and drugs: 26% of 
the researchers (n=11) had more than 20 years of experience, 26% (n=11) 
between ten and twenty years, 12% (n=5) between five and ten years, 26% 
(n=11) between one and five years and none of the respondents had less than 
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one year of experience. From the remaining 12% (n=5), the number of years 
of experience was unknown. All respondents with less than five years of 
experience in the field of alcohol and drugs were involved in the European 
DRUID project where they cooperated with experienced researchers. 
Therefore, in the framework of this study no attention will be paid to 
differences in experience among the respondents. 
Figure 2.1 presents the distribution of the answers to the question which 
study design would be the theoretically preferred design for determining the 


































Figure 2.1. Distribution of the theoretically preferred study design as indicated by the 
responding researchers (N=57). 
When asked for their theoretically preferred design, 46% (n=26) of the 57 
respondents indicated that they would use a case-control study, 35% (n=20) 
preferred to conduct an experimental study, 14% (n=8) a culpability study, 
and the remaining 5% (n=3) preferred a pharmaco-epidemiological case-
crossover study.  
 
In practice however, out of 43 respondents who conducted a study to assess 
the risk themselves, 49% (n=21) indicated that they actually conducted a 
different type of study than the one they preferred in theory.  
Out of these 21 respondents 48% (n=10) preferred an experimental study, but 
conducted a different type of study. The main reasons for this were that the 
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research question was focused on epidemiological research and not on 
experimental research (n=4) or that they were not specialised in conducting 
experimental research (n=3).33% of the 21 (n=7) preferred a case-control 
study, but conducted a different study type. The main reason for this were 
practical problems in the design phase (n=4), such as lack of time and 
manpower, and inability to get cooperation from third parties like police and 
hospitals. Furthermore, some respondents indicated that they were 
specialised in other types of study (n=3) and not in matched or population 
based case-control studies and that the research question was focused on 
experimental research and not on epidemiological research (n=1). 
Out of the 21 respondents 14% (n=3) preferred a culpability study but did not 
conduct one. Two respondents answered the questions in the follow-up 
study. One of them gave as reason that it was too difficult to get the required 
data. The other respondent indicated that the research question required 
experimental instead of epidemiological research. 
Finally, one respondent preferred a pharmaco-epidemiological design, but 
conducted a case-control study. However, the preferred pharmaco-
epidemiological design was in fact highly comparable to a standard case-
control design.  
2.3.2. Results per study type 
The number of responses per study type varied between 4 and 19, although 
some researchers did not fully complete the questionnaire. For both 
culpability studies (5 questionnaires returned, 4 of which fully completed) 
and pharmaco-epidemiological studies (4 returned, 2 of which fully 
completed) the number of respondents was very low. Therefore, these results 
should be treated with special care and be seen as purely indicative.  
 
Case-control studies (n=19) 
Table 2.2 provides an overview of the comparability of case-control studies. 
Comparability rates are higher when more respondents give the same 
answer. For each question the most frequently given answer is presented in 
the table, as well as the total number of responses and the comparability 
score (total number of responses divided by the largest number of identical 
answers). 
Among researchers who indicated to conduct case-control studies, there 
seems to be considerable consensus on the theoretically preferred study 
design. The similarity of the answers was above the 75% criterion on eight 
out of twelve items. It was lower for the applied cut-off level (53%), the type 
of injury (35%), the type of roads (74%), and the reference group for drug 
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positives (74%). Regarding the actual design, however, in general similarity 
was lower, as is shown in Table 2.2. 
Table 2.2. Similarity of case-control studies for both the theoretically preferred design and 




Theoretically preferred Actually applied 
N Prevailing answer Similarity N Prevailing answer Similarity 
Study population 19 
Motor vehicle 
drivers 78.95% 18 
Motor vehicle 
drivers /car drivers 38.89% 
Collection method 
cases 19 Blood 100.00% 18 Blood 88.89% 
Collection method 
controls 
19 Blood 100.00% 17 Saliva 52.94% 
Cut-off level 17 LOQ 52.94% 17 LOQ 88.24% 




and metabolite 75.00% 7 
Parental substance 




19 Recorded 94.74% 18 Recorded 77.78% 
Medication before 
sampling 19 Recorded 100.00% 18 Recorded 94.44% 
Road types control 
sampling 19 
Main roads/ 
highways 73.68% 18 All roads 72.22% 
Confounding 
factors 
16 Age and gender 93.75% 15 Age and gender 100.00% 
Multi drug  19 Separate group 89.47% 16 Separate group 93.75% 
Reference group 
odds ratio 
19 Negative all 
substances 
73.68% 12 Negative all 
substances 
66.67% 
 Average similarity rate            80.63% Average similarity rate            71.85% 
 
 
The follow-up questionnaire provided some more insight in the reasons why 
the theoretical design was not used in practice. Whereas in theory the 
majority of the respondents had a preference for motor vehicle drivers as the 
study population, in practice half of these respondents have included only 
the subset of car drivers in their study. In the follow-up questionnaire, three 
responses to this question were available. All three respondents answered 
that the inclusion of passenger cars only was because of the DRUID 
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guidelines for case-control studies and one respondent added that the 
inclusion of truck drivers would have limited the number of possible 
research sites. All three respondents expected a bias from this deviation. One 
respondent reported that bias size and direction were unknown, another 
respondent expected a substantial underestimation of the risk, as did the 
third one, but without indicating the size of the underestimation.  
In practice saliva collection is the most commonly preferred collection 
method of samples from non-crash involved drivers at the roadside, 
although in theory the preference was for blood collection. Six respondents 
have used oral fluid in practice although they would have preferred blood in 
theory. Five of them replied to the follow-up questionnaire and stated that 
they did not collect blood in practice, since it would have increased the 
refusal rates, it took too much time, it was too costly, or since it was too 
difficult and not practical. Four of them stated that they did not know if the 
use of oral fluid instead of blood could have caused bias, and one stated that 
the use of saliva instead of blood did not induce bias.  
Neither in theory nor in practice, there was comparability concerning the 
preferred injury type of the cases. Some researchers preferred to include all 
drivers, whereas others preferred to include only seriously injured or fatally 
injured drivers. The most frequently mentioned reasons for selecting one 
group or the other were that fatally injured drivers are the most relevant 
group for road safety, that seriously injured drivers cover many of the 
accidents and are better reported than minor injuries, and, finally, that all 
accidents are important regardless of the injury severity. One respondent 
answered that he would have preferred to include fatally injured drivers but 
for practical and toxicological reasons he had chosen for injured drivers. He 
expected this deviation to result in a small underestimation of the risk.  
In theory, the majority of the respondents preferred the use of at least the 
parental substance for the detection of drug positives. In practice, however, 
some researchers only used an inactive metabolite for the detection of some 
drugs. Therefore, comparability for this item was only 57%. No information 
was provided on the reason for the deviation. However, one reason might be 
the choice of body fluid to be collected, since in urine only metabolites of 
psychoactive substances can be detected. 
 
As with the theoretical design, there was almost 75% similarity in practice 
regarding the choice of road types where samples were collected. Most 
researchers included all road types in their study, although in theory they 
would have skipped the residential roads. The inclusion of drivers from 
residential roads was not expected since fewer vehicles pass these roads, 
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especially during night-time hours. Since roadside survey sessions are often 
linked with police activities and locations at residential roads will probably 
be less cost-beneficial from a police perspective, resulting in an exclusion of 
this road type. This was indeed observed by one of the two respondents who 
included only main roads in their study whereas he would have preferred to 
include all road types. The other respondent indicated that the inclusion of 
all road types would have been too hard to manage by the researchers and 
the police. The respondent did not know whether this deviation could have 
induced bias.  
Both in theory and in practice there was less than 75% comparability 
regarding the choice of reference group. The majority opted for the use of 
subjects who were negative for all drugs as a reference group for drug 
positives. But there was also a group of researchers who preferred to use 
subjects who were negative for the specific substance under review. Six 
researchers stated that they did not know yet which method they would use 
in practice. One of the respondents indicated to prefer a reference group that 
was negative for all substances in theory, but that in practice this information 
was not known. However, no bias was expected by this researcher as a result 
of this deviation from his own theoretically preferred study design. 
The type of cut-off level that was used in practice was more uniform than the 
theoretical preference. This was mainly caused by the DRUID studies, where 
the lowest LOQ (Limit of Quantitation) was requested from all partners. One 
respondent stated that he would have chosen a level of impairment instead 
of the legal limit, but that this was asked for by his principals. He expected 
bias from this deviation from his preferred design, but stated that the size 
and direction would depend on the type of substance.  
 
Experimental studies (n=15) 
Table 2.3 gives an overview of the similarity of experimental studies aimed at 
assessing the risk of driving under the influence of psychoactive substances 
other than alcohol. 
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Table 2.3. Similarity of experimental studies for both the theoretically preferred design and 




Theoretically preferred Actually applied 
N Prevailing answer Similarity N Prevailing answer Similarity 
Type of 
experiments 15 On-the-road 73.33% 15 Driving simulator 46.67% 
Main impairment 
indicator 15 SDLP 86.67% 13 SDLP 76.92% 
Comparison BAC 9 
Average of 
indicators 33.33% 5 
Average of 
indicators 60.00% 
Subjects design 14 Within subjects 85.71% 14 Within subjects 71.43% 
Blinded design 15 Double blinded 86.67% 13 Double blinded 46.15% 
Confounding 
factors 
11 Age and gender 100.00% 10 Age and gender 80.00% 
Reference group 
impairment 15 Negative 86.67% 12 Negative 83.33% 
 Average similarity rate            78.91% Average similarity rate            66.36% 
 
 
The preference of experimental researchers concerning the theoretically 
optimal research design was quite uniform. Regarding the research method 
(on-the-road, closed road or laboratory testing) the agreement was slightly 
under the 75% criterion, namely 73%. Regarding the conversion of the results 
of multiple indicators into one equivalent BAC level there was much less 
agreement (33%).  
In practice, for all study design items the similarity was lower than in theory, 
except for the conversion into an equivalent BAC level (60%). 
Most respondents replied (n=11) that they preferred to conduct their 
experimental study by means of on-the-road testing. Of these respondents 
27% (n=4) preferred a simulator study. A closed road study was not 
preferred by any of the respondents. All respondents who preferred a 
simulator study conducted one in practice as well. Four of the respondents 
who preferred an on-the-road test design, also conducted it in practices; 
Three conducted a simulator study, and another three respondents 
conducted experimental lab tests. One respondent did not reply to this 
question. The results of the follow-up questionnaire showed that the use of 
different study methods in practice was based on legislative limitations, the 
absence of equipment and the absence of ethical approval. The researchers 
had different opinions on the size and direction of the bias, ranging from no 
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bias at all to substantial bias, and from underestimation to overestimation. 
As one of the researchers stated, the size and the direction of the bias will 
probably depend on the indicator that has been used and on the substance 
under scrutiny. 
For the conversion of the results of multiple indicators into a single 
equivalent BAC level, different methods were preferred in theory. 
Furthermore, various respondents stated that they did not know what to 
prefer. In practice, the only difference found was that some respondents who 
did have a theoretical preference, stated they did not know how to apply it.  
The theoretically preferred design was a double-blind within-subjects design. 
In practice, however, also one between-subjects design was used, as well as 
four single-blind designs and two open designs. The open design involved 
subjects who were in treatment and in one case the single-blind design was 
chosen for financial reasons and in the other case because the subjects got 
aware of whether they were in the drug group of in the placebo group. No 
bias was expected though by the researchers for any of these deviations from 
the preferred design. 
 
Culpability studies (N=5) 
Table 2.4 provides an overview of the comparability results for culpability 
studies. Since the number of respondents was very low, the results will be 
presented in a much less detailed way than the results of the case-control and 
experimental studies.  
 
For half of the study design items the theoretical agreement was lower than 
the 75% criterion. However, for the actual study designs the similarity was 
lower for only three items. 
Both in practice and in theory the responses of the culpability study 
researchers varied regarding the study population and the injury severity 
that was used. Overall, the comparability of the reported culpability studies 
in practice exactly met the 75% criterion. However, the total number of five 
respondents was too small to draw any firm conclusions from the results. 
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Table 2.4. Similarity of culpability studies for both the theoretically preferred design and the 
actual design; N = number of answers excluding missing values and "I don't know" options; 
* one respondent used both types of reference groups. 
Culpability studies 
Theoretically preferred Actually applied 
N Prevailing answer Similarity N Prevailing answer Similarity 
Study population 5 Motor vehicle 
drivers 
60.00% 4 Motor vehicle 
drivers 
50.00% 
Culpability method 4 At fault 
assessment 





5 Blood 80.00% 4 Blood 100.00% 
Cut-off level 3 Impairment/LOQ/ 
legal limit 
33.33% 4 LOQ 75.00% 
Injury type 4 MAIS, ISS, killed, 
both killed and 
not killed 
25.00% 4 MAIS, ISS, killed, 





5 Parental and 
metabolite 





5 Recorded 100.00% 4 Recorded 75.00% 
Medication before 
sampling 
5 Recorded 100.00% 4 Recorded 100.00% 
Road types 
sampling 
5 All road types 80.00% 4 All road types 100.00% 
Confounding 
factors 
5 Age and gender 100.00% 4 Age and gender 75.00% 
Multi drug in 
single drug group 
or as separate 
group 
5 Separate 80.00% 4 Separate 75.00% 
Reference group 
odds ratio 
5 Negative all/ 
negative substance 
60.00%* 4 Negative 
substance 
100.00% 




Pharmaco-epidemiological studies (N=4) 
Table 2.5 presents the similarity results for pharmaco-epidemiological 
studies. Like for culpability studies, the number of respondents was very 
small (n=4).Therefore, the results will be presented in a very global way.  
Table 2.5. Similarity of pharmaco-epidemiology studies for both the theoretically preferred 
design and the actual design; N = number of answers excluding missing values and "I don't 




Theoretically preferred Actually applied 
N Prevailing answer Similarity N Prevailing answer Similarity 
Study population 4 Population data 
from pharmacy 
records 







Drug free period 3 At least 6 months, 
at least a year, 5 
times t1/2 
33.33% 3 At least 6 months, 
at least a year, 4-5 
times t1/2 
33.33% 
How is a driver 
regarded positive 
4 Date prescription in 
combination with 
number of daily 
defined doses 
75.00% 3 Date prescription 
in combination 
with number of 
daily defined doses 
66.67% 
Information source 
medicinal drug use 






Are passengers in 
or excluded from 
the data 
4 Excluded 75.00% 0  *             -- 
Accident or injury 4 Accident 75.00% 3 Injuries 66.67% 
Window exposure 4 One week, depends 
on drugs 





3 Age and gender 100.00% 3 Age and gender 66.67% 
Multi drug 4 Combination 75.00% 2 Combination, not 
possible 
50.00% 
Reference group 4 Negative all 75.00% 2 Negative all, 
negative substance 
50.00% 




The similarity of the pharmaco-epidemiological studies that have been 
reported by the respondents is below the 75% criterion for both the 
theoretical design (five out of ten questions have a comparability score below 
75%) and the design in practice (all questions have a similarity score below 
75%). However, like for the culpability studies, the number of respondents 
was too small to draw conclusions from these results. 
2.3.3. Overall results 
Based on the literature (Howe and Choi, 1983; Shadis et al., 2002) it was 
expected that case-control studies would have been mentioned by the 
respondents as the theoretically most appropriate study type. However, the 
results from the questionnaire show that in theory only 44% of the 
respondents preferred to conduct a case-control study to determine the risk 
of driving under the influence of psychoactive substances. One could assume 
that this unexpected result might be due to the fact that researchers feel 
inclined to justify the choice of study design they have made in practice. 
However, the results of the questionnaire survey actually show that 49% of 
the respondents did not prefer the type of study they conducted in practice. 
Among the respondents who conducted case-control studies, the percentage 
was even higher (58%) than among the respondents who conducted other 
types of study (42%). This difference was not significant at a 95% confidence 
interval (p=0.42).  
Another possible reason for the lower share of researchers that preferred to 
conduct case-control studies in theory may have been the way that the 
question was phrased. The question referred to the risk of driving under the 
influence of psychoactive substances, and not specifically to the crash risk.  
 
The similarity varied both within and between the four most commonly used 
study designs. Table 2.6 provides an overview of the average similarity rates 
between the theoretically preferred and the study design applied in practice.  
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Table 2.6. Average similarity rates of the theoretical preferred and actual applied 
design for the four most commonly used study designs to assess the risk of DUI. 







Case-control studies 19 81% 72% 
Experimental studies 15 79% 66% 
Culpability studies 5 69% 77% 
Pharmaco-epidemiological studies 4 66% 52% 
 
 
The average similarity rate for the theoretically preferred designs varies from 
67 to 81% and for the designs applied in practice from 52 to 77%. For all 
studies the level of similarity was lower in practice than in theory, except for 
the culpability studies. However, the number of subjects was too small to 
draw any conclusions on this. For the theoretically preferred design, the case-
control and experimental studies have a higher similarity score (not 
significant at 95% confidence level) than the culpability studies and 
pharmaco-epidemiological studies. But in practice, only the similarity of 
culpability studies scores above the 75% criterion that was defined for this 
study.  
The results indicate that despite twenty years of guidelines and 
recommendations, no ‘gold standard’ exists for risk assessments of driving 
under the influence of psychoactive substances. This lack of a ‘gold standard’ 
is partly due to practical limitations and specific research questions, but also 
because researchers apparently do not agree on the ideal study design.  
2.4. Discussion 
2.4.1. Introduction 
As early as 1991, Simpson and Vingilis already stated experiences and 
guidelines from the international workshop (Ferrara and Giorgetti, 1992): 
"What we offer is more of a guidebook than a cookbook, scoping out the 
general methodological features rather than the precise ingredients and the 
exact means for their combination". Now, twenty years later, there is still no 
common standard for determining the crash risk of DUI. Differences in the 
methods are not only determined by technical, ethical, financial and 
legislative limitations, but also from different opinions on the theoretically 
optimal research design. And it is probably a utopia to expect agreement on 
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a ‘cookbook’ for designing studies to assess the crash risk of driving under 
the influence in the near future.  
Nevertheless, it is advisable to focus on standardising at least some design 
aspects or ‘ingredients’ in order to improve comparability of results from 
different studies. Based on the results from this study on comparability and 
the expected bias as reported by the respondents of the follow-up 
questionnaire, certain design aspects could be considered as a starting point 
for further standardisation. This will, however, only be discussed for case-
control and experimental studies, since the number of respondents for the 
culpability and the pharmaco-epidemiological studies was very low.  
2.4.2. Case-control studies 
For case control studies three design items are recommended for 
standardisation based on their low similarity rates: choice of body fluid 
sample for the control population of non-crash involved drivers at the 
roadside, injury severity type and the reference group. A fourth item is the 
choice of the parental substance and/or its metabolite. However, the 
dissimilarity of this item can probably to a large extent be solved by using 
the same body fluid sample in the control population.  
The collection of body fluids among non-crash involved drivers at the 
roadside has been an issue in case-control studies for a long time. The 
collection of blood is considered to be the theoretically most appropriate 
method, since the presence of a psychoactive substance in blood closely 
relates to the presence of an effect of the substance on the central nervous 
system. Furthermore, in most hospital studies blood is collected as a matrix. 
Using results from body fluids in the control population that are different 
from those in the case population would lead to less comparable data and 
therefore to loss of validity. The collection of blood also has several 
disadvantages, such as the high refusal rates and the relatively high cost of 
equipment and personnel (OECD, 2010). In the past decade, oral fluid has 
emerged as an alternative for blood as a body fluid matrix for detecting 
recent drug use. In the DRUID project blood was used at the roadside in only 
four out of thirteen roadside surveys (in three of these four surveys 
additional oral fluid samples were collected). In the other nine roadside 
surveys, only oral fluid was used to collect information of recent drug use by 
a random sample of car drivers. In order to be able to compare all results, 
cut-offs have been proposed for oral fluid that are equivalent to the cut-offs 
for blood. These equivalent cut-offs were obtained by calculating average 
oral fluid-blood ratios after excluding the outliers, as described in (Gjerde et 
al., 2010a). These ratios were based on collection by means of the Statsure 
 53 
collection device, which was used in eleven of the twelve roadside surveys. 
The use of equivalent cut-offs allows comparison of blood results from 
injured or killed drivers with oral fluid results from drivers at the roadside. It 
has to be kept in mind, however, that for some substances the cut-off 
recommended by Gjerde was based on only a few positive cases and that 
these cut-offs are only usable when applying the same cut-offs based on the 
ones that were defined by the Talloires working group (Walsh et al., 2008) as 
was the case in the DRUID project. Furthermore, equivalent cut-offs may 
vary over the different oral fluid collection methods. For these reasons more 
research is needed to establish solid equivalent saliva cut-offs for all 
substances.  
Another option to get comparable outcomes from both hospital and traffic 
populations is mentioned in the DRUID report on the hospital studies 
(Isalberti et al., 2011). In this report the authors suggested collecting oral fluid 
samples both from hospitalised drivers and from drivers at the roadside. 
However, this method has two limitations as opposed to the equivalent cut-
offs method: Firstly, the method is not applicable for all injured drivers since 
it is not always possible to collect an oral fluid sample from a person who is 
severely or fatally injured. Secondly, the one thing that researchers do agree 
on is that theoretically analyzing blood is the best method to gather 
information on recent drug use by injured drivers. Analyzing oral fluid 
samples from injured drivers is considered as a suboptimal method. 
A third solution is the collection and analysis of blood spots. Small drops of 
blood, collected on filter paper, are dried and analyzed in a laboratory. The 
benefit of this method is that it takes only a finger puncture to collect blood, 
which might, depending on national legislation and the permission of 
National Ethics Committees, reduce the necessity of a medical professional to 
collect the sample. The dried blood spot method has been evaluated for 
several substances (Jantos and Skopp, 2011; Skopp, 2007) and the results 
show equivalence to standard blood results for amphetamine, MDMA, 
risperidone, opioids, 6-acetylmorphine, morphine, and benzodiazepines. For 
Zopiclone the result was not equivalent due to degradation after storage 
(Nilsson et al., 2010), but after correction for degradation the blood spot 
method seems usable for Zopiclone as well. As yet, no results have been 
published on the equivalence for THC. If the results for the other substances 
are as promising as the ones for the evaluated substances, then the dried 
blood spot method can be regarded as a good alternative for saliva and 
intravenous blood collection. 
The second recommendation for improving the comparability of case-control 
studies regards the type of injury severity that is included in the study. Both 
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in the theoretically preferred and the actually applied method the level of 
similarity of the injury severity level was quite low. Although Smink et al. 
(2005) concluded that the relationship between relative risk per severity level 
and drug use was not clear, recent results from the DRUID project (Hels et 
al., 2011) indicate that the relative risk does increase with the increase of 
injury severity and therefore, that case-control studies with fatally injured 
drivers result in relatively high odds ratios that are not comparable to the 
odds ratios of studies including injured drivers. Therefore, it is 
recommended to separate reporting on killed drivers and on injured ones. 
For injured drivers it is recommended to use the MAIS coding system to 
scale injury severity since it is one of the most commonly applied injury 
scoring system for injured drivers (Gennarelli and Wodzin, 2006).  
A final recommendation for improving the comparability of case control 
studies is based on the choice of the reference group. This is important since 
it has a strong effect on the resulting odds ratio. It is recommended to use 
subjects who are negative for all substances as a reference group. Using a 
reference group that is only negative for the substance under review will 
result in underestimation of the relative risk associated with that particular 
substance. 
If the reference group consists of subjects who are negative for all included 
substances, the list of substances that are included is of major importance. If 
high risk substances are not included in the study, the relative risk of the 
included substances may either be underestimated or overestimated, 
depending on overrepresentation of the non-included substances in the case 
or control group. It is recommended to use the list of core substances 
composed by the Talloires working group (Walsh et al., 2008) as a starting 
point for the inclusion of substances and add any potentially high-risk 
substances that are expected to be prevalent in either the hospital (case) or 
the roadside (control) samples, e.g. GHB. 
2.4.3. Experimental studies 
For experimental studies the recommendations regard two design aspects: 
the study method and the comparison of outcomes for drugs with the BAC 
standard when two or more risk indicators are used. 
The study method used in experimental studies not only depends on 
methodological factors, but also on legislative and financial factors, and on 
the availability of the right equipment. Most respondents preferred to 
conduct on-the-road driving tests. In practice, however, driving simulator 
studies and experimental lab tests were conducted most frequently by the 
respondents. In experimental lab tests the internal validity is relatively high 
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since the experiment is conducted in a controlled setting. But the external 
validity- the possibility to generalize test results to the real driving 
population - is relatively low. The external validity of on-the-road driving 
tests is relatively high, but the internal validity is lower than that for 
experimental lab tests since driving circumstances may vary between the 
tests. For driving simulator studies the internal and external validity lie in 
between those of experimental lab tests and on-the-road driving tests. Most 
researchers who conducted a different study in practice than they preferred 
in theory, indicate that this may have induced bias. In order to gain more 
information on the potential bias that is induced by each of the three study 
methods, it would be interesting to conduct an experimental study 
comprising all three study types. Until results of such a study are available, it 
is recommended to only compare results from experimental studies with 
results from other experimental studies that have used the same study 
method. 
Finally, the conversion of various impairment indicators into a single BAC 
level and associated risk factor deserves attention. A high proportion of the 
respondents stated that they did not know which method they would prefer 
from a theoretical point of view. In practice, most respondents did not 
convert their results to a single BAC level. For the ones who included a 
conversion, the majority first calculated the equivalent BAC level for every 
single impairment indicator and subsequently used the average BAC level as 
the overall risk indicator. It remains questionable, however, how well a 
limited set of impairment indicators can predict the relative risk of a 
psychoactive substance. 
2.4.4. Strengths and limitations of this study 
The main strength of this study is the detailed insight it provides in the 
divergent designs of studies to assess the risk of driving under the influence 
of psychoactive substances. This seems to result for a large part from the 
different opinions of researchers regarding a ‘gold’ standard.  
Additionally, for a number of study design items this study gives some 
insight in the potential bias or lack of knowledge about it.  
The study also has some limitations.  
Firstly, participating researchers had different backgrounds and may 
therefore have interpreted some questions in a different way. An example is 
the different interpretation of the term ‘risk assessment’ that was used 
throughout the questionnaire. Some researchers may have interpreted risk as 
crash risk, where others might have interpreted it as risk of impairment. In 
experimental studies crash risk can be assessed by linking impairment of 
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other substances than alcohol with alcohol. However, a majority of the 
experimental researchers did not include a comparison with alcohol 
impairment in the study they referred to. This is mainly due to the fact that 
the main research question of experimental research is focused on risk of 
impairment rather than crash risk. In order to avoid misinterpretation of the 
term ‘risk assessment’, it should have been made clear to the respondents 
that the questionnaire was specifically on crash risk. 
Furthermore, the calculation of the overall scores for the various study types 
was based on simple rate calculations, while more sophisticated calculation 
methods might be required. A more appropriate method would probably 
include weighting, based on the impact of study design items on the 
outcome of risk assessment studies. But information to support the use of 
weighting factors is hard to obtain and it will be difficult to isolate the effect 
of single study design items. 
The follow-up questionnaire did ask for the expected size and direction of 
the bias resulting from a respondent’s deviation from the ‘gold standard’. 
The respondents expected no bias for most items. The effect of some design 
items may be calculated by simulating them in existing datasets. This is, 
however, on the condition that the study design item is included in the 
dataset in sufficient quantities to calculate the effect. 
Another limitation is the difficulty of some of the questions. By comparing 
the answers suspicion arose that some of the questions had not always been 
understood correctly. In these cases a clarification was asked in the follow-up 
questionnaire. However, it cannot be ruled out that some questions were 
interpreted incorrectly, but that this has not been noticed as the answer did 
not seem odd. 
 
The items included in the questionnaire were based on a literature review 
and on discussions with co-researchers. However, the list of items was not 
exhaustive. Some relevant items were not included in the questionnaire, but 
emerged during the analysis of the responses, e.g. measuring dose-related 
versus concentration-related impairment in experimental studies.  
Furthermore, the questionnaire was limited to the field of driving under the 
influence of psychoactive substances other than alcohol. The inclusion of 
methodological experts from outside this research field would have provided 
interesting and perhaps also more independent results on the preferred 
theoretical model.   
Finally, when interpreting the results of this study, it is important to bear in 
mind that the numbers of respondents per study type are quite small, and 
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that some of the respondents have worked together on the same studies or in 
the same institutes.  
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3. Prevalence of psychoactive substances in Dutch 
and Belgian traffic4 
3.1. Introduction 
Although the use of psychoactive substances by motor vehicle drivers is 
suspected as a major risk factor in traffic, valid information on psychoactive 
substance use by motorists is sparse (Behrensdorff and Steentoft, 2003; 
EMCDDA, 2008). Prevalence studies are, in general, complex and expensive 
to conduct, partly because of the relatively low incidence of psychoactive 
substances in traffic. For a study to have enough statistical power, many 
drivers need to be included.  
Review studies report a large variation of drivers in general traffic positive 
for one or more psychoactive substances other than alcohol. It is difficult to 
directly compare the results of these roadside surveys because of differences 
in study design, such as the number of substances included, the analytical 
cut-off levels applied and the biological matrix used (EMCDDA, 2008; Kelly 
et al., 2004; Walsh et al., 2004). In Norway 4.5% of the motor vehicle drivers 
were positive for psychoactive substances including illicit drugs, medicinal 
drugs or alcohol (Gjerde et al., 2008). In Thailand 5.5% of the drivers tested 
positive for alcohol and 9.7% of the drivers were positive for other 
psychoactive substances (Ingsathit et al., 2009). In the state of Victoria, 
Australia, 2.4% of the drivers were positive for methamphetamines, 3,4-
methylenedioxy-metamphetamine (MDMA, or Ecstacy), or tetrahydro-
cannabinol (THC, or cannabis). In the United States 11% of drivers were 
positive for illicit and medicinal drugs during daytime hours on Friday and 
14.4% during night time hours on Friday and Saturday nights (Lacey et al., 
2009). In British Columbia, 10.4% of the drivers tested positive for drug use 
on Wednesday and Saturday nights.  
In the European research-project DRUID (Driving Under the Influence of 
Drugs, Alcohol and Medicines) prevalence studies have been conducted 
from 2007 to 2009 in thirteen European countries (Houwing et al., 2011). 
Special attention was given to the comparability of these studies by using a 
                                                 
 
4 This chapter is published as the following article: Houwing, S., Legrand, S.-A., Mathijssen, 
R., Hagenzieker, M., Verstraete, A.G., Brookhuis, K.A. (2012). Prevalence of psychoactive 
substances in Dutch and Belgian traffic. This article is published  in Journal of Studies on 
Alcohol and Drugs (JSAD) 2012; 73 (6) 951-960. 
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common study design (Assum et al., 2007), which included 
recommendations on the type of road users and substances to be included, as 
well as the cut-off levels of these substances. Despite recommendations for a 
common design, some differences could not be ruled out for practical, 
legislative or medical ethical reasons. The main difference in the design of 
these thirteen studies was that some countries used blood as the biological 
matrix, some used oral fluid and some used a combination of both. To be 
able to compare the results from countries that used blood with countries 
that used oral fluid, equivalent cut-offs were applied, as reported by 
Verstraete et al. (2011b) and Gjerde et al. (2010a). When using equivalent cut-
off concentrations in blood and oral fluid, the prevalence of a drug will be 
equal in samples of blood and samples of oral fluid when studying a large 
cohort. Based on the outcomes of these thirteen studies and after application 
of weighing factors for the country size and the size of the represented 
European regions it was estimated that an average of 1.89% of the drivers in 
the European Union were positive for illicit drugs, 1.39% for medicinal 
drugs, 3.48% for alcohol, 0.39 % for poly-drug use, and 0.37% for the 
combined use of alcohol and drugs (Houwing et al., 2011).  
 
Belgium and the Netherlands are two neighbouring countries in Western 
Europe that shared a common history until 1830 when Belgium separated 
from the Netherlands. Comparisons between Belgium and the Netherlands 
are commonly made, because of their historical and cultural bonds. A 
comparison of the Dutch and Belgian results is also interesting because they 
were the only two Western European countries that were involved in the 
DRUID roadside surveys. This article reports and compares the use of 
psychoactive substances in traffic based on results of the Belgian and Dutch 
prevalence study that were conducted in the European DRUID project. 
Furthermore, the Dutch and Belgian results are compared with the estimated 
European mean and with previously conducted national studies in Belgium 
and the Netherlands on the use of psychoactive substances in traffic.  
3.2. Materials and methods 
3.2.1. General design 
A cross-sectional roadside survey was conducted to determine the 
prevalence of psychoactive substances among the general driving population 
in Belgium and the Netherlands. A stratified multi-stage sampling design 
was used. In the first stage five study regions were selected in Belgium and 
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the Netherlands. These regions were meant to be representative for the 
whole country with regard to substance use and traffic. Within these regions 
smaller research areas (five Belgian and six Dutch police regions) were 
selected in the second stage, and within these areas, survey locations were 
selected, where car drivers and drivers from vans were randomly selected 
from actual traffic between January 2007 and August 2009. For each police 
region data were collected during several roadside survey sessions 
distributed over eight 6-hour time periods covering all hours of the day on 
both weekdays and weekend days. The time periods were distributed into 
type of day (weekday-weekend day) and time of the day (04.00-09.59, 10.00-
15.59, 16.00-21.59, 22.00-03.59). 
Drivers were stopped by the police at the request of the research coordinator. 
As soon as an interviewer/nurse was ready for interviewing and blood 
sampling, a driver, (i.e. the next car approaching the research site) was 
stopped. Drivers who were stopped were asked to cooperate with the study 
on a voluntary basis. Drivers who agreed to cooperate were interviewed on 
their drug and medicine use. Apart from self-reported drug use and time of 
administration, data collection also comprised date and time of selection, 
gender and age of the subject, and signs of impairment. In Belgium all 
drivers were asked to provide both a blood and an oral fluid sample. If 
drivers refused to give a blood sample, a single oral fluid sample was 
requested. Participants received a reward of 20 euro in the Belgian study. All 
drivers in the Dutch study were asked to give a blood sample. If drivers 
refused to give a blood sample, an oral fluid sample was requested. 
Participants received a 5 euro reward for an oral fluid sample and 10 euro for 
a blood sample. In case drivers reported recent drug use an additional oral 
fluid sample was requested after collecting a blood sample.  
In the Netherlands as well as in Belgium the breath-test was compulsory for 
all drivers who were stopped. In the Netherlands participants were breath-
tested for alcohol by a police officer after the interview and the blood or oral 
fluid sampling. Drivers who refused to participate were breath-tested for 
alcohol by a police officer and, if possible, additional information was 
collected including information on age, gender, clinical signs of impairment 
and reason for refusal. In Belgium all drivers who were stopped were breath-
tested before the request regarding participation in the study.  
3.2.2. Ethical approval 
In Belgium, the protocol was approved by the ethics committee of Ghent 
University Hospital. Participants needed to sign an informed consent. No 
ethical approval was needed in the Netherlands. After having been informed 
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about the project, the ethics committee made clear that “the project is not 
encompassed by the law on ethics committees and consideration regarding 
bio-medical research projects. Therefore, the project does not have to be 
announced to the ethics committee”. Hence, no informed consent was 
requested. However, participants in the Netherlands were informed both in 
writing and by oral communication about the study and its voluntary nature.  
3.2.3. Sample preparation and analysis 
Venous blood samples were collected in glass tubes containing 20 mg 
sodium fluoride and 143 IU heparin sodium (BD Plymouth, Brest in the 
Netherlands and Terumo, Leuven in Belgium). In the Netherlands, oral fluid 
samples were taken by having the participant spit into a polypropylene 
container (Deltalab, Barcelona, Spain). In Belgium, oral fluid samples were 
collected by using the Statsure Saliva Sampler (Statsure Diagnostic Systems, 
Inc., Brooklyn, MA). In the Netherlands, estimated blood alcohol 
concentration (BAC) was measured with a handheld breath alcohol analyzer 
of the police teams using a Dräger Alcotest 7410 Plus com screening device 
(Dräger Safety Inc., Lübeck, Germany). In Belgium, BAC was estimated from 
both oral fluid and whole blood. For drivers from whom only oral fluid 
samples were collected results for ethanol (alcohol) in oral fluid were 
converted using the following formula: 
 
Calculated blood ethanol (%) = measured ethanol in oral fluid (g/L) x 1.22  
 
The applied factor of 1.22 was based on the average conversion factor 
between blood and oral fluid that was calculated from the Belgian DRUID 
results of those drivers from whom both blood and oral fluid samples were 
collected (Verstraete et al., unpublished observations).  
In Belgium, the following methods were used for the toxicological analysis of 
the whole blood samples: an enzymatic method for ethanol analysis, a solid 
phase extraction followed by ultra performance liquid chromatography-
tandem mass spectrometry (UPLC-MS/MS) analysis for all substances except 
cannabinoids, enzyme-linked immunosorbent assay (ELISA) screening 
(qualitative) for cannabinoids and liquid-liquid extraction followed by gas 
chromatogaphy-mass spectrometry analysis for samples that gave positive 
result at the ELISA screening for cannabinoids.  
An enzymatic method for ethanol analysis and protein precipitation 
followed by UPLC-MS/MS for all other substances was used for the Dutch 
toxicological analysis of whole blood samples. Four rounds of proficiency 
testing were organized in the participating countries during the study. 
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In the Netherlands, the conversion factor of breath alcohol concentrations 
into BACs in percentages is 1:23 (Mathijssen and Twisk, 2001). However, in 
the other European countries that were involved in the DRUID roadside 
surveys a higher conversion factor of 1:21 is used (Melethil, 2011). To be able 
to compare the Dutch alcohol results with the results for other EU countries, 
all BAC results from the Netherlands were multiplied by a factor 1.095 
(23/21). 
3.2.4. Equivalent cut-offs 
In total, 23 substances were included in the analysis. Selection of these 
substances was based on their prevalence of use in the general population 
and their possible influence on driving ability. Results were presented by 
using equivalent cut-offs. When using equivalent cut-off concentrations in 
blood and oral fluid, the prevalence of a drug will be equal in samples of 
blood and samples of oral fluid when studying a large cohort. The reason for 
applying equivalent cut-offs is that, for many substances, the concentrations 
in oral fluid are much higher than in blood, whereas for some compounds 
the concentrations are lower (Verstraete et al., 2011b). Table 3.1 provides an 
overview of the applied cut-off concentrations. In case both blood and oral 
fluid samples were available, the result from the blood analysis was leading.  
3.2.5. Substance groups and classes 
For calculating prevalence, substances of the same type were aggregated into 
substance groups. All groups were mutually exclusive, meaning that each 
record was either negative or linked to one of the following groups: alcohol, 
amphetamines, cocaine, THC, illicit opiates, benzodiazepines, Z-drugs, and 
medicinal opioids. Samples in which only THC-COOH (a metabolite of THC 
that is detectable in blood, and in very low concentrations in oral fluid) was 
detected were regarded as negative. Samples that included substances from 
two or more substance groups were included either in the drug-drug 
combination group or in the alcohol-drug combination group depending on 
the presence of alcohol. More detailed information on the aggregation into 
substance groups and classes can be found in Houwing et al. (2011). 
Morphine and codeine concentrations could be classified as medicinal 
opioids or as illicit opiates. Morphine and codeine were regarded, in general, 
as medicinal opioids, except in those cases when they were detected in 
combination with each other and the concentration of morphine was higher 
than the concentration of codeine. A higher concentration of morphine 
would suggest the use of an illicit opiate such as heroin. 
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Table 3.1. Applied cut-offs for psychoactive substances other than alcohol; THC-
COOH is not included in this table since THC-COOH was not analysed in oral fluid. 
Substance 
Cut-off in oral 
fluid (ng/mL) 
Cut-off in whole 
blood (ng/mL) 
Substance group 
Amphetamine 360 20 
Amphetamines 
Methamphetamine 410 20 
MDA 220 20 
MDEA 270 20 
MDMA 270 20 
Cocaine 170 10 
Cocaine 
Benzoylecgonine 95 50 
THC 27 1.0 Cannabis 
6-Acetylmorphine 16 10 Illicit opiates 
Diazepam 5.0 140 
Benzodiazepines 
Flunitrazepam 1.0 5.3 
Lorazepam 1.1 10 
Alprazolam 3.5 10 
Clonazepam 1.7 10 
Nordiazepam 1.1 20 
Oxazepam 13 50 
Methadone 22 10 Medicinal opioids  
Morphine 95 10 Medicinal opioids 
or illicit opiates Codeine 94 10 
Zolpidem 10 37 
Z-drugs 
Zopiclone 25 10 
 
3.2.6. Weighing factors 
Because random sampling was applied, drivers were expected to be 
representative of gender and age during sampling sessions. However, 
because police preferences had to be considered, the selection of samples 
could not be distributed equally with traffic volumes over the different 
periods. To correct for the difference between distribution of roadside 
samples and distribution of traffic over eight different periods, weight factors 
were calculated by dividing the general distribution of traffic by period by 
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the distribution of sampled drivers in the same period. The weighing 
procedure in the Netherlands was based on 2007–2008 national trip 
distribution data from the National Travel Survey collected by the Dutch 
Central Bureau of Statistics (CBS, 2011), and the weighing procedure in 
Belgium was based on 2007 traffic counts from the Flemish Government’s 
Agency for Roads and Traffic (AWV, 2007).  
3.2.7. Statistical analysis 
Weighted prevalence was calculated by using descriptive statistics by means 
of the statistical software SAS Version 9.2 (SAS Institute, Cary, NC). Tables 
were created by using a FREQ procedure including a statement on the 
weight factors to be used. Weighted prevalence of the substance under 
scrutiny was calculated by dividing the weighted number of positives for 
this substance by the weighted total of samples. For calculating confidence 
intervals, the Wilson confidence interval formula (Wilson, 1927) was used 
because lower and upper confidence limits calculated using traditional 
approximations may result in limits outside the (0,1) interval. Possible 
differences in substance use between the two countries were investigated 
with binomial logistic regression in SPSS Version 16.0.1 (SPSS Inc., Chicago, 
IL). Type of country was used as a covariate (with two categories: 0 = 
Belgium, 1 = The Netherlands), and each substance was included as a 
dependent variable (also with two categories: 0 = negative, 1 = positive). In all 
statistical tests, the conventional critical 5% level was used to assess whether 
the obtained odds ratio (OR) significantly deviated from 1.  
3.3. Results 
3.3.1. Study population 
In the Netherlands, 5,064 drivers were asked to participate in this study. Of 
these drivers, 242 (4.8%) declined and 4,822 (95.2%) agreed to participate. In 
Belgium, 6,155 drivers were asked to participate. Of these drivers, 3,206 
(52.1%) refused and 2,949 (47.9%) agreed to participate. Of the 4,822 
participating drivers in the Dutch study, 3,476 (72%) provided a blood 
sample, 1,068 (22%) provided an oral fluid sample, and 278 (6%) provided 
both a blood and an oral fluid sample. As stated previously, in case both 
blood and oral fluid samples were collected, the results of the blood analysis 
were leading. In the Belgian study, 2,750 (93%) of the 2,949 participating 
drivers provided both blood and oral fluid samples, and 199 (7%) provided 
an oral fluid sample only. Table 3.2 provides an overview of the distribution 
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of the participating drivers by age and gender. No information on age was 
available from 5 drivers in the Netherlands and 21 drivers in Belgium. 
Table 3.2. Distribution roadside survey sample by age and gender; excluding 5 
missing values for respondents in the Netherlands and 21 missing values for 
respondents in Belgium. 
Age 
Respondents NL (n=4817) Respondents BE (n=2928) 
Male Female Total Male Female Total 
18-24 7.3% 3.2% 10.5% 6.3% 3.8% 10.1% 
25-34 15.1% 5.9% 21.1% 12.6% 8.5% 21.5% 
35-49 23.8% 12.0% 35.8% 25.3% 12.5% 37.8% 
50+ 23.6% 9.0% 32.6% 22.7% 8.4% 31.1% 
Total 69.8% 30.2% 100% 66.8% 33.2% 100.0% 
 
 
There was no significant difference in the age and gender distribution 
between the two survey samples. Distribution of drivers in the Dutch 
roadside sample was comparable with the national distribution on gender, 
which accounts for 70.3% and 29.7% of male and female drivers, respectively 
(CBS, 2011). Distribution by gender in the Belgian DRUID study was 
comparable to the distribution found in the 2007 Belgian roadside survey of 
drinking and driving, where 67% of the drivers were male and 33% of the 
drivers were female (Dupont, 2009).  
 
A comparison of the response group with the nonresponse group in the 
Belgian study (Houwing et al., 2011) showed that there was a small but 
significant overrepresentation of male drivers among the nonresponse group. 
This overrepresentation was mainly present in the 25- to 34-year-old age 
group. The prevalence of illicit drugs was generally higher among young 
male drivers. Furthermore, it was shown that from 4:00 A.M. to 9:59 A.M. on 
both weekday/weekend days and from 10:00 A.M. to 3:59 P.M. on weekends, 
the refusal rates were highest. Alcohol prevalence among respondents did 
not differ with the prevalence found in non-respondents (p = .321). 
The nonresponse rate in the Netherlands was only 4.8%. The prevalence of 
alcohol was slightly higher for the nonresponse group than for the response 
group. However, the BAC distribution of the combined response and 
nonresponse group was almost identical to the BAC distribution of the 
response group alone. The self-reported use of psychoactive substances other 
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than alcohol was higher for the nonresponse group. After correction for the 
unknown answers, 6.5% of the non-respondents reported the use of 
psychoactive substances in the past 12 hours versus 3.6% of the respondents. 
When the self-reported use of the nonresponse group would have been 
added, the self-reported use of the total study population would increase just 
one tenth of a percentage point, from 3.6% to 3.7%. 
3.3.2. Prevalence 
Table 3.3 provides a general overview of the prevalence of psychoactive 
substances in Dutch and Belgian traffic. As mentioned above, the substance 
groups were divided into four drug categories: alcohol, illicit drugs, 
medicinal drugs, and combined use of drugs or drugs with alcohol. 
Table 3.3. Adjusted general distribution of core substances including 95% confidence 
intervals. 
Category Substance group 
Prevalence in the 
Netherlands (%) 
N = 4822 
Prevalence in 
Belgium (%) 
N = 2949 
Negative Negative 94.49 (93.81 - 95.10) 89.35 (88.18 - 90.41) 
 
Alcohol 
Alcohol alone >0.01 % 2.15 (1.78 - 2.60) 6.42 (5.59 - 7.36) 
Alcohol 0.05 - 0.08 % 0.26 (0.15 - 0.44) 1.33 (0.97 - 1.81) 
Alcohol 0.08 – 0.12 % 0.14 (0.07 - 0.29) 0.42 (0.24 - 0.72) 
Alcohol 0.12 % and 
higher 
0.21 (0.12 - 0.39) 0.41 (0.23 - 0.71) 
 
Illicit drugs 
THC alone 1.67 (1.34 - 2.07) 0.35 (0.19 - 0.64) 
Cocaine alone 0.30 (0.18 - 0.50) 0.20 (0.09 - 0.43) 
Amphetamine alone 0.19 (0.10 - 0.36) -- 




Benzodiazepines alone 0.40 (0.25 - 0.62) 2.01 (1.57 - 2.59) 
Medicinal opioids alone 0.16 (0.08 - 0.32) 0.75 (0.50 - 1.13) 
Z-drugs alone 0.04 (0.01 - 0.15) 0.22 (0.10 - 0.47) 
 
Combinations 
Multiple drugs 0.35 (0.22 - 0.56) 0.30 (0.16 - 0.58) 
Alcohol – drugs 0.24 (0.13 - 0.42) 0.31 (0.16 - 0.58) 
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Alcohol  
In both countries, single alcohol use (BAC > .01%) was the most prevalent 
substance. The prevalence of single alcohol use in Belgian traffic (6.42%) was 
significantly higher (OR = 3.15, 95% CI [2.46, 4.03]) than in Dutch traffic 
(2.15%) (Figure 3.1). For each of the three BAC groups, the prevalence in 
Belgium was at least twice as high as in the Netherlands. However, the 
relative difference decreased at higher BAC levels. Alcohol was used in 
combination with other psychoactive substances far less frequently than 
alone. In the Netherlands, the prevalence of alcohol in combination with 
other psychoactive substances was 0.24%, which was 10% of the total 
prevalence of alcohol. In Belgium, the prevalence of alcohol in combination 
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Figure 3.1. Prevalence of substances alone and in combination; prevalence in 
percentages; AMP = amphetamines, COC = cocaine, THC = cannabis, OPI = illicit 
opiates, BDZ = benzodiazepines, ZDR = Z-drugs, MOPI = medicinal opioids. 
Illicit drugs 
The illicit drug class consisted of four different illicit drug groups: 
amphetamines, cocaine, cannabis, and illicit opiates (Table 3.1). In the 
Netherlands, 2.17% of all drivers were positive for illicit drugs, whereas in 
Belgium the prevalence was lower, at only 0.64%, a significant difference (OR 
= 0.27, 95% CI [0.16, 0.45]). THC was by far the most frequently detected 
illicit drug in the Netherlands (1.67%) and in Belgium (0.35%). The THC 
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prevalence in Belgium was significantly lower than in the Netherlands (OR = 
0.21, 95% CI [0.11, 0.40]). Cocaine was detected among 0.30% of the drivers in 
the Netherlands and among 0.20% of the drivers in Belgium (OR = 0.69, 95% 
CI [0.26, 1.88]). This difference was not significant. Amphetamines were 
detected among 0.19% of the Dutch drivers and were completely absent 
among the Belgian drivers. Because of the absence of amphetamines in the 
Belgian study sample, a value of 0.1 was added to each of the four cells 
(Agresti, 1996), which resulted in a non-significant difference (OR = 0.02, 95% 
CI [0.00, 8.97]) between the Dutch and Belgian prevalence. Illicit opiates were 
rarely present (0.01%) in the Netherlands and sparsely detected in Belgium 




The medicinal drugs class consisted of three different drug groups: 
benzodiazepines, medicinal opioids, and Z drugs (see Table 3.1). Medicinal 
drugs were significantly more prevalent in general traffic in Belgium (2.98%) 
than in the Netherlands (0.60%) (OR = 6.40, 95% CI [4.00, 10.25]). The most 
frequently detected medicinal drugs were benzodiazepines. In the 
Netherlands, 0.40% of the drivers were screened positive for 
benzodiazepines, as did 2.01% in Belgium (OR = 5.16, 95% CI [3.08, 8.66]) 
(Figure 3.1). Medicinal opioids were detected relatively frequently in 
Belgium (0.75%) but significantly less in the Netherlands (0.16%) (OR = 4.60, 
95% CI [2.04, 10.37]). Z drugs were significantly more prevalent in Belgium 
(0.22%) than in the Netherlands (0.04%) (OR = 5.12, 95% CI [1.08, 24.31]). 
 
Drug–drug and alcohol–drug combinations 
Patterns of the prevalence of combinations of psychoactive substances were 
more or less the same in the Netherlands (0.24% alcohol–drugs and 0.35% 
drug–drug combinations) and in Belgium (0.31% alcohol–drugs and 0.30% 
drug–drug combinations). The corresponding odds ratios were not 
significant (alcohol–drugs, OR = 1.37, 95% CI [0.62, 3.00]; drug–drug 
combinations, OR = 0.76, 95% CI [0.34, 1.71]). Both in Belgium and in the 
Netherlands, cocaine was detected with approximately the same frequency 
alone as it was in combination with other substances. For THC, Z drugs, and 
medicinal opiates and opioids, the share of combined use was approximately 
25% of the total use, whereas for alcohol and benzodiazepines the proportion 
was about 10% in both countries. For amphetamines (0.00% in Belgium) and 
illicit opiates (0.01% in the Netherlands), the prevalence was too low to 
compare between countries. 
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3.3.3. Comparison with previous studies in the Netherlands and 
Belgium 
In the Netherlands, only one previous prevalence study had been conducted 
in the past 10 years on the prevalence of drugs and medicines in traffic 
(Mathijssen and Houwing, 2005). For alcohol prevalence, data were available 
on a yearly basis since 1974, but this information is only gathered during 
weekend nights (DVS, 2011). For the prevalence of alcohol during other time 
periods, only data from the European research project IMMORTAL 
(Impaired Motorists, Methods of Roadside Testing and Assessment for 
Licensing) were available (Mathijssen and Houwing, 2005). 
Between 2000 and 2004, a roadside survey was conducted in the Dutch 
Tilburg police district as part of the European IMMORTAL study. The 
prevalence of single illicit drugs was higher in the IMMORTAL study (4.5%) 
than it was in the Dutch DRUID study (2.17%). However, the results of the 
IMMORTAL study were mainly based on urine samples in which drugs are 
detectable for a longer period than in blood and oral fluid (Verstraete, 2004). 
Therefore, a direct comparison between the prevalence rates of the 
IMMORTAL and the DRUID study was not possible.  
 
In Belgium, national data on the prevalence of alcohol in traffic were 
available for the years 2003, 2005 and 2007 (Dupont, 2009). No previous data 
were available on the prevalence of other psychoactive substances in traffic. 
The prevalence of alcohol in the DRUID study was somewhat higher than 
the results from the biannual roadside survey on alcohol use, which found an 
average prevalence of 2% during the whole week for a BAC of 0.5 g/L and 
higher. In the DRUID study, this prevalence was 2.33%. These results did not 
significantly differ from each other. 
3.3.4. Comparison with DRUID mean 
Within the DRUID project, a European mean was estimated based on the 
prevalence of psychoactive substances in 13 different European countries 
including the Netherlands and Belgium using a uniform study design 
(Houwing et al., 2011). Figure 3.2 presents the comparison of the Dutch and 
Belgian prevalence data (including 95% confidence intervals) with the 



























Figure 3.2. Comparison of national prevalence in Belgium and the Netherlands for 
various groups of substances including 95% confidence intervals with the estimated 
European mean. ETH = ethanol (alcohol); THC = single tetrahydrocannabinol 
(cannabis); COC = single cocaine; AMP = single amphetamines; OPI = single illicit 
opiates; BDZ = single benzodiazepines; MOPI = single medicinal opioids; ZDR = single 
Z drugs; ETH + DRU = alcohol–drugs combinations; DRU + DRU = drug–drug 
combinations. 
The results show that the relative position of the Belgian and Dutch results 
toward the European mean was mirrored for all substances. 
Benzodiazepines, medicinal opiates and opioids, and alcohol were more 
frequently detected in Belgium as opposed to the European mean, whereas 
in the Netherlands they were less frequently detected than in Europe. 
However, the prevalence of amphetamines and THC in Dutch traffic was 
above the European average, and the prevalence of these substances in 
Belgium was below average. The prevalence of cocaine, illicit opiates, Z 
drugs, alcohol–drugs, and drug–drug combinations in traffic varied between 
the two countries; but, for all of these substances, the European mean was 
included in the confidence interval for both countries. 
3.4. Discussion 
3.4.1. Discussion of the results 
Despite the fact that Belgium and the Netherlands are neighbouring 
countries, the use of psychoactive substances in traffic was far from similar. 
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In Belgium, the use of alcohol and medicinal drugs in traffic was higher than 
in the Netherlands, whereas the measured use of illicit substances in traffic 
was substantially higher in the Netherlands as compared with Belgium. 
The higher prevalence for alcohol in Belgium might be related to differences 
in the enforcement level. The enforcement level for alcohol (number of 
alcohol tests per 100,000 inhabitants) is estimated to be three to four times 
lower in Belgium than it is in the Netherlands (Veisten et al., 2011). 
Furthermore, cultural differences may be causing higher alcohol use in 
Belgian traffic. For example, in Belgium, people tend to go out eating and 
drinking more often. This is reflected in the number of restaurants per 10,000 
inhabitants. In the Netherlands, the number of restaurants per 10,000 
inhabitants is approximately 35 (BHC, 2011), whereas in the Flanders 
region—where about 60% of all Belgian inhabitants reside—the number of 
restaurants per 10,000 inhabitants is approximately 48 (GUIDEA, 2011).  
The higher use of medicinal drugs in Belgium might be explained by a 
higher consumption of medicines in the general population. The average 
expenditure per person on medicines has been approximately 15%–20% 
higher in Belgium than in the Netherlands (SFK, 2011). The low expenditure 
in the Netherlands could partly be explained by a reluctant prescription 
policy of general practitioners. 
 
The relatively low prevalence of illicit drugs that was found in Belgium may 
be related to the high nonresponse level. It can be expected that drivers who 
had recently used an illicit drug would be less likely to participate in the 
study because they might be afraid that the test results would be used for 
legal purposes (drug driving legislation of 1999). A lower participation rate 
of drug-positive drivers would result in nonresponse bias. Based on a 
comparison of the detected prevalence of illicit substances among injured 
drivers (Isalberti et al., 2011) and in the general population (Ravera and De 
Gier, 2008), a higher prevalence of illicit drugs in Belgian traffic would 
indeed be expected. The detected prevalence of illicit drugs in the general 
population was in fact comparable for the two countries, and the detected 
prevalence of illicit drugs among injured drivers was even higher for 
Belgium than it was for the Netherlands. 
Another indication of nonresponse bias can be derived from the odds ratios 
for illicit drugs that were calculated by Hels et al. (2011). Because of the low 
prevalence of illicit drugs in Belgium, only an adjusted odds ratio for getting 
seriously injured in a car crash could be calculated for cannabis. The Belgian 
odds ratio for cannabis (4.88) was approximately three times higher than the 
mean adjusted odds ratio (1.38) in Hels et al. (2011) which was based on the 
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combined data of four included countries (Belgium, Denmark, The 
Netherlands, and Lithuania). If the mean adjusted odds ratio would be 
applied to the Belgian hospital data, the estimated prevalence for THC in 
Belgian traffic is likely to be more comparable to the Dutch prevalence, 
although it is impossible to estimate the exact size of the potential 
nonresponse bias. Finally, keep in mind that, in this study, prevalence is 
based on predetermined limits of detection and not on limits of impairment. 
3.4.2. Strengths and limitations 
The main strength of the present study is the similar design of roadside 
surveys performed in both Belgium and the Netherlands, which makes it 
possible to compare the results between the two countries as well as with the 
estimated European mean. By using equivalent cutoffs for drugs in blood 
and oral fluid, the limitation of the comparability of the results when 
including two different body fluid samples (blood and oral fluid) was 
overcome. Another strength of this study is that blood and oral fluid samples 
were used, not urine samples. Blood and oral fluid can be used to detect 
recent drug use, whereas urine samples may reflect drug intake up to several 
days ago (Verstraete, 2004; Walsh et al., 2008). Furthermore, the study 
provides recent prevalence data of different psychoactive substances in the 
general driving population in Belgium and the Netherlands. For Belgium, 
this is the first large-scale study that includes information on the prevalence 
of illicit drugs in traffic. 
A limitation of this study is that the list of analyzed substances was not 
exhaustive. For example, there was no screening for gamma-hydroxybutyric 
acid (GHB), only seven benzodiazepines were screened for, and selective 
serotonin reuptake inhibitors were not included. The very high nonresponse 
rate (52.1%) in Belgium is another limitation of the study because it could 
lead to nonresponse bias, especially for illicit drugs. Based on the assessment 
on possible confounding effects of nonresponse by comparing age, gender, 
and alcohol data, we can conclude that the possibility of nonresponse bias 
cannot be totally ruled out. Despite that there was a significant difference (p < 
.001) in self-reported use of psychoactive substances other than alcohol 
between the response and the nonresponse group in the Netherlands, the 
actual bias seems to be very small because of the small size of the 
nonresponse group. 
Another limitation is that the studies in Belgium and the Netherlands did not 
collect oral fluid in the same way. The collection procedure may have 
influenced the concentrations of the samples, as described in previous 
literature (Crouch, 2005; Langel et al., 2008; O'Neal et al., 2000; Verstraete et 
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al., 2011a). Furthermore, the results from Chapter 5 show that THC 
concentrations in oral fluid samples collected by spit tubes were on average 
5.9 times higher than THC concentrations collected by the StatSure collection 
device. These findings indicate that the applied equivalent cutoff 
concentrations might have been too high for the Dutch study. 
Finally, despite the large sample size of the Belgian and Dutch prevalence 
study, the cell counts for some substances were small or even zero, which 
resulted in less stable comparisons between the estimates of both countries. 
3.5. Conclusion 
The Netherlands and Belgium are neighboring countries. Nonetheless, 
statistical significant differences are present in the prevalence of psychoactive 
substances in traffic. In general, medicinal drug use and alcohol were more 
frequently detected in Belgian traffic, whereas illicit substances were more 
prevalent in the Netherlands. However, when comparing the results of 
roadside surveys with hospital data and data from illicit drug use in the 
general population, it is likely that the observed prevalence of illicit drugs at 
the Belgian roadside was underrepresented and that the prevalence of illicit 
drugs in Belgian traffic is probably higher than the current results show. 
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4. Prevalence of alcohol and other psychoactive 
substances in injured drivers: comparison 
between Belgium and the Netherlands5 
4.1. Introduction 
The prevalence of drugs, medicines and/or alcohol in injured drivers has 
been the object of research in different European countries but also in 
Australia, Canada, South Africa and the United States already for many 
years (Raes et al., 2008). These studies showed that alcohol and/or drugs are 
frequently detected in injured drivers, more frequently than in the general 
driving population. Alcohol was found in a higher percentage than any other 
substance. In most studies, cannabis and benzodiazepines were the most 
frequently detected illicit and medicinal drug respectively. Due to differences 
in methodology, study location or study design (different substances 
included, matrix or cut-offs applied) there is a large variation in the 
percentages of alcohol or drug-positive samples in the different studies. This 
variation in study design makes it difficult to compare the results from the 
different studies. 
 
Few prevalence studies have been performed in Belgium and the 
Netherlands. Only two studies on the prevalence of drugs and alcohol 
among injured drivers have been performed in Belgium (Meulemans et al., 
1998; Schepens et al., 1998; Verstraete, 2000). Both studies are dated (1998). 
Schepens and colleagues performed the first study where blood and urine 
samples of drivers injured in weekend car crashes in Belgium were tested for 
different drugs and alcohol. Data on the prevalence of these psychoactive 
substances are available for injured drivers sampled between the first of July 
1994 and the third of June 1995. The Belgian Toxicology and Trauma Study 
(BTTS) undertook a prospective study on the presence of alcohol and illicit 
and medicinal drugs in patients admitted to the emergency departments of 
five selected hospitals in Belgium. The study was performed between 
January 1995 and June 1996. More recent studies were performed in the 
                                                 
 
5 This chapter is published as the following article : Legrand, S.-A., Houwing, S., 
Hagenzieker, M., & Verstraete, A (2012). Prevalence of alcohol and other psychoactive substances 
in injured drivers: comparison between Belgium and the Netherlands. This article is published in 
Forensic Science International (FSI) 2012; 220 (1-3) 224-231. 
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Netherlands. One was part of the IMMORTAL (Impaired Motorists, Methods 
of Roadside Testing and Assessment for Licensing) project (Assum et al., 
2005; Smink et al., 2005). In the study performed by Smink and colleagues 
blood samples of about 1000 injured drivers, collected from October 1998 to 
September 1999, were analysed for the presence of alcohol, illicit and 
medicinal drugs. From the IMMORTAL study, data on the prevalence of 
alcohol and drugs for about 200 injured drivers sampled during the 2000-
2004 period are available. 
 
Within the European DRUID project (Driving Under the Influence of Drugs, 
alcohol and medicines) a study on the presence of alcohol and other drugs in 
injured drivers admitted to the emergency departments of five hospitals in 
Belgium and three hospitals in the Netherlands was undertaken. The study 
was performed between 2008 and 2010, using a uniform study design 
(Goessaert et al., 2010). This article presents the results of a comparison of the 
prevalence of psychoactive substances in seriously injured Belgian and 
Dutch drivers. These results will be compared to those from previous studies 
on prevalence of alcohol and drugs in injured drivers performed in Belgium 
(BE) and the Netherlands (NL).  
4.2. Materials and Methods 
4.2.1. Study population 
In Belgium blood samples were collected from seriously injured drivers 
admitted between January 2008 and May 2010 to the emergency department 
of Ghent University Hospital, Regional Hospital of Namur, University 
Hospital Sart-Tilman (Liège), Leuven University Hospital and Brussels 
University Hospital. These 5 hospitals were selected because they 
participated in the ‘Belgium Toxicology and Trauma Study’ in 1995 
(Meulemans et al., 1998; Verstraete, 2000). In the Netherlands blood samples 
were collected between March 2008 and April 2010 from injured drivers 
admitted to the emergency department of hospitals in the cities of Enschede, 
Nijmegen and Tilburg. Only drivers of personal cars or vans, aged more than 
18 years and with a Maximum Abbreviated Injury Scale (MAIS) ≥2 were 
included (Association for the Advancement of Automotive Medicine 
(AAAM), 2008). In total 535 samples were collected (Belgium: 348; The 
Netherlands: 187). For the calculation of the alcohol prevalence in the 
Netherlands one subject was excluded as a consequence of incomplete 
toxicological analysis. 
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4.2.2. Ethical approval 
The study protocol was approved by the ethics committees of the 
participating hospitals in the Belgian study and the three participating Dutch 
hospitals. The toxicological and patient data were separated from the clinical 
files and anonymised in order to guarantee the privacy of the participants. 
No reference was made to the study in the medical record. Informed consent 
was mandatory in Belgium but not in the Netherlands. 
4.2.3. Data collected 
The data collection took place in the emergency departments of the selected 
hospitals. A flow chart on the data collection procedure and a thesaurus for 
the medical personnel were prepared. Apart from a blood sample, patient 
information was gathered through a short questionnaire. The interview of 
the patient was preferably done face-to-face. If this was impossible (e.g. 
because the patient remained unconscious), partial information was gathered 
from other sources (e.g. medical record). Relatives of the patient who were 
present in the hospital were allowed to give certain information (such as age 
of the patient or which vehicle type the patient drove at the moment of the 
crash) if patients were unable to answer. It was stressed that the 
questionnaire was anonymous. When patients refused to participate in the 
study, the reason was recorded. The information gathered included patient 
information and information about the accident. The patient information 
registered included: age, gender, education, date and time of sampling, 
medication administered prior to blood sampling and severity of injuries. 
The following accident data were recorded: date and time of the accident, 
time of admission, name of hospital, vehicle type, type of accident 
(single/multi vehicle), speed limit at the location of the accident, safety belt 
use and weather and road conditions. 
4.2.4. Toxicology 
Blood samples were taken using a 5 mL glass collection tube containing 
potassium oxalate and sodium fluoride. In Belgium samples were stored 
frozen in the hospitals. Regular shipments (under cooled conditions) took 
place to the laboratory of the Department of clinical chemistry, microbiology 
and immunology of Ghent University where the toxicological analyses were 
performed using fully validated methods. In the Netherlands blood samples 
were stored in solid carbon dioxide in the hospitals. After transportation to 
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the Netherlands Forensic Institute (NFI) in The Hague, blood samples were 
stored at -20°C until analysis. 
The analyses included determination of ethanol and 22 other psychoactive 
substances or metabolites in whole blood (see Table 4.1). 
The following methods were used for the toxicological analysis: enzymatic 
method for ethanol analysis, solid phase extraction followed by UPLC-
MS/MS analysis for all substances except cannabinoids, ELISA screening 
(qualitative) for cannabinoids and liquid-liquid extraction followed by GC-
MS analysis for samples that gave a positive ELISA result for cannabis 
(Blencowe et al., 2011; Goessaert et al., 2010). An enzymatic method for 
ethanol analysis and protein precipitation followed by UPLC-MS/MS for all 
other substances were used for the Dutch toxicological analysis of the whole 
blood sample. Four rounds of proficiency testing were organized for the 
participating countries during the study. 










Ethanol 0.1 g/L MDA 20 
6-acetylmorphine 10 MDEA 20 
Alprazolam 10 MDMA 20 
Amphetamine 20 Methadone 10 
Benzoylecgonine 50 Methamphetamine 20 
Clonazepam 10 Morphine 10 
Cocaine 10 Nordiazepam 20 
Codeine 10 Oxazepam 50 
Diazepam 20 THC 1 
Flunitrazepam 2 THCCOOH 5 
Lorazepam 10 Zolpidem 20 
 Zopiclone 10 
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4.2.5. Data analysis 
For the description of the studied population chi-square analysis was used to 
search for differences between the two countries. SPSS statistics 17 (IBM, 
Somers, NY, USA, 2009) was used for statistical analysis. P-values with 
Pearson’s Chi square or Fisher’s exact tests and confidence intervals (95%) 
for difference in proportions were calculated to determine the significance of 
the differences. The level of significance was set at p<0.05. Confidence 
intervals were calculated with the Wilson method (Wilson, 1927). 
4.3. Results 
4.3.1. Description of the driver sample 
A total of 535 samples were included in this comparison (see Table 4.2). 
About 70% of the included drivers were male, There were significantly more 
male drivers in the Netherlands compared to Belgium (p= 0.011). No 
differences in the age distribution were found for both genders (p= 0.112 for 
male and p= 0.893 for female drivers). Twenty-four percent of all drivers 
included were 18 to 24 years old. The age group 50 and over accounted for 
20%. Almost 45% of the accidents occurred on a weekday, 15% on a weekend 
night. Significantly more weekend day accidents were observed in Belgium, 
while in the Netherlands more occurred during weeknights (p = 0.001). No 
significant differences in the distribution by quarter of the year were seen (p= 
0.262). The highest proportion was found in the fourth quarter (app. 29%). Of 
the 444 drivers for whom data were available about seat belt use, 28% did not 
wear it. No difference in use of seat belt was seen between Dutch and Belgian 
injured drivers (p= 0.553). Approximately 93% of the study population was 
driving a car, almost 7% a small van with no differences between both 
countries (p= 0.547). A significant difference was found for type of accident, 
with a higher proportion of multi-vehicle collisions in Belgium (51%) 
compared to the Netherlands (37%) (p=0.004). In Belgium more MAIS 2 
scores were seen (62%) compared to the Netherlands (49%) (p=0.025). The 
non-response in Belgium was about 5% and in the Netherlands unknown 
because there was no registration of drivers who refused or of cases that 
were missed. A recently conducted roadside survey showed no large 
differences between the prevalence of psychoactive substances in the four 
parts of the Netherlands. Based on this distribution, the expected bias from 
the covered area was small (Isalberti et al., 2011). 
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Table 4.2. Description of the driver sample; * Significant difference between BE and NL (p≤.05). 
Characteristic Category Belgium The Netherlands 
Time period*6 
Weekday 146 (43.1%) 90 (48.1%) 
Weeknight 45 (13.3%) 46 (24.6%) 
Weekend day 96 (28.3%) 23 (12.3%) 
Weekend night 52 (15.3%) 28 (15.0%) 
Gender, age*7 
Male, 18-24 53 (22.6%) 50 (33.3%) 
Male, 25-34 78 (33.2%) 39 (26.0%) 
Male, 35-49 56 (23.8%) 35 (23.3%) 
Male, 50+ 48 (20.4%) 26 (17.3%) 
Female, 18-24 18 (18.0%) 5 (13.5%) 
Female, 25-34 28 (28.0%) 12 (32.4%) 
Female, 35-49 32 (32.0%) 11 (29.7%) 
Female, 50+ 22 (22.0%) 9 (24.3%) 
Type of vehicle 
Personal car 324 (93.1%) 176 (94.1%) 
Van 24 (6.9%) 11 (5.9%) 
Quarter of the year8 
1 86 (24.8%) 53 (28.3%) 
2 69 (19.9%) 46 (24.6%) 
3 88 (25.4%) 36 (19.3%) 
4 104 (30.0%) 52 (27.8%) 
MAIS*9 
2 208 (61.7%) 91 (48.9%) 
3 97 (28.8%) 66 (35.5%) 
4 20 (5.9%) 16 (8.6%) 
5 12 (3.7%) 13 (7.0) 
Type of accident*10 
Single vehicle 158 (48.9%) 101 (62.7%) 
Multi-vehicle 165 (51.1%) 60 (37.3%) 
Seatbelt use11 
Yes 215 (71.4%) 106 (74.1%) 
No 86 (28.6%) 37 (25.9%) 
Median time between accident and sampling 1 hour 33 minutes 1 hour 21 minutes 
                                                 
 
6 9 missing values BE study  
7 12 missing values BE study 
8 1 missing value BE study 
9 11 missing values BE study; 1 missing value NL study 
10 25 missing values BE study; 26 missing values NL study 
11 47 missing values BE study; 44 missing values NL study 
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4.3.2. Overview of the toxicological results 
In Belgium more drivers were found positive for alcohol and drugs than in 
the Netherlands. In the Dutch driver population 66.1% was negative for all 
substance groups, compared to 47.4% in Belgium (see Table 4.2). Alcohol 
(≥0.1g/L) was the most prevalent substance among the injured drivers in 
Belgium (42.5%) and the Netherlands (29.6%). About 38% of the injured 
drivers in Belgium tested positive for alcohol above the legal limit (0.5g/L) 
compared to 28% in the Netherlands (p= 0.003). Although Belgium had a 
higher percentage of drivers positive for alcohol with a BAC > 1.3 g/l (29.0% 
compared to 17.2% ;(p= 0.010), the distribution of the BACs (>0.1 g/L) was 
similar, with approximately 65% of BACs higher than 1.3 g/L. In Belgium 
there were, besides more positive findings for alcohol, more positives for 
THC (BE: 8.0%; NL 0.5%, p < 0.001) and medicinal opiates (BE: 3.3%; NL: 
0.5%, p= 0.005) than in the Netherlands. In the Netherlands no illicit opiates 
and benzodiazepines were found. In Belgium about 7% of the drivers was 
found positive for benzodiazepines and 0.6% for illicit opiates. For 
amphetamines (BE: 2.6%; NL: 2.2%), cocaine (BE: 2.3%; NL: 2.1%) and Z-
drugs (BE: 1.8%; NL: 0.5%) the percentages were similar in Belgium and the 
Netherlands (Fisher exact test with p: 0.288, 1.00 and 0.430 respectively). A 
higher prevalence of single drug and combined drug use was found in 
Belgium. Around 13% of the Belgian drivers were found positive for an 
alcohol-drug combination (in NL: 4.3%, p<0.001) and 2.5% for a drug-drug 
combination (in NL: 0.5%, p<0.05). 
 
The median concentration was calculated for the two most prevalent 
substances: alcohol and THC. No large difference in the median alcohol 
concentration (≥0.1 g/L) in Belgium and the Netherlands was found (BE: 1.59 
g/L; NL: 1.51g/L). In Belgium 30 drivers had a THC concentration at or above 
the cut-off (1 ng/ml), the median concentration of THC was 2.7 ng/ml. Only 
one case of THC was found in the Netherlands with a concentration of 19.7 
ng/ml, which is much higher than the ones found in Belgium (maximum 
concentration was 14.2 ng/ml). 
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Table 4.3. Prevalence (%) of alcohol and drugs in injured drivers in Belgium and The 
Netherlands; - no information available, a Not only injured drives but also killed drivers, 
b drug+alcohol (≥0.8 g/L), c Drivers included in the study had the choice between providing a 
blood sample or a urine sample. About 1/3 of the drivers provided a urine sample. 









Sample size 2053 348 184 187 
Sample Blood (alcohol, 
benzodiazepines) 
& urine 
Blood Blood (66%) or 
urine (34%)c 
Blood 
Vehicle type Car; motorbike 
and cycle, moped, 
bicycle 
Car and vans Cars, small 
vans and 
minibuses 















- 42.5 (37.4-47.8) 
29.9 
- 29.6 (23.5-36.5) 
25.3 
Alcohol (≥0.5 g/L) 
0.1g/L≤BAC≥0.5g/L 
28.2 38.2 (33.3-43.4) 
4.3 
17.4 28.0 (22.1-34.8) 
1.6 
BAC <0.1  57.5  70.4 
BAC <0.5 71.1    
BAC 0.1-0.5  4.3  1.6 
BAC 0.2-0.5   1.2  
BAC 0.5-0.79 2 2.9 2.2 2.7 
BAC 0.8-0.99 1.7    
BAC 0.8-1.3  6.3 2.5 8.1 
BAC 1.0-1.49 6.5    
BAC 1.5-1.99 7.4    
BAC ≥2.00 10.6    
BAC >1.3  29 12.7 17.2 
Amphetamines 
Alone 
3.0 2.6 (1.4-4.9) 
0.9 










6.0 7.6 (5.3-10.9) 
1.5 




2.0 0.6 (0.2-2.1) 
0.0 




8.5 7.3 (5.0-10.5) 
1.5 
3.6 0.0 (0.0-2.0) 
Z-drugs 
Alone 
- 1.8 (0.8-3.8) 
0.9 




5.5 3.3 (1.9-5.7) 
1.8 
- 0.5 (0.0-2.9) 
0.5 
Opiates (medicinal & illicit) 7.5 - 0.5 - 
Alcohol-Drug combination - 13.2 (10.0-17.2) 8.3b 4.3 (2.2-8.2) 
Drug-Drug combination 4.3 2.5 (1.3-4.7) 7.2 0.5 (0.0-2.9) 
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4.4. Discussion 
4.4.1. Comparison with previous studies  
Only two studies on the prevalence of alcohol and drugs in injured drivers 
could be identified in Belgium: the study of Schepens et al. and the Belgian 
Toxicology and Trauma study (BTTS), carried out in 1994-1995 & 1995-1996 
respectively. In the Netherlands two studies were found that were carried 
out in 2005: the study that was part of the bigger IMMORTAL project 
(Assum et al., 2005) and a study by Smink and colleagues (Smink et al., 2005). 
 
When comparing the findings of present studies with the prevalence found 
in previous studies one should consider that there are differences with 
regard to the substances included in the different substance groups. For 
example in the DRUID project a division was made between the illicit (6-
acetylmorphine) and the medicinal opiates (e.g. morphine, codeine, and 
methadone). In the IMMORTAL study the opiates group consisted of 
morphine, heroin and codeine and in the BTTS morphine, heroin and 
prescribed opiates. Secondly there are also differences with regard to the 
sample (blood, urine, serum) that was collected and analysed (see Table 4.3). 
Finally the inclusion criteria were not the same (e.g. type of vehicle, age of 
the drivers, MAIS and time period of data collection). Keeping in mind these 
limitations, a direct comparison of the results found in present study with 
those from previous research becomes difficult. In order to avoid 
misinterpretation of the findings, the limitations of every comparison are 
mentioned. 
 
For the Netherlands the highest prevalence of alcohol and drugs was found 
in the Smink study (Smink et al., 2005). We will not compare our findings 
with this study, because it studied only drivers who were suspected of drug 
or alcohol use. According to the Dutch legislation it is not allowed to take a 
blood sample without suspicion of alcohol or drug use (e.g. symptoms of 
drug use observed during medical examination), hence the high number of 
positives for alcohol >0.5 g/L found.  
 
The results from the DRUID study and the IMMORTAL study are more 
similar (see Table 4.3). A limitation of both the Dutch DRUID and the 
IMMORTAL study was the small sample size (184 and 186 respectively). 
Therefore, as the authors recognise, the small number of collected samples 
make more profound analyses impossible. While the sample size and the 
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driver characteristics (only car and vans; about 80% male drivers) are quite 
similar in these two studies, in IMMORTAL a third of the results were based 
on analysis of urine.  
A higher percentage of the IMMORTAL driver population tested positive for 
one or more substances (44.6%) compared to the DRUID study (33.9%). 
About 17% of the injured drivers in the IMMORTAL study tested positive for 
alcohol ≥0.5g/L (alone or combined with other substances) compared to 28% 
in the DRUID study. More than 10% of the drivers in both studies had a 
BAC≥1.3g/L (IMM: 12.7%; DRUID: 17.2%). Approximately 3% of the injured 
drivers in the IMMORTAL study tested positive for THC and 
benzodiazepines, while in the DRUID study no benzodiazepines and only 1 
case of THC were found. In the IMMORTAL study the screening on THC 
and benzodiazepines was performed on urine in one third of the cases, and 
in DRUID screening of all samples was on whole blood. This may give also 
an overestimation of the prevalence of THC and benzodiazepines found in 
the IMMORTAL study. Secondly, the screening for benzodiazepines was 
wider in the IMMORTAL study (16 benzodiazepines) than in the DRUID 
study (8 benzodiazepines), which makes it more likely to find 
benzodiazepines in the blood of the injured drivers included in the 
IMMORTAL study. When calculating the prevalence of THC and/or 
THCCOOH in the present DRUID study for the Netherlands, 2.0% 
prevalence was found (in Belgium: 9.9%). Almost no drug-drug 
combinations were found among the injured drivers in the DRUID study, 
which was a bit surprising since these were detected more frequently than 
single drugs in the IMMORTAL study, but this could also be explained by 
the testing of urine samples. Also the prevalence of alcohol-drug 
combinations was higher in the IMMORTAL study (8.3%, alcohol > 0.2 g/L) 
compared to the DRUID study (4.3%).  
 
In general, the prevalence of drugs reported in the DRUID project was much 
lower than the prevalence reported in the IMMORTAL study. The 
differences could be explained by the difference in the biological matrix 
(IMMORTAL) (urine in one third of the IMMORTAL cases and whole blood 
in DRUID) or the (number of) substances screened for (e.g. differences in 
benzodiazepines /amphetamines). 
 
In Belgium, the BTTS study collected data about drivers of motor vehicles 
and bicycles, aged more than 14 years, involved in traffic accidents that led at 
least to 24-hour hospitalisation. In the BTTS toxicological analyses were 
performed on blood and urine samples taken from injured drivers admitted 
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to the same 5 hospitals selected in the present project. When comparing the 
DRUID and BTTS, one should keep in mind that in the BTTS urine was the 
matrix for drug testing (except for benzodiazepines) while blood was 
analysed in DRUID. No significant difference in gender distributions was 
found in both studies. Regarding time period distribution, there were fewer 
weekday accidents in DRUID. 
In the toxicological analyses, alcohol remains the most common finding. The 
percentage of BAC above 0.5 g/L was 28.2% in the BTTS and 38.2% in the 
present study. When taking into account only the prevalence among drivers 
of a car about 34.0% of the drivers in the BTTS was found positive for 
alcohol. This prevalence is similar to the one found in the DRUID study. The 
THC prevalence is lower in the BTTS (BTTS: 6.0%; DRUID: 7.6%). Cocaine 
prevalence appears also to be higher in the DRUID sample (2.3%) compared 
to the BTTS findings (0.7%), while the prevalence of amphetamines (BTTS: 
3.0%; DRUID: 2.6%), benzodiazepines (BTTS: 8.5%; DRUID: 7.3%) and 
medicinal opioids (BTTS: 5.5%; DRUID: 3.3%) was lower. A small difference 
was found with regard to the drug-drug combinations. In the BTTS 4.3% of 
the drivers were found positive for two or more drugs (amphetamines, 
benzodiazepines, barbiturates, cannabis, cocaine, opiates, methadone or 
propoxyphene), compared to only 2.5 % in the DRUID study. Because urine 
was analysed, it is possible that a certain number of drivers were found 
positive in the BTTS because they had taken drugs several days before the 
accident. If the analysis in the BTTS would have been performed on blood 
the number of injured drivers positive for drugs would probably be even 
lower.  
 
The second study performed in Belgium included all injured weekend 
drivers (N= 211) admitted to the emergency units in Antwerp from July 1994-
June 1995. Comparing our findings with those from the Schepens study is 
delicate due to great differences in study design (urine samples were tested 
for (il)legal drugs instead of blood; only weekend drivers). In general, about 
half of the injured drivers included in both studies were found positive and a 
similar prevalence of alcohol was found in the Schepens et al. study (BAC 
≥0.5g/L: 35.5%) and the DRUID study (BAC≥0.5 g/L: 38.2%). 
4.4.2. Comparison of Belgium and the Netherlands 
The Netherlands is a larger country than Belgium (BE: 30500 km2; NL: 41500 
km2 and with more inhabitants (NL: 16.485.787; BE: 10.750.000) but with 
fewer traffic accidents involving personal injury (in 2009 NL: 19.378 
compared to BE: 40.700 and in 2010: BE: 729 killed drivers and 45369 injured 
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drivers; NL: 640 killed drivers; 17.000 injured drivers) and a lower 
prevalence of alcohol and drugs in the general driving population (Belgisch 
Instituut voor de Verkeersveiligheid, 2011; European Commission, 2011; 
Stichting Wetenschappelijk Onderzoek Verkeersveiligheid, 2010). It should 
be stated that in the past few years a decrease of the number of killed and 
injured drivers was observed in both countries. The higher alcohol 
enforcement in both countries (more alcohol tests and hours spent by the 
police on testing) could be one of the explanations. Secondly, in Belgium a 
per se legislation for illicit drugs is applied: in case a defined cut-off value of 
a substance concentration in the blood sample of the driver is exceeded s/he 
will be prosecuted. 
 
Fewer drivers were found positive in the Netherlands compared with 
Belgium. This is a remarkable finding since the sample of drivers in the 
Netherlands is younger (33% below 24 years compared to 23% in BE) and 
included more men (80%) than in Belgium (54%). Thirdly, more single-
vehicle accidents were registered in the Dutch study (63%, versus 49% in BE). 
A higher prevalence is expected since studies showed that these groups 
(young males and single vehicle accidents) are more likely to test positive 
(Bogstrand et al., 2011; Longo et al., 2000; Palmentier et al., 2009; Ricci et al., 
2008).  
 
Alcohol was the most common finding in both countries. In the present 
study about 10% more drivers tested positive for alcohol (≥0.1 and ≥0.5 g/L) 
in Belgium than in the Netherlands. In contrast to the difference in alcohol 
prevalence, the distribution of alcohol concentrations is similar in both 
studies. The drivers found positive for alcohol in both studies had high blood 
alcohol concentrations (35.3 % of the Belgian drivers had a BAC ≥0.8 g/L 
compared to 25.3% of the Dutch drivers). The median blood alcohol 
concentration in the Dutch and Belgian injured driver population was about 
1.5 and 1.6 g/L respectively. 
 
The lower prevalence of alcohol found in the Dutch DRUID study could be 
the result of the higher enforcement of drink-driving legislation in the 
Netherlands. The enforcement level for alcohol (number of alcohol tests per 
100.000 inhabitants) is estimated to be 3 to 4 times lower in Belgium than it is 
in the Netherlands . However the number of alcohol tests recently increased 
in Belgium (about 750.000 alcohol tests performed in 2010). Recently, the 
Belgian government announced an increase in the numbers of alcohol tests in 
the next two years. The level of alcohol enforcement expressed in hours that 
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the police was performing alcohol testing in traffic was 250.000h in the 
Netherlands and 42.000h in Belgium (Veisten et al., 2011). 
 
In Belgium more information on the prevalence of alcohol in randomly 
selected drivers can be found in the results from the roadside surveys 
performed in the DRUID project and the studies conducted by the Belgian 
Institute for Traffic Safety where drivers were sampled during police 
controls. In the study of 2007, 2.0% of the drivers were found positive for 
alcohol (≥0.22 mg/L in alveolar air or ≥0.5 g/L in blood) and this increased up 
to 2.6% in 2009 (Belgisch Instituut voor de Verkeersveiligheid, 2010b). The 
authors of that study remark that most drivers were sampled in Flanders and 
a generalisation of the results to national level should be made cautiously. 
Secondly, the percentage of positives differed a lot during the week and 
weekend (during the weekend nights the percentage alcohol positives 
increased from 2% up to about 10%). Subjective data on the prevalence of 
alcohol and drugs in the general driving population can be found in a survey 
among drivers in traffic. About 13% of the interviewed drivers admitted to 
have been driving under the influence of alcohol and 0.75% under the 
influence of drugs, once or more in the past month (Belgisch Instituut voor 
de Verkeersveiligheid, 2010a).  
Recent findings from the roadside surveys performed in the DRUID project 
confirm these results found in both countries (Isalberti et al., 2011). 
Participants in these roadside surveys were randomly selected drivers from 
moving traffic in 6 Dutch and 5 Belgian police regions from January 2007 to 
August 2009. About 5000 Dutch drivers and 3000 Belgian drivers were 
randomly selected from general traffic. Single alcohol use (>0.1 g/L) was the 
most prevalent substance in both countries. The prevalence of single alcohol 
use in Belgian traffic (≥0.1 g/L) (6.4%) is significantly higher (p = <0.001) than 
in Dutch traffic (2.2%). About 2.2% of the Belgian drivers were found positive 
for a BAC ≥ 0.5g/L compared to 0.6% of the Dutch drivers. In general the 
alcohol prevalence in Belgium was at least twice as high as in the 
Netherlands. In the roadside study of the IMMORTAL project 2.1% of the 
sampled drivers were found positive for alcohol (BAC≥0.2 g/L). The alcohol 
prevalence (BAC ≥0.5g/L) found in the Belgian DRUID study was also higher 
than the prevalence found in previous studies.  
 
A surprising finding is the lack of benzodiazepines (0%) or illicit opiates 
(0%) found in the Netherlands. An explanation for these differences in 
prevalence may be found when comparing the prevalence of 
benzodiazepines found in the injured driving population (hospital studies) 
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with the prevalence found in the general driving population (roadside 
surveys also performed within the DRUID project). We found that 
benzodiazepines were less prevalent in the general driving population in the 
Netherlands (0.44%) compared to Belgium (2.28%). Secondly 
benzodiazepines much more consumed in Belgium than in the Netherlands 
(see Figure 4.1). Consequently it is likely to find fewer injured drivers 




































Figure 4.1. Comparison of the distribution of drivers positive for medicinal drugs in 
the injured driving population and in the general driving population (Roadside 
survey) in Belgium and The Netherlands. 
Another possible explanation for a lower prevalence of benzodiazepines in 
injured drivers in the Netherlands could be the introduction of a recent law 
(1 January 2009) that reduced the reimbursement by the health insurance of 
the costs of a prescription for benzodiazepines. Six months after the new law 
the use of benzodiazepines (expressed in defined daily doses) already 
decreased with about 17.5% (Stichting Farmaceutische Kengetallen, 2009a, 
2009b). This negative trend was also measured in the first months of 2010 
(Stichting Farmaceutische Kengetallen, 2009a). Secondly, more physicians 
prescribe SSRI’S (Selective Serotonin Reuptake Inhibitors) and Z-drugs 
instead of benzodiazepines (Bakker et al., 2002; Kwaliteitsinstituut voor de 
Gezondheidszorg CBO, 2009). The recent decrease in price of SSRI’s 
supported this trend (Stichting Farmaceutische Kengetallen, 2009c, 2010). 
Another explanation could lay in the sample characteristics. A Belgian study 
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showed that benzodiazepines use is higher among older respondents and 
also more common in women (Pelfrene et al., 2004). The same results were 
found in Dutch studies (Groenewegen et al., 1999; Van Rijswijk et al., 2000). 
More men and young drivers were injured in an accident in the Netherlands 
than in Belgium. Furthermore, the high prevalence of benzodiazepines in 
Belgium was expected. Despite the slight decrease in use of benzodiazepines 
in Belgium, the fact is that Belgium still has one of the highest 
benzodiazepines consumptions in Europe (Borrenbergen, 2011; Rijksinstituut 
voor ziekte- en invaliditeitsverzekering. Dienst voor geneeskundige 
verzorging. Wetenschappelijke raad, 2008; Van der Heyden, 2009). Finally it 
should be mentioned that in the DRUID study the blood samples were only 
screened for a limited list of benzodiapines. It may be possible that drivers 
were using other benzodiazepines than those screened for within the DRUID 
project. 
 
The prevalence of illicit drugs and THC in severely injured drivers in the 
Netherlands was also low. Only one driver was found positive for THC 
(0.5%) compared to the 3.4% found in the IMMORTAL study. Again the THC 
prevalence found in the injured driving population can be compared to the 
prevalence found in the general driving population (see Figure 4.2). 
Surprisingly a much higher THC prevalence was found in the injured 
driving population in Belgium (7.6%) compared to the Netherlands (0.5%), 
while a higher THC prevalence in the general driving population was found 







































Figure 4.2. Comparison of the distribution of drivers positive for illicit drugs in the 
injured driving population and in the general driving population (Roadside survey) in 
Belgium and the Netherlands. 
One would expect a higher prevalence of THC in the Netherlands since a 
strong association was found between the availability of drugs (the coffee 
shops) and the prevalence of use. Several studies tried to link the Dutch 
enforcement and legal system (‘the coffee shop system’) to the prevalence of 
use of cannabis in the Netherlands. Findings showed that by facilitating 
relatively easy access to cannabis, the Dutch youth are more likely to have 
used frequently, and are more likely to start using cannabis early (before age 
13), compared to their European neighbors (MacCoun, 2011). Secondly the 
lifetime prevalence of cannabis use is much higher among male than female 
subjects. Since more young male drivers were sampled in the Dutch study, 
again, a higher prevalence of cannabis is expected (Degenhardt et al., 2008; 
Kuntsche et al., 2009; Ter Boght et al., 2006). Thirdly research showed that 
about one third of the Dutch drivers stated to drive even after using cannabis 
on the same day (Roomer and Akouele, 2006). 
 
A possible explanation for the difference in THC prevalence between the 
Belgian and the Dutch DRUID studies could be differences between the 
laboratories in both countries. However, the same matrix (whole blood) and 
cut-offs where used and four rounds of proficiency testing were organised in 
both during the study. Since the time between accident and sampling is less 
than three hours in both studies and the median interval was 1.55 h (BE) and 
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1.35 h (NL), no difference is expected. Furthermore it can be mentioned that 
some Dutch injured drivers were found positive for the metabolite THC-
COOH. The presence of THC-COOH indicates past use of cannabis. When 
calculating the prevalence of THC and/or THC-COOH 1.6% of the Dutch 
drivers were found positive compared to the 0.5% drivers found positive for 
THC. Finally, given the low number of included subjects the confidence 
intervals give a more accurate prevalence (0.0-2.9%) 
 
A limitation of the DRUID study was that the Dutch data collected in three 
hospitals covered only the South and Eastern part of the Netherlands. 
However when comparing the prevalence of alcohol and drugs in the study 
population with those in general traffic, no differences were found. 
Consequently, no bias is expected. The Belgian data were grouped under the 
three Belgian regions (Brussels, Flanders and Wallonia) and collected in the 
same five hospitals as the data from the BTTS. About 81% of the drivers was 
sampled in Flanders compared to 60% in the BTTS. Despite a prolongation of 
the initial period of sample collection and an extra incentive when collecting 
more than 200 samples, the number of samples collected in Brussels (3%) and 
Wallonia (16%) stayed low. The BTTS reported the same problems with 
regard to sample collection in Brussels and Wallonia. Finally, it should also 
be kept in mind that in the DRUID study analyses were performed on only 
23 target analytes, while in the BTTS a much broader screening (e.g. all 
benzodiazepines) was performed. 
4.5. Conclusion 
Only two studies on the prevalence of alcohol and drugs in injured drivers in 
Belgium and the Netherlands could be identified in each country. 
Comparing the prevalence of alcohol and drugs found in present and 
previous studies was difficult due to differences in matrix collected 
(blood/urine/serum), toxicological analyses (methods used and substances 
screened for), study design (e.g. time between accident and sampling), as 
well as inclusion criteria handled (age, time period, MAIS, type of vehicle). 
To overcome this comparability problem a uniform study design was used in 
the DRUID study. The DRUID study provides besides comparable data also 
recent data on the prevalence of alcohol, illicit and medicinal drugs in 
Belgium and the Netherlands. The prevalence of alcohol in DRUID was 
higher than in the comparable studies (BTTS and IMMORTAL) in the past. 
This does not necessarily mean a worsening of the problem of driving under 
 92 
the influence of alcohol in the last 10 or 15 years, as it is possible that the 
absolute number of alcohol-related crashes has decreased.  
 
Keeping the differences in study design in mind some overall conclusion can 
be drawn regarding the prevalence of alcohol and drugs in Belgium and the 
Netherlands. In general some deviations in prevalence are found when 
comparing the DRUID results in the Netherlands with previous surveys (no 
benzodiazepines, low THC and drug-drug combinations). These differences 
could be explained by differences in (DRUID) enforcement level, drug 
driving legislation and enforcement, prescription policies (benzodiazepines), 
cultural differences and uncertainty of the data due to a small sample size. 
The results from the Belgian DRUID study are more similar to the results 
from previous studies, especially the prevalence of the illicit drugs where no 
increase of prevalence of illicit drugs or medical drugs is observed in the 
period between 1998 and 2010. However, in the same period an increase of 
the prevalence of alcohol was found (BTTS: 34.0% only car drivers; DRUID: 
38.2%). 
 
In the present study a higher prevalence of alcohol and drugs in seriously 
injured drivers was found in Belgium compared to the Netherlands. Alcohol 
was the most prevalent finding in both studies. The distribution of blood 
alcohol concentrations in the Dutch and Belgian study was similar with very 
high blood alcohol concentrations in both and a similar median blood alcohol 
concentration (about 1.6 g/L). The lower prevalence of alcohol in the 
Netherlands is associated with a much lower number of crashes and killed 
and injured drivers (compared to the Netherlands, Belgium has 3.2 times 
more crashes involving injuries, 4.1 times more injured and 1.7 times more 
fatally injured people). 
 
One notable finding is the low prevalence of THC and benzodiazepines in 
the Dutch injured driver population. Despite the high prevalence of THC 
found in the general driving population surprisingly almost no THC was 
found in the Dutch injured driver population. The one Dutch driver found 
positive for THC had a very high THC concentration (about 19 ng/mL). In 
addition no benzodiazepines were found in the Dutch injured drivers. This 
could be expected since a low prevalence was found in the general driving 
population (Belgium had a prevalence of about five times higher than the 
Netherlands). For the other illicit drugs (amphetamines, cocaine and illicit 
opiates) and medicinal drugs (z-drugs and medicinal opioids) no larger 
differences were observed. 
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When looking for explanations for the differences in prevalence found above 
different aspects such as differences in alcohol enforcement between the 
countries, differences in sample collection and consumption patterns should 
be kept in mind. 
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5. Repeatability of oral fluid collection methods 
for THC measurement12 
5.1. Introduction 
Cannabis is the most frequently used illicit drug in traffic (Houwing et al., 
2011; Lacey et al., 2009; Mallick et al., 2007). A recently conducted European 
study among injured and killed drivers in nine different European countries 
showed that THC, which is the active substance of cannabis, was detected in 
up to 7.6% of injured and 6.1% of killed drivers (Isalberti et al., 2011). In 
many countries, driving under the influence of THC is considered as illegal 
in the national Road Traffic Act (EMCDDA, 2007).  
The confirmation of cannabis use in traffic is mainly based on analysis of 
blood, although in some countries (e.g. Australia and Belgium) oral fluid is 
used as a standard (Lillsunde and Gunnar, 2005; Verstraete et al., 2011a). For 
screening purposes, however, oral fluid is used more often because blood 
sampling is invasive and expensive. Oral fluid sampling is regarded as a less 
invasive and cheaper alternative for blood sampling when screening drivers 
for drug use in traffic (Bosker and Huestis, 2009; Huestis and Cone, 2004; 
Niedbala et al., 2001; Toennes et al., 2005; Verstraete, 2004).  
The practical benefits of oral fluid collection compared to the collection of 
blood stimulate the discussion on the usability of oral fluid for confirmation 
analysis. However, the question can be raised how reliable oral fluid results 
are for determining specific ’per se’ concentrations of THC. The weak 
relationship between oral fluid and blood/serum concentrations for THC has 
been demonstrated in several studies (Gjerde et al., 2010a; Kauert et al., 2006; 
Kauert et al., 2007; Milman et al., 2011; Wille et al., 2009). The most 
commonly mentioned reason in literature is that oral fluid concentrations of 
THC are not necessarily based on the transfer from blood to oral fluid, but 
that they are merely the result of contamination of oral fluid by THC 
deposition on membranes and debris that are left in oral cavities (Bosker and 
Huestis, 2009; Drummer, 2008). Furthermore, it is well known in literature 
(Crouch, 2005; Drummer, 2008; O'Neal et al., 2000; Verstraete et al., 2011a) 
                                                 
 
12 This chapter is accepted for publication as the following article: Houwing, S., Smink, B.E., 
Legrand, S.-A., Mathijssen, M.P.M., Verstraete, A. G. & Brookhuis, K.A. Repeatability of oral 
fluid collection methods for THC measurement. This article is published in Forensic Science 
International (FSI) 2012; 223 (1-3) 266-272. 
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that the results of oral fluid drug testing can also be affected by the sampling 
method and the collection devices. O’Neal et al. (2000) found that on average 
codeine concentrations in specimens collected by spitting were 3.6 times 
higher than concentrations collected by acidic stimulation and 1.3 to 2.0 times 
higher than concentrations collected by nonacidic stimulation. These results 
are in line with a recently published study of Verstraete et al. (2011a) in 
which a factor of 1.5 was found for THC between nonacidic and acidic 
stimulation and a factor of 1.3 for codeine. Factors for five other substances 
ranged from 1.3 to 2.7. 
One issue that to our knowledge has only been reported once is the 
repeatability of THC concentrations in oral fluid in samples obtained by the 
same collection method. Repeatability tells something about the precision of 
a method. It means that under the same conditions, a second test by the same 
collection method should lead to the same results. If the repeatability of a 
method is low, the method could be regarded as not precise enough to be 
used. The study of Niedbala et al (2001) compared Intercept® oral fluid test 
results of simultaneously obtained samples from visitors of a coffee shop.  
In our present study we assessed the correlation between THC 
concentrations of two subsequently collected oral fluid samples for two 
different sampling methods. Furthermore, we compared THC concentrations 
collected by both methods. 
Additionally we evaluated the measurements of the sampling devices with 
respect to the Belgian legal limit for THC in traffic (10 ng/mL in oral fluid). In 
the Netherlands, confirmation analysis is based on blood samples. Therefore, 
no qualitative evaluation was possible for the Dutch legislation. 
5.2.  Materials and methods 
5.2.1. Location and subjects 
All oral fluid samples were collected in a so-called ‘coffee shop’ in 
Doetinchem (the Netherlands). In the Netherlands a coffee shop is a type of 
bar where selling and using soft drugs for personal consumption is tolerated. 
In the ‘coffee shop’ that participated in our study a special room was 
reserved for the collection of the samples. This room was separated from the 
area of the coffee shop in which the cannabis was actually smoked in order to 
decrease the possibility of contamination by air. Two adjacent windows were 
opened during the study to ventilate the room that was approximately 55m3. 
According to Niedbala et al. (2005), the risk of contamination of the collection 
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devices by polluted air would most likely be eliminated when using a 
separated room with open windows. 
Customers of the coffee shop were invited to participate by means of posters 
that were placed in the smoking area of the coffee shop. Each participant 
received an incentive of five euro. 
5.2.2. Sample collection 
Two methods were used to collect oral fluid samples. The first collection 
method was by using the Statsure Saliva samplerTM (Saliva Diagnostic 
Systems, Framingham, MA). This device was used in the European DRUID 
project (Driving Under the Influence of Drugs, Alcohol and Medicines) in 
Belgium and ten other countries for collecting oral fluid samples from the 
general driving population (Houwing et al., 2011). The Statsure sampling 
pad is made of cellulose and is not treated with chemicals stimulating the 
production of saliva. Oral fluid is gathered by placing the collection pad 
under the tongue. The indicator of the device turns completely blue when a 
sufficient amount of oral fluid is collected. The Statsure device contains 1.0 
mL of buffer fluid which is added to the oral fluid. The second collection 
method was by spitting into a polypropylene tube (Deltalab, Spain).  
After collection, oral fluid samples were stored in solid carbon dioxide at 
about -80˚C (dry ice). After transportation to the Netherlands Forensic 
Institute (NFI) in The Hague, oral fluid samples were stored at -20˚C until 
analysis. The Statsure samples were transported on dry ice from the NFI to 
the toxicological laboratory in Ghent for analysis, while the spit tube samples 
remained for analysis at the NFI. 
5.2.3. Sample preparation and analysis 
The concentration of the oral fluid samples collected by the Statsure device 
needed to be corrected since the expected sample of oral fluid is 
approximately 1.0 mL, but in practice the volume varies considerably. 
Therefore, the collected volumes of oral fluid were determined for each 
sample by weighting using the following correction formula, under the 
assumption that the volume of buffer in the device is constant (1 mL), where 











The UPLC-MS/MS method for the analysis of the samples obtained with 
Statsure has been described by Goessaert et al. (2010).  
The first step in sample preparation of the spit tubes was defrosting the oral 
fluid samples. Next, the concentration of THC in oral fluid samples collected 
by spitting into a polypropylene tube was determined after protein 
precipitation followed by centrifugation, by LC-MS-MS on a Water Acquity 
UPLC®-system with a Waters Quattro premier XE triple quadrupole mass 
spectrometer. Chromatography employed a reversed-phase UPLC® column 
(BEH C-18, 100 x 2.1-mm i.d., 1.7 µm particle diameter) and a 17-min 
gradient elution (methanol / 10 mM ammonium bicarbonate pH 10.0, 5/95 to 
95/5). Injection volume was 10 µL. The eluent was introduced to the 
electrospray source of the triple quadrupole MS instrument at a flow-rate of 
500 µL/min. Molecular ions were fragmented using an optimized collision-
induced dissociation voltages for each compound (positive ion mode). Parent 
ions (m/z 315.3 for THC and m/z 318.3 for Delta 9-THC-d3) and product ions 
(m/z 193.2 and 259.5 for THC and m/z 196.2 for Delta 9-THC-d3) were 
detected after collision.  
5.2.4. Method validation 
The linear range for the assay was 1 - 200 ng/mL for THC. The lowest 
concentration of the calibration curve was considered as the limit of 
quantification (LOQ). The limit of detection was 0.8 ng/mL for THC. No 
interfering compounds were present in blank oral fluid samples. The within-
day precision was determined on two concentration levels by repeated 
analysis (n=10) and was < 15 %. The between-day reproducibility was 
determined at two concentration levels by analysis on different days (n=4) 
and was < 15%. However, calibration curves were included in each analytical 
run. 
The method validation results of the analytical method used for the 
quantification of THC in Statsure samples have been given in Goessaert et al. 
(2010). Briefly, the extraction recovery was 53%, LOQ was 1 ng/mL, the 
imprecision 8.8% and the inaccuracy – 3.9%. 
5.2.5. Statistical analysis 
The quantitative analysis procedure is based on visual inspection of data 
patterns using a Bland-Altman plot, as described in Bland and Altman (1986) 
and Hanneman (2008). The Bland-Altman plot consists of the average of the 
paired values on the x-axis and the difference between the paired values on 
the y-axis. Correlation measures cannot be used when comparing two 
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samples from one method since a correlation coefficient gives an analysis of 
the deviation from a line with any slope, but for this purpose we want to 
measure the deviation from a line with a slope of exactly 45 degrees. 
Mean value, bias from the mean, standard deviation of the difference, limits 
of agreement, and proportion error are reported together with the plot. The 
limits of agreements are drawn by using a 95% confidence interval. This 
confidence interval is calculated by the average difference plus or minus two 
times the standard deviation of the average difference. The proportional 
error can be established by dividing the limits of agreement by the mean 
value of the measurements obtained with the established method. 
In principle, simultaneous collection would be the best method to gather the 
oral fluid samples. However, this was not possible since the collection of two 
spit samples at once or a spit sample while collecting oral fluid by means of 
the Statsure device was very difficult. Therefore, all samples have been 
collected in sequence. Since the THC concentration in oral fluid was not 
likely to change a lot due to elimination between the collection of the first 
and second sample, this sequential method was regarded as acceptable by 
the authors. In those pairs with both a spitting sample and a Statsure sample, 
the order of the samples varied. In pairs that contained two samples from the 
same collection method, sample number one was always collected before 
sample number two. 
No error margin is determined at present for the Belgian legal limit. In this 
study we will regard a 30% margin as the acceptable error, based on the 
measurement uncertainty currently used in the Swiss legislation (Senna et al., 
2010).  
For statistical analysis of qualitative results (positive or negative according to 
the Belgium legislation), Cohen’s Kappa was used to determine consistency 
between the two samples. The Kappa statistic is normally performed to 
determine consistency among raters. In this study for each pair the first 
bivariate result was compared with the second bivariate result. The Kappa 
score was interpreted by using a scoring list published by Landis and Koch 
(1977), in which 0-20% reflects a slight agreement, 21-40% a fair agreement, 
41-60% a moderate agreement, 61-80% a substantial agreement and 81-100% 
an almost perfect agreement. 
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5.3. Results  
5.3.1. Comparison of the sample concentrations 
In total 117 sets of oral fluid samples were collected. The major part of the 
included sets consisted of two samples, but seven sets consisted of three 
samples and one set consisted of four samples. In order to analyze 
comparable pairs for the Statsure each set of three samples, e.g. a set with the 
samples X1, Y1, Y2, was divided into three sets of two samples: (X1, Y1), (X1, 
Y2), and (Y1, Y2). The remaining set of four samples was divided into 6 pairs 
based on the same principle. The conversion of the sets into unique pairs led 
to a total of 136 pairs, divided into three groups for analysis: 28 pairs of 
Statsure samples, 47 pairs of spit tube samples , and 61 pairs with one 
Statsure and one spit tube sample. 
 
Table 5.1 shows the distribution of THC concentrations for each collection 
method. THC concentrations varied from 0 to 12,063 ng/mL for the spit tube 
samples and from 0 to 5,446 ng/mL for the Statsure samples.  
Eight Statsure pairs, five spit tube pairs, and two combined pairs consisted of 
negative samples only. The inclusion of negative pairs in the sample could 
influence the results if one of the methods would have more negative 
samples, since an exact agreement in THC values is easier to achieve in 
negative samples than in positive samples. For this reason, all negative pairs 
and the pairs with outliers were removed from the dataset before analysis on 
repeatability, which led to an inclusion of twenty Statsure pairs, forty-two 
spit tube pairs and fifty-nine combined pairs. 
The median THC concentration for the first and second sample of the twenty 
Statsure pairs did not differ (p < 0.911) between the first sample and the 
second sample (50.4 and 69.3 ng/mL, respectively). Moreover, the highest 
concentration samples was almost evenly distributed over the first and 
second samples of the twenty pairs: eleven and nine, respectively.  
The median THC concentration of the forty-two spitting samples that were 
taken first did not differ (p < 0.48) from the median of the samples that were 
taken second (135.5 and 70.1 ng/mL, respectively). Furthermore, the highest 
samples were almost evenly divided between the first and second samples: 
twenty-two and twenty, respectively.  
Among the fifty-nine THC positive pairs consisting of both a Statsure and a 
spitting sample the median THC concentration of the Statsure samples (58.3 
ng/mL) was lower (p < 0.001) than the median of the spitting samples (206.5 
ng/mL). 
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1 394.8 n.a. 2417.4 n.a.  33 1.8 0.9 n.a. n.a. 
2 352.8 n.a. 1373.8 n.a.  34 4.8 0.0 n.a. n.a. 
3 137.3 n.a. 330.8 n.a.  35 0.0 0.0 n.a. n.a. 
4 11.8 n.a. 119.3 n.a.  36 41.6 89.2 n.a. n.a. 
5 0.0 n.a. 0.0 n.a.  37 22.7 17.9 n.a. n.a. 
6 1328.2 n.a. 2443.9 n.a.  38 5446.3 1412.0 n.a. n.a. 
7 44.8 n.a. 718.7 n.a.  39 13.4 16.5 n.a. n.a. 
8 108.1 n.a. 4178.7 n.a.  40 0.0 0.0 n.a. n.a. 
9 16.7 n.a. 55.5 n.a.  41 285.0 301.7 n.a. n.a. 
10 3.5 n.a. 1.3 n.a.  42 0.0 15.2 n.a. n.a. 
11 2.4 n.a. 0.0 n.a.  43 0.0 0.0 n.a. n.a. 
12 89.0 n.a. 161 n.a.  44 0.0 0.0 n.a. n.a. 
13 12.7 n.a. 25 n.a.  45 85.3 63.0 n.a. n.a. 
14 1154.6 n.a. 12063.2 n.a.  46 59.1 84.2 n.a. n.a. 
15 281.4 n.a. 92.4 n.a.  47 84.9 75.5 n.a. n.a. 
16 94.3 n.a. 29.3 n.a.  48 12.2 3.1 n.a. n.a. 
17 306.7 n.a. 281.7 n.a.  49 0.0 0.0 n.a. n.a. 
18 456.1 n.a. 631.3 n.a.  50 0.0 0.0 n.a. n.a. 
19 8.6 n.a. 22.9 n.a.  51 0.0 0.0 n.a. n.a. 
20 1101.9 n.a. 206.5 n.a.  52 340.2 390.7 n.a. n.a. 
21 608.7 n.a. 1861.6 n.a.  53 0.0 0.0 n.a. n.a. 
22 0.0 n.a. 0.0 n.a.  54 174.2 84.2 n.a. n.a. 
23 17.6 n.a. 91.3 248.2  55 798.7 443.9 n.a. n.a. 
24 19.1 n.a. 6.2 72.3  56 9.2 15.6 n.a. n.a. 
25 532.5 n.a. 11119 75.3  57 130.5 202.1 n.a. n.a. 
26 130.9 n.a. 667 31.7  58 884.4 n.a. 1174.0 n.a. 
27 131.8 n.a. 6230.9 429  59 604.6 n.a. 3099.0 n.a. 
28 41.6 n.a. 2683.3 3886.6  60 7.8 n.a. 177.0 n.a. 
29 32.7 4.5 219.4 0.0  61 155.7 n.a. 1107.0 n.a. 
30 29.4 n.a. 62.6 26.1  62 58.3 n.a. 21.0 n.a. 
31 253.3 566.7 n.a. n.a.  63 134.9 n.a. 1716.0 n.a. 
32 37.6 32.9 n.a. n.a.  64 186.2 n.a. 842.0 n.a. 
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65 18.1 n.a. 15.0 n.a. 92 n.a. n.a. 30.7 22.5 
66 1.4 n.a. 22.0 n.a. 93 n.a. n.a. 3764.4 998.5 
67 6.7 n.a. 32.0 n.a. 94 n.a. n.a. 0.0 10.7 
68 26.6 n.a. 53.0 n.a. 95 n.a. n.a. 215.2 121.5 
69 80.2 n.a. 89.0 n.a. 96 n.a. n.a. 0.0 0.0 
70 150.1 n.a. 333.0 n.a. 97 n.a. n.a. 804.2 48.1 
71 32.7 n.a. 172.0 n.a. 98 n.a. n.a. 425.6 774.8 
72 38.7 n.a. 1432.0 n.a. 99 n.a. n.a. 4355.8 4622.3 
73 72.5 n.a. 1928.0 n.a. 100 n.a. n.a. 107.1 409.4 
74 26.0 n.a. 72.0 n.a. 101 n.a. n.a. 185 139.8 
75 408.4 n.a. 3636.0 n.a. 102 n.a. n.a. 0.0 0.0 
76 0.0 n.a. 7.0 n.a. 103 n.a. n.a. 0.0 14.3 
77 493.3 n.a. 498.0 n.a. 104 n.a. n.a. 0.0 0.0 
78 8.0 n.a. 0.0 n.a. 105 n.a. n.a. 587.9 75.9 
79 n.a. n.a. 3318.6 2650.3 106 n.a. n.a. 325.5 201.7 
80 n.a. n.a. 3355.7 22.2 107 n.a. n.a. 288.8 981.1 
81 n.a. n.a. 89.7 15.7 108 n.a. n.a. 998.5 6991.7 
82 n.a. n.a. 197.2 7.2 109 n.a. n.a. 0.0 8.4 
83 n.a. n.a. 152.8 398 110 n.a. n.a. 0.0 69.9 
84 n.a. n.a. 65.6 0.0 111 n.a. n.a. 10.5 307.2 
85 n.a. n.a. 0.0 14.4 112 n.a. n.a. 81.8 188.1 
86 n.a. n.a. 0.0 0.0 113 n.a. n.a. 0.0 0.0 
87 n.a. n.a. 5.4 0.0 114 n.a. n.a. 118.2 99.7 
88 n.a. n.a. 6.3 4.8 115 n.a. n.a. 266.6 203.2 
89 n.a. n.a. 0.0 8.9 116 n.a. n.a. 0.0 6.9 
90 n.a. n.a. 189.5 8.5 117 n.a. n.a. 18.6 29.3 
91 n.a. n.a. 7.2 15.3      
 
The mean THC concentration was also much lower (p < 0.01) for the Statsure 
samples (200.0 ng/mL) than for the samples that were obtained by spitting 
(1178.1 ng/mL). The observed average ratio between the spit tube and the 
Statsure samples increased at higher concentrations. The ratio for pairs 
which only contained THC concentrations below the linear range of 200 
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ng/ml was 1.7, for pairs which contained only THC concentrations below 
1000 ng/ml it was 1.9 and for all pairs the ratio was 5.9.  
5.3.2. Repeatability  
Figure 5.1 shows the Bland-Altman plot for both methods, together with the 
30% acceptable error margin (open line) and the limits of agreement at the 
95% confidence interval (closed line). The mean THC concentration of both 
samples in each pair is displayed on the X-axis, whereas the difference in 
THC concentrations between the first and second sample is displayed at the 
Y-axis. For both methods the results are presented using an original scale 
with back transformed limits of agreement. Due to the larger spread of the 
results at higher concentrations, a log scale was used. However, since the 
interpretation of results by log scaling is in general more difficult, the log 
scale has been transformed into a normal scale again.  
 
The average bias was -100.3 ng/mL (range -2017.1 to 156.7ng/mL) for the 
Statsure; for the spitting method it was almost the double at -200.2 ng/mL 
(range -5521.9 to 2296.6 ng/mL). The standard deviation from the mean was 
454.7 ng/mL for the Statsure and 1056.6 ng/mL for the spitting method. The 
limit of agreement was -2.0 to 2.0 times the mean for both methods. 
The Bland-Altman plot shows that for the spitting method 86% of the results 
(n=36) were outside the area between the predefined acceptable error margin 
of 30%. The results for the Statsure were relatively better but still 70% of the 




Figure 5.1. Detailed view of the Bland-Altman plot for the Statsure and spit tube 
including back transformed limits of agreement (closed line) and predefined 
acceptable error margin of 30% (open line). 
Comparison with the Niedbala et al. study 
Niedbala et al. (Niedbala et al., 2001) collected paired oral fluid samples 
simultaneously from 21 subjects in a Dutch ’coffee shop‘ by using the 
Intercept collection device following a single smoked dose (n=16), a single 
oral dose of marijuana (n=3) or after passive use (n=2). For each pair, one 
specimen was collected from the right side of the mouth and one from the 
left side. For each of the subjects several pairs were collected at different time 
frames ranging from immediately to 72 hours after smoking. In order to be 
able to compare the repeatability of the results from Niedbala et al. with the 
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results of the present study, only sample pairs were included that were 
collected after recent cannabis smoking (≤ 1 hour ago). In total 30 pairs were 
selected for analysis.  
Figure 5.2 presents a detailed view of the Bland-Altman plot for those pairs 
that had a mean THC concentration below 50 ng/mL, together with the lines 




Figure 5.2. Detailed view of the Bland-Altman plot for the consecutive collected 
samples of the Statsure and the simultaneously collected samples of the Intercept 
device (Niedbala et al., 2001) including a back transformed predefined acceptable 
error margin of 30%. 
In general the results from both methods show the same pattern with 
increasing bias at higher THC concentrations. The results from the Intercept 
device seem to show more agreement (50% (n=15) of the pairs were within 
the 30% error margin) than the results from the Statsure device (30% (n=6) 
within the 30% error margin).  
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5.3.3. Agreement rate based on qualitative results 
For the qualitative analysis all samples are compared with the legal limit for 
THC in traffic of 10 ng/mL as it is applied in the Belgian Road Traffic Act. For 
each pair of THC samples we determined whether the samples were either 
positive or negative according to the Belgian Traffic Law. No outliers were 
removed from this analysis since all results were regarded as usable for the 
qualitative analysis. Table 5.2 shows the agreement rating of Statsure pairs. 
The numbers in the cells represent the corresponding number of pairs. 
Ideally, in case there is a total agreement between the first and the second 
sample, the upper right and the lower left corner of the cells would be empty. 
Table 5.2. Agreement of Statsure pairs. 
  2nd Statsure sample 
  Negative  
(< 10 ng/mL) 
Positive  




Negative (< 10 ng/mL) 10 2 12 
Positive (≥ 10 ng/mL) 2 14 16 
Total  12 16 28 
 
The correlation between the first and second spit tube sample was found to 
be Kappa = 0.708 (p < 0.01). This correlation can be regarded as substantial, 
based on the interpretation of Landis and Koch (1977).  
In four out of 28 Statsure pairs there was no agreement on whether the result 
was above or below the legal limit for THC. For these four pairs the average 
value of the highest concentrations was 18.9 ng/mL with a range of 12.2 to 
32.7 ng/mL. 
 
Table 5.3 provides an overview of the agreement of spit tube pairs against 
the Belgian legal limit. 
Table 5.3. Agreement of spit tube pairs. 
  2nd spit tube sample 
  Negative  
(< 10 ng/mL) 
Positive 
 (≥ 10 ng/mL) 
Total 
1st spit tube 
sample 
Negative (< 10 ng/mL) 10 6 16 
Positive (≥ 10 ng/mL) 4 27 31 
Total  14 33 47 
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The correlation between the first and second spit tube sample was found to 
be Kappa = 0.511 (p < 0.01). This correlation can be regarded as moderate.  
Ten out of 47 spit tube pairs had no agreement on whether the subject would 
score above or below the legal THC limit. The average concentration of the 
highest sample from each of the ten deviant pairs was 86.9 ng/mL with a 
range of 10.7 to 219.4 ng/mL. The concentrations of the deviant pairs for the 
spitting method were considerably higher than the Belgian legal limit. 
 
The results show that the level of agreement between two consecutively 
collected oral fluid samples is relatively higher for the Statsure sampling 
method. The deviant pairs of the Statsure device were on average closer to 
the legal limit than the deviant pairs of the spit tubes. The highest THC 
concentration in the deviant sample was 22.7 ng/mL above the Belgian legal 
limit of 10 ng/mL, whereas the highest THC concentration for the deviant 
spit tube samples was 209.4 ng/mL above this legal limit.  
5.4. Discussion 
Results show that the sampling repeatability from two consecutively taken 
oral fluid samples is lower than the predefined 30% acceptable error margin, 
both for the Statsure and the spit tube collection method. However, this 
study was conducted among users who in general consumed cannabis very 
recently. Results from Niedbala et al. (9) showed higher agreement between 
two simultaneously collected samples when cannabis was consumed more 
than one hour before. For samples that were collected within one hour after 
smoking, THC results from Intercept samples seemed to be a little more in 
agreement with each other as compared to the Statsure samples. This 
difference might be explained by the simultaneous collection with the 
Intercept device versus the consecutive collection with the Statsure device. 
The variation in THC concentrations between consecutively collected spit 
tube samples was much higher than the variation between consecutively 
collected Statsure samples. The higher correlation between two Statsure 
samples might be explained by the fact that the absorption pad is put more 
or less at the same spot in the mouth (under the tongue) and that for spitting 
oral fluid could be collected from all parts of the mouth. Since mucosal cells 
and debris are collected over a larger area, more variation in THC 
concentrations could be expected. Compared to blood and urine sampling, 
where the sample is homogenous, this adds another important source of 
variability of the THC concentrations. 
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The results also show that in general the concentrations of the samples 
collected by spit tubes are almost six times higher than the corresponding 
concentrations collected by the Statsure in people who have very recently 
consumed cannabis. This was much higher than expected from the results 
from the O’Neal et al. (O'Neal et al., 2000) study. In this study it was reported 
that codeine concentrations were a factor 1.3 to 2.0 higher for spit tubes than 
for collection devices with nonacidic stimulation. Oral fluid containing 
higher THC concentrations will probably be contaminated more recently, 
which will result in a less homogenous spread over the oral cavity and the 
oral fluid. Therefore, these results could have shown more variability. 
Another potential reason for the difference is the higher lipophilicity of THC 
compared to codeine. If only sample pairs of samples within the linear range 
would have been taken into account though, the mean concentrations of the 
spit tubes would have been a factor 1.7 higher than the Statsure samples. 
This factor is in line with the O’Neal et al. study. 
THC adsorbed on cell debris of the mucosa might have contributed to the 
higher THC concentrations from spitting samples. The higher THC 
concentrations in spitting samples may potentially also be caused by the 
origin of the oral fluid. The Statsure samples were all placed in the vicinity of 
the orifice of the submandibular duct, whereas the oral fluid collected by 
spitting was collected from the whole oral cavity. More research is needed to 
investigate the influence of the sample preparation and the origin of the oral 
fluid on the THC concentration in oral fluid collected by spit tubes. 
The concentrations of the oral fluid samples collected by the Statsure device 
were corrected since the volume of the samples varies in practice. For the 
Statsure samples in this study the average volume was 0.34 mL, ranging 
between 0.15 and 1.51 mL. Both the large variation and the difference 
between the average volume (0.34 mL) and the expected volume (1.0 mL) 
showed that correction of the concentrations was indeed necessary. For the 
spitting samples no information was available on volumes. However, the 
effect of differences in sample volume was not expected to be large since no 
buffer fluid was used for diluting the spitting samples. 
The low repeatability of THC measurement in oral fluid leads to the question 
whether there are alternatives for THC collection in oral fluid. An alternative 
mentioned in literature (Day et al., 2006; Milman et al., 2010; Moore et al., 
2011) is the analysis of THCCOOH in combination with THC analysis. 
According to these studies the presence of contamination could be defined 
by using the THCCOOH concentration. As THCCOOH may come from the 
blood or transport by some other mechanism, it is stated that enzymes 
necessary for conversion of THC to THCCOOH are not known to be present 
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in the oral mucosa. However, a limitation of this method is that 
concentrations for THCCOOH are very low (measured in ng/L, whereas 
THC is measured in ng/mL). Therefore, THCCOOH in oral fluid is at present 
not yet detectable by most laboratories. 
Blood spot collection might be a second alternative for the collection of oral 
fluid samples, since it is, like oral fluid sampling, less invasive than blood 
collection by venipuncture. Although, no correlation results are known for 
THC, for some other substances a high correlation was observed with blood 
obtained from venipuncture (Jantos and Skopp, 2011; Skopp, 2007). 
 
Strengths and limitations 
This was only the second study that has data on the repeatability of oral fluid 
collection methods available. The strength of this study is that it provides 
insight in the potential problems of using oral fluid as a matrix for detecting 
THC use and especially when oral fluid samples are used for quantitative 
measurements.  
A second strength of this study is that each of the Statsure samples was 
weighted to define the corrected concentration. A recent Norwegian study 
(Gjerde et al., 2010b) showed that lower volumes of oral fluid contained more 
frequently THC and that samples with low volumes should not be discarded 
from analysis. In this study all samples were included despite differences in 
volume.  
A limitation of the present study is that the samples had to be taken 
consecutively. This might have affected the results. Furthermore, the study 
was performed on people who in majority had consumed cannabis less than 
one hour before, while in the population of drivers the interval between 
smoking and collection might be longer. The results are therefore only 
applicable for very recent cannabis use and not for cannabis use in general. 
Results from Niedbala et al. (9) indicate that if the interval between smoking 
and collection had been longer, the agreement between the two samples 
would probably have been better. One can also conclude that it is not 
recommendable to use spit tubes for law enforcement purposes because of 
the low repeatability of the sampling process. 
A final limitation is that the spitting samples with THC concentrations above 
the linear range of the validated method of 1-200 ng/mL were not diluted. 
However, additional experiments showed that the bias for THC in spiked 
spitted oral fluid samples up to 20,000 ng/ml (calculated as the percent 
deviation of the observed concentration from the expected concentration, 
n=27) was less than 15%, three samples excepted, As a consequence, the 
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calibration curve for THC in spitted oral fluid is expected to be linear up to 
20,000 ng/ml.  
 
Further research 
The results from this study may provide an interesting start for further 
research on the repeatability of oral fluid collection methods. If oral fluid is 
used as a matrix for legal purposes, it might be valuable to study the effect of 
the collection method on the results in more detail. 
 
Conclusions 
The repeatability of both the Statsure collection method and the ordinary spit 
tubes is low when applied among subjects who have consumed cannabis 
very recently. In comparison with the Belgian legal limit, results of the 
Statsure collection method are more in agreement with each other than 
results of the spit tubes. Furthermore, it was observed that samples obtained 
by spitting had 1.7-5.9 times higher THC concentrations than samples from 
the Statsure collection method, depending on the choice of the upper limit of 
THC concentrations that were included for analysis. The results of this study 
may have implications for confirmation analysis in oral fluid when applied 
for legal purposes.  
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6. Random and systematic errors in case-control 
studies estimating the injury risk of driving 
under the influence of psychoactive 
substances13 
6.1. Introduction 
Between 2006 and 2010 six population based case-control studies were 
conducted during the European research-project DRUID (DRiving Under the 
Influence of Drugs, Alcohol and Medicines) in order to determine the risk of 
being seriously injured while driving with psychoactive substances (Hels et 
al., 2011). These case-control studies were performed in Belgium (BE), 
Denmark (DK), Finland (FI), Italy (IT), Lithuania (LT) and the Netherlands 
(NL). All six studies were screened for the same 23 substances applying 
uniform analytical cut-off levels. Cases were seriously injured drivers 
admitted to hospitals after a traffic crash and controls were randomly 
selected drivers from the general traffic. In epidemiological research, case-
control studies are used to compare determinants (e.g. the presence of drugs) 
between injured and non-injured drivers. The main outcome measure of 
case-control studies is the odds ratio, which estimates relative risk, since 
relative risk calculations cannot always be used (Schmidt and Kohlmann, 
2008). This is due to the fact that there is no denominator for the incidence 
rates, since the controls are only a sample of the underlying denominator (or 
study base). Some case-control studies may have the possibility to calculate 
relative risk. However, when choosing logistic regression as method for 
analysis, odds ratios will per definition be the outcome measure. An example 
of such a study is a case-control study from New Zealand by Connor et al. 
(2004)). Although an odds ratio and a relative risk calculation are not 
identical measures, the odds ratio can be used as an estimate of the relative 
risk, as long as the likelihood of a crash is small. In Figure 6.1 it can be 
observed that the odds ratio approximates the RR when the number of cases 
                                                 
 
13  This chapter is published as the following article: Houwing, S., Hagenzieker, M., 
Mathijssen, M.P.M., Legrand, S.-A., Verstraete, A. G., Hels, T., Bernhoft, I.M., Simonsen, 
K.W., Lillesunde, P., Favretto, D., Ferrara, D., Caplinskiene, M., Movig, K. & Brookhuis, K.A. 
Random and systematic errors in case-control studies calculating the injury risk of driving under the 
influence of psychoactive substances. This article is published online in Accident Analysis and 
Prevention (AAP) 2013; doi: 10.1016/j.aap.2012.12.034. 
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(a and c) is relatively small compared to the number of controls (b and d). An 
odds ratio larger than 1 indicates a higher relative risk compared to a sober 
driver, while conversely an odds ratio smaller than 1 indicates a lower 




Exposed a b a+b
Unexposed c d c+d
Total a+c b+d a+b+c+d
OR = (a/b)/(c/d)
RR = (a/a+b)/(c/c+d)  
Figure 6.1. Calculation of odds ratios (OR) and relative risk (RR); derived  
from Hels et al. (2011); a = number of positive cases, c = number of negative  
cases, b is number of positive controls, d = number of negative controls.  
Odds ratios were calculated for each of the six individual countries as well as 
for all six countries combined. The advantage of a pooled odds ratio was that 
the number of samples was much larger so that even odds ratios for less 
prevalent substances could be calculated. The odds ratios of the six DRUID 
case-control studies as well as for all countries together are presented in 
Table 6.1. Drivers were considered seriously injured in case of a MAIS-score 
(Maximum Abbreviated Injury Scale) of 2 or higher (Garthe et al., 1999; 




Table 6.1. Odds ratios indicating the relative risk of being seriously injured (MAIS ≥2) due to driving under the influence of psychoactive substances 
according to country, adjusted for age and gender, and 95% confidence intervals (adapted from Hels et al., 2011); na = not possible to calculate due 
to low cell counts. Inf = infinity. 
Category Substance group Belgium Denmark Finland Italy Lithuania The Netherlands All countries 
Alcohol 












































































Cocaine na na na 1.17 
0.4-3.4 














Illicit opiates and opioids na na na 
1.38 
























































na na 8.01 
5.34-12.01 
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In general, the highest odds ratios were calculated for drivers using alcohol-
drug combinations, drug-drug combinations and for drivers with high blood 
alcohol concentration (BAC) levels (Hels et al., 2011). The risk posed by 
alcohol use increased at higher BAC levels, as has been found in previous 
case-control studies (Borkenstein et al., 1974; Compton et al., 2002; Krüger 
and Vollrath, 2004; Mathijssen and Houwing, 2005; Movig et al., 2004). 
However, the results of the DRUID case-control studies show that the 
calculated odds ratios for alcohol varied widely between countries. The odds 
ratios for illicit drug use showed large variations between countries as well, 
with odds ratios differing by up to a factor of 100. However, the confidence 
intervals were wide and for most countries the number of positive samples 
for illicit drugs was too small to calculate an odds ratio. The odds ratios for 
medicinal drugs varied less than those for illicit drugs and alcohol. 
Nonetheless, in Italy the calculated odds ratio of 0.2 for benzodiazepines and 
Z-drugs (including zolpidem and zopiclone) was much lower than the odds 
ratio of 4.37 found in Denmark. 
 
In sum, the results from these case-control studies showed large variations in 
the relative risks for driving under the influence of psychoactive substances. 
The differences between the odds ratios of the case-control studies could 
reflect actual differences in relative risk for driving under the influence in the 
different countries. However, it is hard to believe that drivers in different 
countries show such large differences for the relative risk of serious injury 
while driving under the influence of psychoactive substances. Therefore, the 
observed differences between the odds ratios could also be at least partially 
explained by different types of errors.  
Depending on the source of the error they can be divided into random errors 
and systematic errors (Rothman, 1986). A random error can be described as 
sampling variability. This variability is visualized in case-control studies by 
confidence intervals. An increase of the sample size leads to a decrease of the 
confidence interval, producing results with higher precision and power. A 
systematic error is often referred to as bias. Bias is generally described as the 
difference between the observed value and the true value. It is, unlike 
random error, not affected by sample size.  
 
In epidemiological literature different types categorisations of bias exist. In 
this study we used the classifications of Kleinbaum et al. (1982) and Rothman 
(1986) who distinguish three main types of bias: selection bias, information 
bias and confounding. Firstly, selection bias can be described as a deflection 
that results from the selection process of the study population. An example 
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of selection bias is detection bias, where there are differences in detecting 
exposed and non-exposed participants. For instance, detection bias may 
occur when drivers are not selected at random from moving traffic, but 
mainly based on suspicion. As a result the prevalence of psychoactive 
substances in traffic is overestimated and the odds ratio will consequently be 
underestimated. Selection bias is regarded as the most common type of bias 
in case-control studies (Schulz and Grimes, 2002). Secondly, information bias 
can be described as a deviation based on inaccuracy of the measurement, or 
classification, of study variables. An example of information bias is 
misclassification bias where a subject is assigned to a wrong group due to a 
measurement error of an instrument, or in case of an interview due to 
selective recall or misunderstanding the questions. Finally, confounding arises 
when a result is distorted by one or more variables that are associated both 
with exposure and with the outcome (Rothman, 1986). The most commonly 
included confounding factors in case-control studies that assess the risk of 
driving under the influence of psychoactive substances are gender and age 
(Blows et al., 2004; Brault et al., 2004; Haworth et al., 1997; Hels et al., 2011; 
Mathijssen and Houwing, 2005; Mura et al., 2003). 
 
Guidelines were formulated at the start of the DRUID surveys concerning 
several design issues to ensure that the results were representative and 
comparable (Assum et al., 2007). According to these guidelines a cross-
sectional roadside survey had to be conducted to determine the prevalence of 
psychoactive substances among the general driving population. The method 
of this roadside survey was based on a stratified multi-stage sampling 
design. In the first stage of this design study regions were selected in the 
participating countries. These regions were meant to be representative for the 
whole country with regard to substance use and traffic. Within these regions 
smaller research areas were selected in the second stage, and within these 
areas, survey locations were selected, where car drivers and drivers from 
vans aged 18 and above were randomly selected from actual traffic. In each 
country, data were collected during several roadside survey sessions 
distributed over 8 six-hour time periods covering all hours of the day on both 
weekdays and weekend days. The time periods were distributed into type of 
day (weekday-weekend day) and time of the day (04.00-09.59, 10.00-15.59, 
16.00-21.59, 22.00-03.59). Due to the preferences of the police that had to be 
taken into account, it turned out that the distribution of the samples over the 
different time periods in the six countries could not always be representative 
for the distribution of traffic volumes over the time periods. In order to 
adjust for these differences, weight factors were calculated for each country 
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by dividing the national traffic proportion per time period by the proportion 
of sampled drivers for these time periods.  
The case population consisted of seriously injured drivers (MAIS >= 2) of cars 
and small vans aged 18 and above.  
A list of 23 core substances was included together with analytical cut-off 
levels for whole blood and oral fluid. Oral fluid samples had to be collected 
by means of the Statsure Saliva Sampler device.  
However, for practical, financial and/or legal reasons not all studies were 
conducted according to these guidelines. Furthermore, some issues were not 
addressed in the guidelines, but could have caused variation in the odds 
ratios anyway (e.g. the minimum number of samples and the maximum 
proportion of non-response). Therefore, several sources of random and 
systematic errors could have led to differences in the results between the six 
DRUID case-control studies. 
 
The main objective of this study is to provide insight in the different types of 
errors that could explain the variance in the results of the six DRUID case-
control studies. The results of this assessment may clarify the large inter-
country variation that was observed between the odds ratios.  
6.2. Method 
The method that was applied to explore the source of errors in the DRUID 
case-control studies consisted of three steps: the first step was to prepare a 
list of potential indicators for errors based on the available data from the six 
case-control studies. Table 6.2 provides an overview of these indicators for 
potential errors categorized by type of error (random and systematic error) 
and by type of bias (selection bias, information bias and confounding) 
according to the categorization of Kleinbaum et al. (1982) and Rothman 
(1986). This categorization is supported by Wacholder et al. (1992) who wrote 
two companion papers on issues involved in selecting controls for case-
control studies. They state that the selection of controls should be 
comparable to the selection of cases in three ways: the study base should be 
the same, confounding factors should be used to eliminate any distortion by 
other factors, and the measurement errors should be comparable. These 
principles should reduce the three previously mentioned types of bias in 
case-control studies: selection bias, information bias and confounding. 
However, they also state that the effectiveness of these principles is 
constrained by the availability of resources and time. 
 
 116 
Table 6.2. Indicators of potential errors. 
Type of error Type of bias Indicator  Short explanation 
Random error  Sample size Influences accuracy  
Low cell counts Low frequency in a cell 
leads to less accurate 
odds ratios 
Systematic error Selection bias Geographic area covered 
by cases and controls 
Difference in area 
covered when sampling 
cases and controls may 
result in bias 
Size of non-response Large non-response may 
result in larger bias 
Age and gender 
distribution of response 
and non-response group 
Differences may indicate 
non-response bias 
Non-random sampling Over representation of 
specific groups may lead 
to bias 
Injury scale Differences in inclusion 
criteria may lead to 
incomparable case 
populations 
Information bias Sampling method cases 
and controls 
Different sampling 
methods in cases and 
controls may lead to bias  
Analytical method Differences in sensitivity 
of the methods of 
analysis may lead to bias  
Time between accident 
and sampling 
Differences in time 
between accident and 
sampling may lead to 
bias 
Confounding  Confounding factors 
controlled for 
Control for different 
confounding factors may 
lead to bias 
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In the second step, information was gathered for each of the potential 
indicators from the relevant DRUID reports on prevalence (Houwing et al., 
2011; Isalberti et al., 2011) and risk estimates (Hels et al., 2011). These 
prevalence reports included the national reports for the six participating 
countries, which provided detailed information concerning the hospital 
studies and the roadside surveys. 
 
In the third and final step, the collected information from the DRUID reports 
was used to interpret the calculated odds ratios. A quantitative assessment of 
bias was not possible, since this would require a large amount of detailed 
data on e.g. the use of psychoactive substances in the general population for 
each study region, which were not available. Therefore, in this study bias is 
only discussed in qualitative terms based on the information derived from 
the reports on the prevalence and risk studies by searching for deviations 
between the six studies on each of the indicators. The likelihood of bias was 
divided into two categories: no indication of bias and indication of bias. In 
case of potential bias, an estimation of the size and direction of bias is 
provided when possible. Apart from the discussion on potential bias, 
random errors are discussed in terms of statistical power. 
6.3. Results 
Relevant information for each country was gathered from the individual 
DRUID reports and then categorised into the various indicators for potential 
errors. Table 6.3 presents an overview of the results of this analysis of 
potential errors.  
 
  
Table 6.3. Summary of results of the assessment of potential errors; see text for further explanation; AMP = amphetamines, BEN = benzoylecgonine, 
BZD = benzodiazepines, COC = cocaine, OPI = illicit opiates, ALC = alcohol, OF = oral fluid. 
Indicator  Belgium (BE) Denmark (DK) Finland (FI) Italy (IT) Lithuania (LT) Netherlands (NL) 
Sample size N controls 2,949 
N cases 348 
N controls 3,002 
N cases 839 
N controls 2,706 
N cases 54 
N controls 1,086 
N cases 676 
N controls 1,264  
N cases 385 
N controls 4,822 
N cases188 
Low cell counts Sufficient cell counts 
for calculating OR’s 
for all substances 
except AMP, BEN, 
COC and OPI  
Sufficient cell counts 
for calculating OR’s 
for all substances 
except AMP, BEN, 




calculating OR’s for 
all substances 
Sufficient cell counts 
for calculating OR’s 
for BEN, THC and 
drug-drug 
combinations 
Sufficient cell counts 
for calculating OR’s 
for ALC and BZD 
and ZDR 
Sufficient cell counts 
for calculating OR’s 




covered by cases and 
controls  
Cases and controls 
cover the same area, 
although the 
distribution of the 
cases over the 
hospitals was not 
representative.  
Cases and controls 
do not cover the 
same area. However, 
no significant differ-
ence in age, gender 
and substance use 
was observed 
between hospital and 
non-hospital regions  
Cases and controls 
cover the same area. 
Cases and controls 
cover the same area. 
Cases and controls 
cover the same area. 
Cases and controls 
do not cover the 
same area. No 
significant difference 
in age and gender 
was observed 
between regions, but 
total substance use 
differed.  







Cases not observed 
Controls 24% 
Cases not observed 
Controls 5% 
Cases not known  
Age and gender 
distribution of 
response and non-
response group  
Controls: 
Overrepresentation 
of male drivers aged 
25-34 in control 
population. BAC 









for age and gender, 
although male 
drivers 18-24 and 
female drivers 35-49 
were somewhat over 
represented  
No information 
available for cases  
Controls: No 
information available 
although a higher 
prevalence of 
substances was 
reported in the non-
response group 
based on police 
records. 
No information 
available for cases  
No non response 
observed in both 
cases and controls 
Controls: Female 
drivers, mainly 
between 18-34 years, 
were over 
represented among 
non- respondents,  
No information 
available for cases  
 
Controls: Males aged 
25-34 were over 
represented and 
females aged 35+ and 
males 50+ were 
under represented.  
No information 
available for cases  
 
  
Indicator  Belgium (BE) Denmark (DK) Finland (FI) Italy (IT) Lithuania (LT) Netherlands (NL) 
Non-random 
sampling 
Not observed Not observed Not observed  Part of the drivers 
were preselected 
based on clinical 
signs of alcohol 
impairment 
Not observed Not observed 
Inclusion criteria 
cases and controls 
MAIS2+ Danish Trauma 
score 2+ 









OF(Statsure), for 94% 
of the controls 
ethanol by 
conversion breath 





by conversion breath 




(Statsure), ethanol by 
conversion breath 






(spit tubes), ethanol 
by conversion breath 
alcohol into blood 
alcohol 
Cases blood 
Analytical method Extraction: Solid 
phase and liquid-





GC-MS for THC 
Extraction: Solid 
phase and liquid-




































Mean 1.33 hr 
Median 1.20 hr 
Mean 1.05 hr 
Median 1.00 hr 
Mean 1.50 hr  
Median 1.83 hr 
Mean 1.42 hr 
Median 1.00 hr 
Mean 0.78 hr 
Median 0.75 hr 
Mean 1.21 hr 
Median 1.08 hr 
Confounding factors 
controlled for 
Age and gender, 
control population 
weighted for the 
volume of the traffic 
flow over 8 different 
time periods 
Age and gender, 
control population 
weighted for the 
volume of the traffic 
flow over 8 different 
time periods  
Age and gender, 
control population 
weighted for the 
volume of the traffic 
flow over 8 different 
time periods 
Age and gender, 
control population 
weighted for the 
volume of the traffic 
flow over 8 different 
time periods 
Age and gender, 
control population 
weighted for the 
volume of the traffic 
flow over 8 different 
time periods 
Age and gender, 
control population 
weighted for the 
volume of the traffic 
flow over 8 different 
time periods 
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6.3.1. Random errors 
Sample size 
The sample size is the number (n) of individual samples in a study. The 
precision and thus statistical power of a study increases with the sample size. 
Statistical power represents the probability that a test will find a significant 
difference if there is an actual difference. If the power is low, the confidence 
intervals will increase and may result in fewer significant outcomes (Cohen, 
1988). However, odds ratios which are close to 1 are more sensitive to 
significance than odds ratios that differ more from 1. Therefore the number 
of cases and controls is used as an indicator for the power of the study, 
instead of the number of significant outcomes, which may be regarded as a 
more direct indicator. 
The results for the assessment on the sample sizes of the six DRUID case-
control studies are presented in Table 6.3. The sample size for the hospital 
cases varied between 54 for the Finnish study and 839 for the Danish study. 
The sample size of the control samples which were collected at the roadside 
ranged between 1,086 for the Italian study and 4,822 for the Dutch study.  
Only the Belgian and the Danish study included relatively high number of 
samples in both the case (BE:348 and DK:839) and the control populations 
(BE: 2,949 and DK:3,002) (Houwing et al., 2011; Isalberti et al., 2011). Despite 
the relatively small numbers of samples in the control population, the Italian 
study has a greater precision than the studies from Finland, Lithuania and 
the Netherlands. This greater precision is a result of the relative large 
number of cases in the Italian case-control study (n=676). 
 
Low cell counts 
As described above, the sample size provides information concerning the 
study power. In addition, the distribution of the samples over the four cells 
in a case-control study (see Figure 6.1) provides valuable information on the 
accuracy of the outcomes as well. In the report on risk estimates (Hels et al., 
2011) the issue of low cell counts was explored by an alternative method to 
calculate overall odds ratios. In this alternative method the lowest cell count 
for each odds ratio calculation was both decreased and increased by 1 to 
investigate the effect of a small change of the data. If the difference between 
the odds ratio of the decreased value and the increased value was larger than 
a factor 2, the study was regarded as too susceptible to bias due to low cell 
counts and therefore not sufficient to enable calculation of the overall odds 
ratios. The results of the analysis on low cell counts (Hels et al., 2011) showed 
low cell counts for all substances in the Finnish case-control study. The 
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Lithuanian, Italian and Dutch study each only had sufficient cell counts for 
three of the substance groups. In Denmark and Belgium the results of the 
case-control study seemed to have the highest accuracy with sufficient cell 
counts for five and six substance groups, respectively.  
Therefore, the Belgian and Danish studies were considered to have the 
highest study power. Both studies were also the only studies that were 
regarded as having a sufficiently large sample size of both cases and controls 
(see Section 3.1.1 on the sample size).  
6.3.2. Systematic errors 
Geographic area covered by cases and controls 
One of the basic principles of a population based case-control study is that 
both the case and control population should be drawn from the same study 
population (Rothman and Greenland, 1998). If the use of psychoactive 
substances varies according to region, and the cases are not collected from 
the same region as the controls, then the odds ratio calculations may not be 
valid.  
The results of the analysis on the area covered by the cases and controls 
showed that the only two countries in which the case-control study did not 
cover the same area for both cases and controls were Denmark and the 
Netherlands. Since there were no differences in the age and gender 
distributions between the hospital and non-hospital regions in both 
countries, a decision was made to include all the results from the Dutch and 
Danish roadside study in the odds ratio calculations (Hels et al., 2011). 
However, a significantly lower prevalence was found for the total substance 
use in the Dutch regions that did not include a hospital providing case 
samples. No significant differences were found for any of the separate 
substance groups though. In Denmark no differences were found for 
substance use in the additional calculations of the control samples. Therefore, 
we have concluded that the effect of selection bias related to the areas 
covered by the cases and controls is not likely to be of influence in Denmark 
and the Netherlands. 
In Belgium the inclusion of hospital samples seemed to vary over the study 
regions: the share of injured drivers in Flanders was over-represented (81% 
of the cases and 57% of the controls), and the share in Wallonia (16% of the 
cases and 39% of the controls) was under-represented (Houwing et al., 2011; 
Isalberti et al., 2011). However, additional analysis of the prevalence results 
in traffic by region did not show any significant differences between the 
substance use in Flanders and Wallonia. Therefore, the effect of bias due to 
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selection bias in the case samples in Belgium is expected to be very small. For 
all other studies no selection bias was observed in the case samples.  
 
Size of non-response  
A large share of non-response in a study increases the likelihood of a 
selection bias. This selection bias may lead to an underestimation of the share 
of illicit drug users, since drivers who were positive for illicit drugs can be 
assumed to be less likely to participate voluntarily because of the risk of 
being detected positive for drugs in the vicinity of the police who were 
present at the scene and took care of stopping the drivers. The share of non-
response in the hospital studies, varied between 0 (not observed) and 8.5% 
(Isalberti et al., 2011), which can be considered as relatively low. Based on the 
information on the size of the non-response in the case population as shown 
in Table 6.3, it can be concluded that the presence of non-response bias in the 
case population is likely to be small.  
The non-response rates in the roadside surveys showed larger variations 
with a range of between 0 and 52%. In Italy, non-response was non-existent 
since participation was mandatory. In Lithuania, Belgium and Finland the 
proportion of non-respondents at the roadside was very high at 25%, 48% 
and 52%, respectively. Based on this information, we assess that there was 
likely to be an overestimation of the odds ratios for illicit drugs in these three 
countries.  
 
Age and gender distribution of response and non-response group 
Age and gender differences between the response and non-response groups 
may indicate selection bias, since both age and gender can be associated with 
different patterns in drug use by car drivers (Hels et al., 2011). Results from 
the roadside surveys in the DRUID project indicate that illicit drug use is 
more prevalent among young male drivers, whereas the use of medicinal 
drugs is relatively more frequently detected in female drivers aged 35 and 
older (Houwing, 2011). The only hospital study (cases) which collected data 
from the non-response group was the Belgian hospital study. No significant 
differences were found for age and gender distribution in this study. For the 
other hospital studies no information was available (DK and FI) or no non-
response was observed (IT, LT and NL).  
 
The results from the roadside surveys (controls) showed that in Belgium and 
the Netherlands male drivers, aged 25-34, were over represented in the non-
response group, in Denmark there was an over representation of young male 
drivers, aged 18-24, and female drivers aged 35-50 and in Lithuania female 
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drivers were generally over represented. In the Italian roadside survey no 
non-response group was observed at all, since refusal to participate led to a 
large penalty by the police. In Finland and Belgium drivers were first 
stopped and breath tested by the police, before they were asked to 
participate in the study. In these two countries a large share of drivers 
already declined to participate when the police asked them to drive to the 
researchers. In Finland, no information was recorded from these drivers on 
age, gender and reason for refusal. But from police records information was 
available on positive substance detections in those non-participating drivers 
whom the police suspected of driving under the influence of substances 
other than alcohol (Houwing et al., 2011). This information indicated that 
substance use was more frequently detected among non-respondents.  
 
In summary, it can be concluded that differences between the response and 
non-response group may have led to be an under representation of illicit 
drug use by car drivers in Belgium and Finland. Differences were detected in 
Denmark and the Netherlands as well, but since the total non-response rate 
was relatively low the effect is likely to be small. In Lithuania, it may be 
assumed that due to the over representation of female drivers in the non-
response group the prevalence of illicit drugs in traffic is overestimated 
whereas the prevalence of medicinal drugs is underestimated. In Italy no 




One of the objectives of the hospital studies and roadside surveys was to 
gather information on substance use for a representative sample of drivers in 
order to calculate odds ratios. Therefore, sampling needed to be carried out 
on a random basis. The process of random sampling can be endangered by 
selection bias. Detection bias is a form of selection bias, which can occur due 
to oversampling of certain sub-populations. The presence of detection bias is 
hard to reveal. However, in the DRUID report on the case-control studies 
(Hels et al., 2011) it was noted, based on personal communication with the 
Italian researchers, that in the Italian roadside survey drivers who showed 
clinical signs of alcohol impairment had partially been preselected. 
Therefore, alcohol use in Italian traffic is expected to be overestimated, 
causing an underestimation of the odds ratios for alcohol use. This detection 
bias may also have been present for users of psychoactive substances other 
than alcohol, in the event that they showed signs of impairment as well. We 
assess that the Italian odds ratios for alcohol and other psychoactive 
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substances were likely to be underestimated. For all other countries no 
indication was found for bias due to non-random sampling. 
 
Inclusion criteria for cases and controls 
The inclusion criteria for the roadside surveys were the same for all 
countries: drivers of cars and small vans, during all times of the day and all 
days of the week (Houwing et al., 2011). For the hospital studies the 
inclusion criteria were seriously injured drivers, aged 18 years and older, 
driving a car or small van, with a MAIS score (Maximum Abbreviated Injury 
Scale) of 2 or higher (Isalberti et al., 2011). Furthermore, the time between the 
accident and sampling had to be less than three hours. In Denmark and Italy 
a national injury scale was applied instead of the MAIS-scale. In Denmark 
this scale was based on injury severity and in Italy injured drivers were 
included if the prognosis of recovery from injury was 20 days or longer 
(Isalberti et al., 2011). Based on the national study of Danish hospital results 
in the DRUID report on risk estimates (Hels et al., 2011), no large differences 
are expected for the Danish study due to the difference in the inclusion 
criteria for injured drivers. The potential effect of the divergent Italian 
inclusion criteria is hard to estimate since it is based on the number of days 
of care that is needed and not on the severity of the injury. 
 
Sampling method cases and controls 
The theoretically most appropriate method for comparison of cases and 
controls is by comparing blood samples from injured drivers with blood 
samples from non-injured drivers (Walsh et al., 2008). Blood samples were 
collected from all injured drivers in the hospital studies. However, for the 
roadside surveys blood samples were only collected in Lithuania (all 
samples), the Netherlands (78% of all samples), Belgium (93%) and Italy 
(73%). All other collected samples were oral fluid. Therefore, equivalent cut-
offs between blood and oral fluid concentrations were developed in order to 
be able to compare blood and oral fluid concentrations (Verstraete et al., 
2011b).  
 
Another issue concerning sampling of body fluids was the difference in 
collection method for oral fluid samples. In the Netherlands oral fluid 
samples were collected by using polyethylene spit tubes, whereas in all the 
other countries oral fluid samples were collected by using a Statsure© oral 
fluid collection device with non-acidic stimulation. The guidelines prescribed 
the use the Statsure© device for collecting oral fluid (Assum et al., 2007). 
However, the Dutch roadside survey had already started by the time this 
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decision was made and in order to keep the same oral fluid collection 
procedure during the whole study the Dutch researchers decided to continue 
working with the spit tubes.  
The equivalent cut-offs that were used in the DRUID studies were based on 
concentrations for the Statsure© collection device. A recent study (Houwing 
et al., 2012) shows that THC concentrations in oral fluid collected using spit 
tubes are in general almost six times higher than THC concentrations 
collected by a device without acidic stimulation. Results for codeine 
sampling by different oral fluid collection methods showed a factor ranging 
from 1.3- 2.0 (O'Neal et al., 2000). In the DRUID case-control studies, 
however, the same equivalent cut-offs were applied for samples collected 
with spit tubes as for those with the Statsure© device.  
 
It can be concluded that the potential bias by using blood-oral fluid 
comparisons instead of blood-blood comparisons is likely to be absent for all 
countries except for the Netherlands where 22% of the roadside samples 
were analyzed in oral fluid. Therefore, it can be assumed that the difference 
in the sampling method between the cases and controls has led to a (small) 
overestimation of the Dutch prevalence results in the controls.  
In four of the six roadside surveys (Denmark, Finland, Italy, the 
Netherlands), ethanol (alcohol) concentrations were measured by handheld 
breathalyzers of the police.  
In Belgium BAC was measured from both oral fluid and whole blood. The 
estimated blood ethanol concentration was a factor 1.22 higher than the 
measured ethanol concentration in oral fluid. This factor was based on the 
average conversion factor between blood and oral fluid that was calculated 
from the Belgian DRUID results of those drivers from whom both blood and 
oral fluid samples were collected (Verstraete et al., unpublished 
observations). In Denmark, due to missing data of the police, ethanol 
concentrations were measured in oral fluid in 6% of the drivers at the 
roadside by using the same factor of 1.22 as was used in the Belgian study.  
In the Netherlands the conversion factor of breath alcohol concentrations into 
blood alcohol concentrations in percentages is 1:23 (Mathijssen and Twisk, 
2001). However, in the other European countries that were involved in the 
DRUID roadside surveys a higher conversion factor of 1:21 is used (Melethil, 
2011). In order to be able to compare the Dutch alcohol results with the 
results for other EU countries, all blood alcohol concentrations (BAC) results 
from the Netherlands were multiplied by a factor 1.095 (23/21). In Lithuania, 
ethanol concentrations were directly measured in blood. 
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Based on the conversion factors that were applied, no substantial bias was 
expected for alcohol measurements. 
 
Method of toxicological analysis 
Differences in accuracy of the analytical methods may lead to biased results 
as well. Information on the methods was available for the extraction, 
separation and detection methods. Extraction of the samples was based 
either on liquid-liquid or solid phase extraction, chromatographic separation 
was performed by gas chromatography or liquid chromatography High 
Performance or Ultra Performance. Detection of substances was based on 
mass spectrometry or nitrogen/phosphorus detection.  
 
Four separate rounds of proficiency testing were performed. The results of 
the proficiency testing show that both qualitative and quantitative 
performance improved during the testing program (Pil et al., 2010). 
Therefore, bias due to differences in the analytical methods is not likely.  
 
Time between accident and sampling 
Based on the information in the databases from the six hospital studies it can 
be concluded that time between accident and blood sampling varied between 
zero minutes and three hours. The time span between accident and sampling 
could cause an underestimation of the number of case samples (and 
concentration of substances therein). This is due to the process of 
metabolisation, since psychoactive substances with a short half-life, such as 
heroin, could already be metabolised after only three hours. For all countries 
the mean and median times, shown in Table 6.3, were between one and two 
hours, except for Lithuania that shows a shorter time period. The recorded 
time between accident and sampling in Lithuania had a timeframe with both 
mean and median values of approximately 45 minutes. Since the differences 
between the countries are relatively small and the maximum time between 
accident and sampling was set at 3 hours, we assess that the presence of bias 
due to differences in time between accident and sampling is of the same 
order for all countries. 
 
Confounding factors 
Deconfounding is, like the presence of an identical study base for both cases 
and controls, one of the main principles of comparative case and control 
selections (Wacholder et al., 1992). Confounding factors are variables that co-
vary both with substance use and crash risk. Taking into account different 
types of confounding factors can cause variation between the results of case-
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control studies. In the DRUID project all the case-control studies’ results 
were calculated by the Technical University of Denmark (DTU), ensuring a 
uniform method of statistical analysis. The results of all countries were based 
on a similar set of variables (age and gender). Furthermore, the data from all 
six roadside surveys were weighted for the volume of traffic flow in the 
different time periods. There are probably other confounding factors that 
were not detected in these studies. Age and gender were included as 
confounding variables in all calculations and since the data were adjusted for 
differences in traffic volume between time periods, and therefore we assume 
that the potential effect of confounding has been reduced. However, since 
confounding has only been eliminated for those factors that we had data 
available for, any influence of confounding on the estimated odds ratios 
cannot be ruled out. 
6.4. Discussion and conclusions 
Based on the results of the assessment of potential bias due to random and 
systematic errors it can be concluded that each of the national case-control 
studies showed indications of potential bias. 
The assessment for the Belgian case-control indicated a potential 
overestimation of the odds ratio for cannabis due to the likelihood of non-
response bias in the control sample, in combination with a large proportion 
of non-respondents. Relatively high odds ratios for illicit drugs were 
observed which supports the likelihood of the presence of at least some non-
response bias in the roadside survey. For all other substances the odds ratios 
were relatively close to the overall odds ratio. 
In Denmark, a small overestimation of the odds ratio for illicit drugs was 
possible due to the likelihood of a non-response bias in the control sample. 
However, the effect of the potential non-response bias was probably small, 
because of the low non-response rate (5%). For the other substances the 
presence of bias was not likely. 
In Finland, the odds ratio for illicit drugs and alcohol was likely to be 
overestimated due to non-response bias in the control sample in combination 
with a large share of non-respondents. These expectations were supported by 
the results of the comparison with the overall odds ratios for alcohol and 
illicit drugs in Table 6.1, which shows relatively high odds ratios for Finland. 
The Finnish results were expected to be less precise because of the small 
number of cases (n=54). This has resulted in relatively large confidence 
intervals. 
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In Italy, the odds ratios for alcohol were likely to be underestimated due to a 
selection bias in the control population. There may have been an 
underestimation for the other substances as well, since the police tended to 
include drivers with clinical signs of impairment. These findings were 
supported by the results of Table 6.1 in which generally the odds ratios for 
the Italian study were considerably lower than those of the other countries. A 
very important principle of a case-control study is that selection of 
participants has to be independent of exposure. Since this principle was not 
(fully) met in the Italian study, a proper interpretation of the Italian results 
was not possible. 
In Lithuania, the odds ratios for alcohol and illicit drugs were likely to be 
underestimated due to the large under representation of female drivers in 
combination with the large (24%) non-response bias. Furthermore, the 
precision of the study was relatively low due to the small number of control 
samples.  
In the Netherlands, an overestimation of the odds ratio for illicit drugs was 
possible due to the likelihood of a non-response bias in the control sample 
and due to selection bias resulting from lower prevalence of substance use in 
traffic in regions that were not included in the case study. The non-response 
rate was very low though and therefore, the effect of the potential non-
response bias was likely to be small. On the other hand, a potential 
underestimation of the odds ratios can be noted for all substances, except 
alcohol, due to the use of too low cut-offs in the control sample as a result of 
the different method of oral fluid sampling. Finally, the precision of the 
study was relatively low due to the small number of case samples. 
 
Taking the results of all countries together, we conclude that the most 
commonly found errors seem to be caused by selection bias (systematic 
errors) and were due to relatively small sample sizes and low cell counts for 
individual substances (random errors).  
 
The present analysis of potential bias due to random and systematic errors is 
qualitative. Therefore, it cannot be determined here to what extent these 
errors would have explained the differences in odds ratio between the 
countries. First of all, the confidence intervals of the odds ratios were very 
large which means that even large differences, such as the difference 
between the odds ratios for cannabis in the Netherlands (OR 0.29, CI 0.04-
2.11) and Finland (OR 25.38, CI 1.86-345.78), might (theoretically) be 
considered a result arising from the different sample sizes. Furthermore, 
some differences between the odds ratios of the DRUID case-control studies 
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may arise from unknown confounding factors that are country related as was 
expressed by Hargutt et al. (2011) (e.g. climate, road conditions, and density 
of traffic).  
 
It is clear from the results of this study that the presence of uniform 
guidelines was not sufficient in excluding differences in the design and 
protocol of the six national DRUID case-control studies. Deviations from the 
guidelines such as those mentioned in the present study were caused by 
practical, financial and legal limitations. Such limitations are difficult to 
overcome for researchers. Therefore, it would be utopic to expect that future 
studies will be fully comparable with each other. Previous review studies on 
drug use in traffic that included case-control studies have discussed the issue 
of comparability between different study types. Only two studies were found 
in literature that have compared the calculated odds ratios from a case-
control study with the odds ratios that were calculated by a case-crossover 
design (Brault et al., 2004; Ravera et al., 2011). The effects of errors on the 
outcomes of case-control studies are also discussed in literature. Connor et al. 
(2004) mentioned the effect of errors on the comparability of case-control 
studies that studied the effect of alcohol use among drivers, as was done 
more recently by Krueger et al. (2008). Houwing et al. (2009) formulated a list 
of comparability indicators for case-control studies assessing the risk of 
driving under the influence of psychoactive substances, including a list of 
study design items, which could lead to errors. Another review study on 
drugs and driving (OECD, 2010) listed methodological problems such as 
issues concerning body fluid samples, the elapsed time between accident and 
sampling, and the problem of determining the contribution of the substance 
to the accident as opposed to the possible contribution of confounding 
factors. The report concludes that the inconsistency of results of 
epidemiological studies on cannabis use is at least partially attributable to 
differences in study design and approach. Although these studies show that 
the presence of errors have been mentioned in literature, none of the 
previous studies was able to provide more insight into the degree that 
variation was caused by study errors. This is due to the fact that before the 
start of the European DRUID project there were no case-control studies 
conducted with comparable study designs that estimated the risk of driving 
under the influence of psychoactive substances other than alcohol. In the 
present study, the only major difference in study design between the six 
DRUID case-control studies was the use of two different types of body fluids 
for analyzing substance use in the control population. If we assume that the 
use of equivalent cut-offs adjusted for the larger part of differences in 
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substance concentrations between both matrices, we can conclude that the 
variation in odds ratios caused by errors is in particular large for alcohol at 
BACs of 0.5 g/L and above, and for illicit drugs. The results also show that 
standardization of case-control designs will probably not lead to comparable 
odds ratios and that further action is needed. 
 
The results of this study reflect the importance for future review studies or 
meta-analyses of epidemiological studies that estimate the risk of driving 
under the influence of psychoactive substances to include assessments of 
potential errors. These assessments are essential for better understanding the 
relationship between observed and actual risk estimations. Furthermore, we 
advise that future case-control studies in the field of driving under the 
influence include a pilot study with an assessment on potential bias. This 
would allow identification of the presence of potential limitations in the 
study design that could result in bias. The list of potential indicators that was 
used in this study could be used as a guidance, as long as it is kept in mind 
that this list is tailored to the DRUID case-control studies. Therefore, 
including additional variables in this list might be necessary. Finally, an a 
priori calculation of sample size could provide valuable information in how 
to maximize the precision of the study given certain limitations regarding 
resources and time.  
6.4.1. Strengths and limitations 
The main strength of this study within the DRUID project is that it provides 
insight in the source of errors in case-control studies to investigate the injury 
risk of driving under the influence of psychoactive substances. The results 
may also be valuable for future reviews of similar case-control studies. 
Another strength of this study is that it allowed the comparison of studies 
that included the same set of psychoactive substances at the same cut-off 
levels. This made it possible to examine the differences between the odds 
ratios. 
 
A limitation of this study was the lack of relevant information on the non-
response group of the case populations. Therefore, it was not possible to 
detect non-response bias, although such a bias may well have been present. 
Another limitation is the qualitative nature of the method of assessment. The 
results provide at the very most information on the direction of the bias, but 
not on the exact bias between observed and real odds ratios. Furthermore, no 
information was available for the storage time of the samples before analysis. 
Degradation of analytes could well have influenced the results of the surveys 
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(Langel et al., 2008). Reporting information on the storage time of samples 
may be of added value as well when assessing studies for potential bias.  
Finally, the numbers of samples from seriously injured drivers were very 
small in some of the national case-control studies (e.g. Finland). A large 
number of cases is important for the precision of the study. However, in 
some countries the accident rates are lower than in other countries which 
could make it difficult to collect a sufficient number of cases. In order to 
increase the number of case samples it may be recommendable to enlarge the 
study base or the period of sample inclusion, or to include injured drivers 
with a MAIS score of 1 (light injury) in future as well in case of potential low 
cell counts, under the assumption that there is no clear relationship between 
injury severity and the presence of drugs (Smink et al., 2005).  
To what extent the number of samples needs to be increased depends on the 
purpose of the study. Odds ratios for cannabis use in traffic from two 
previously conducted case-control studies with more or less the same design 
(Brault et al., 2004; Mathijssen and Houwing, 2005) indicated only a minor 
increase of the relative risk (respectively an odds ratio of 1.6 and 1.29). 
Taking into account a power of 80% and a two-sided significance level of 
95%, a very large sample size of thousands of cases and controls (Kelsey et 
al., 1996) is needed for calculating significant elevated risks for low odds 
ratios like the one for cannabis. However, if the main aim of a study is to 
determine which psychoactive substances have the highest risks, a smaller 
sample size will probably be sufficient. 
The number of samples from each of the national DRUID case-control studies 
was too small to calculate a significant odds ratio for cannabis. However, the 
combined number of samples from all six DRUID case-control studies would 
have been sufficient if all studies were conducted as originally planned. In 
practice, even the combined number of cases and controls appeared to be too 
small to result in a significant odds ratio for cannabis. This was due to the 
fact that most studies did not meet their target number of samples because of 
practical, financial, medical ethical and legal limitations. 
6.4.2. Conclusions  
The results provide clear indications that in spite of uniform guidelines 
differences between the odds ratios in the various national DRUID case-
control studies may indeed be at least partially explained by random and 
systematic errors. In general, most errors in this study can be attributed to 
selection bias and to small sample sizes and cell counts. Therefore, the 
authors recommend that in epidemiological studies assessing the risk of 
psychoactive substances in traffic special attention should be given to avoid 
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these potential sources of bias. The list of potential indicators that was 
developed in this study may be useful both as guidance for review studies 
and for future epidemiological studies in the field of driving under the 
influence in order to minimize the effect of potential sources of errors.  
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7. General discussion and conclusions 
The main objective of this thesis is to provide insight in how to provide the 
best estimate of the injury risk of driving under the influence of psychoactive 
substances. More specifically, this study intended to find answers to the 
following research questions that were formulated in Section 1.4. Each 
research question will be discussed in the following sections: 
 
7.1 Which are the possible methods to estimate the risk of driving under 
the influence of psychoactive substances? 
7.2 What is the most preferred case-control design and which design is 
most commonly used in practice? 
7.3 What is the prevalence of psychoactive substances in general traffic? 
7.4 What is the prevalence of psychoactive substances among seriously 
injured drivers? 
7.5 Is there any difference between substance concentrations collected by 
means of spitting tubes and by a commercial oral fluid collection device 
7.6 What is the effect of random and systematic errors on the odds ratios of 
case-control studies? 
 
The main question of this thesis is what is the best estimate of the injury risk of 
driving under the influence of psychoactive substances? This question will be 
answered in Section 7.7. Next, it will be discussed how the results of thesis 
could be used in the light of drug driving legislation (Section 7.8). Finally, the 
main findings of this thesis will be highlighted in Section 7.9. 
7.1. Methods for estimating the risk of driving under the 
influence of psychoactive substances 
The injury risk of driving under the influence of psychoactive substances can 
be calculated by means of different study types. These study types can be 
classified into epidemiological studies and experimental studies. The 
epidemiological studies that estimate the injury risk can in general be 
subdivided in three types of study designs: case-control studies, culpability 
studies and pharmaco-epidemiological studies.  
A case-control study is an epidemiological study design in which 
psychoactive substance use is compared between crash involved drivers and 
non-crash involved drivers from traffic. For both groups of drivers the odds 
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of substance use is calculated. These odds are divided by each other to 
generate an odds ratio, which can be used as an estimate of relative risk. 
Case-control studies have been mentioned (Howe and Choi, 1983; Shadis et 
al., 2002) as the theoretically most appropriate study type to estimate risk. 
However, this is not shared by all researchers in the field of driving under 
the influence. A major disadvantage of case-control studies is that they are 
expensive and time-consuming. Therefore they have not been commonly 
conducted (Houwing et al., 2009; Ramaekers et al., 2004).  
A less expensive epidemiological study design is the culpability study. 
Culpability studies are nested case-control studies, which are used to 
compare culpability rates of drug-positive accident-involved drivers with 
culpability rates of drug-negative accident-involved drivers (Drummer, 
2009). The classification of culpability is based on a structured culpability 
analysis that is assessed without previous knowledge on the use of 
psychoactive substances by the driver.  
The third epidemiological study design is the pharmaco-epidemiological 
study, which compares accident rates of medicine users with non-medicine 
users. For this purpose, information from pharmacy records or health 
insurance databases is linked with crash records (Ravera et al., 2011). As the 
name of this design already explains, this design can only be applied to 
calculate the relative accident or injury risk for licit drugs, and not for illicit 
drugs or alcohol. 
Besides epidemiological studies, experimental studies are used to determine 
the risk associated with driving under the influence of psychoactive 
substances. Experimental studies are applied to assess possible impairment 
of various skills and abilities that are related to driving (Brookhuis et al., 
2003). At present, these experimental studies generally involve administering 
a drug to volunteer subjects and then measuring their performance in 
driving simulators, on closed courses, or in on-the-road situations in actual 
traffic (Ramaekers et al., 2004). For the additional assessment of the crash risk 
of licit and illicit drugs, the results are related to the results for alcohol at 
specific BACs, for which more or less standardized and accepted odds ratios 
have been derived from epidemiological research (Brookhuis et al., 2003; 
Krüger et al., 2008). Experimental studies can be used for all substances and 
substance combinations and are particularly valuable for substances that are 
not commonly used in traffic. 
Although in general the alternative study designs for case-control studies are 
less difficult to conduct and less expensive than case-control studies, they 
have some methodological limitations (as elaborated upon in Chapter 2) 
when used for calculating the risk of drug driving. Despite these limitations, 
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it is clear that present knowledge on the crash risk of driving under the 
influence would have been very limited without the additional results of 
experimental, pharmaco-epidemiological and culpability studies. 
7.2. The most preferred case-control design in theory and 
the most commonly used case-control design in 
practice 
In 2010, a questionnaire was sent to researchers in the field of driving under 
the influence of psychoactive substances. In this questionnaire experts in the 
field were asked for their preferred study design to determine the risk of 
driving under the influence. The results of this questionnaire are discussed in 
detail in Chapter 2. There appeared to be considerable consensus on their 
preferred study design in the hypothetical situation that no financial, legal or 
practical limitations were present. On eight of the twelve study design items 
that were included in the questionnaire the share of identical answers 
exceeded the predefined limit of 75%. The only items which showed a lower 
share of agreement was on the applied cut-off level (53%), the type of injury 
(35%), the type of roads (74%), and the reference group for drug positives 
(74%).  
Table 7.1 shows what the preferred case-control design would look like, 
based on the prevailing answers of the questionnaire. 
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Table 7.1. Similarity of case-control studies for the preferred design; N = number of 
answers excluding missing values and "I don't know" options. 
Theoretically preferred design case-control studies 
  N Prevailing answer Similarity 
Study population 19 Motor vehicle drivers 79% 
Collection method cases 19 Blood 100% 
Collection method controls 19 Blood 100% 
Cut-off level 17 Lowest Limit of Quantitation 53% 
Injury type 17 Serious injury 35% 
Substance and/or metabolite 16 
Parental substance and 
metabolite 
75% 
Time between accident and 
sampling 
19 Recorded 95% 
Medication before sampling 19 Recorded 100% 
Road types control sampling 19 Main roads and highways 74% 
Confounding factors 16 Age and gender 94% 
Multi drug  19 Separate group 89% 
Reference group odds ratio 19 Negative all substances 74% 
 Average similarity rate                               81% 
 
However, for practical, legal and financial reasons a lot of researchers were 
forced to deviate from their preferred study design. Table 7.2 provides an 
overview of study design items that were most commonly used in practice 
within case-control studies. 
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Table 7.2. Similarity of case-control studies in practice; N = number of answers 
excluding missing values and "I don't know" options. 
Design case-control studies in practice 
  N Prevailing answer Similarity 
Study population 
18 
Motor vehicle drivers or car 
drivers 
39% 
Collection method cases 18 Blood 89% 
Collection method controls 17 Saliva 53% 
Cut-off level 17 Lowest Limit of Quantitation 88% 
Injury type 16 Serious injury 31% 
Substance and/or metabolite 
 7 
Parental substance and 
metabolite 
57% 
Time between accident and 
sampling 
18 Recorded 78% 
Medication before sampling 18 Recorded 94% 
Road types control sampling 18 All roads 72% 
Confounding factors 15 Age and gender 100% 
Multi drug  16 Separate group 94% 
Reference group odds ratio 12 Negative all substances 67% 
 Average similarity rate               72% 
 
The similarity of the twelve study design items that had been actually 
applied by these researchers was in general somewhat lower in practice than 
it was the case with the similarities as shown in Table 7.1. However, the 
prevailing answers were almost identical. The main difference between the 
preferred design in theory and the design that was applied most commonly 
in practice, was the sampling method that was used to collect information on 
substance use from the control population. Whereas all respondents would 
include blood sampling in their theoretical preferred designs, in practice oral 
fluid was mainly sampled. The main reasons for collecting oral fluid samples 
instead of blood that were mentioned were that the collection of blood would 
have increased the refusal rates, that it took too much time, that it was too 
costly, or that it was too difficult and not practical. The collection of oral fluid 
samples among the general driving population may have led to an 
overestimation of drug use in the control samples, since in general, substance 
concentrations are higher in oral fluid than in blood. If more drivers were 
screened positive for drugs at the roadside, the odds ratios for psychoactive 
substances will be lower. In order to adjust for this potential underestimation 
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of the odds ratios, equivalent cut-offs were used in the analysis of the case-
control studies within the DRUID project. However, the use of these 
equivalent cut-offs may not be usable for studies that use other cut-off levels 
for blood or other oral fluid collection devices. Furthermore, the present cut-
offs should be seen as a practical cut-off to improve comparability rather 
than as exact cut-offs. 
In the future, the use of Dried Blood Spots (DBS) as described by Jantos and 
Skopp (2011) may solve the previously mentioned issues of collecting blood 
samples from the general driving population. However, the DBS-method is 
not yet accurate enough for all substances and when these issues would be 
overcome, additional time will still be needed for laboratories to have the 
necessary equipment available for analysis. 
7.3. The prevalence of psychoactive substances in Dutch 
traffic 
The prevalence of psychoactive substances among the general driving 
population in the Netherlands was studied in Chapter 3, in which the results 
of the Dutch roadside survey were compared with the results in Belgian 
traffic. More than 5,000 drivers from cars and small vans were randomly 
selected from Dutch traffic during all days of the week and all times of the 
day and asked to cooperate with the study on a voluntary base. Drivers who 
agreed to cooperate were interviewed on recent drug and medicine use. 
Additionally, the drivers were asked to give a blood sample. If drivers 
refused, an oral fluid sample was requested.  
The results of this study showed that 5.5% of all drivers were positive for one 
or more psychoactive substances. Alcohol was the most prevalent single 
substance in Dutch traffic. When corrected for time of the day and day of the 
week, single alcohol use was observed among 2.15% of the general driving 
population.  
Furthermore, 2.17% of all drivers were positive for illicit drugs. THC was by 
far the most frequently detected illicit drug (1.67%), followed by cocaine 
(0.30%), amphetamines (0.19%), and illicit opiates (0.01%). 
The most frequently detected medicinal drugs in Dutch traffic were 
benzodiazepines. On average, 0.40% of the drivers were positive for 
benzodiazepines. Medicinal opioids (0.16%) and Z-drugs (0.04%) were 
detected less frequent.  
With regard to combined use, cocaine was detected with approximately the 
same frequency alone as it was in combination with other substances. For 
THC, Z-drugs, and medicinal opiates and opioids, the share of combined use 
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was approximately 25% of the total use, whereas for alcohol and 
benzodiazepines the proportion was about 10%. The total use of alcohol in 
combination with other psychoactive substances was 0.24%, whereas the 
total use of drug-drug combinations was 0.35%. 
Although the Netherlands and Belgium are neighboring countries, statistical 
significant differences were present in the prevalence of psychoactive 
substances in traffic. In general, medicinal drug use and alcohol were more 
frequently detected in Belgian traffic, whereas illicit substances were more 
prevalent in The Netherlands. However, when comparing the results of 
roadside surveys with hospital data and data from illicit drug use in the 
general population, it is likely that the observed prevalence of illicit drugs at 
the Belgian roadside was underrepresented and that the prevalence of illicit 
drugs in Belgian traffic is probably higher than the current results show. 
 
Compared to the other European countries in which drivers were screened 
for these substances as part of the DRUID project, the results for the 
Netherlands were below the European average for benzodiazepines, 
medicinal opioids and alcohol, and above the European average for 
amphetamines and THC. The Dutch roadside survey had only 5% non-
respondents, which is very low for this kind of study. However, since the 
non-respondents had higher BAC’s the results for alcohol were slightly 
underestimated.  
The list of DRUID substances did not contain screening for gamma-
hydroxybutyric acid (GHB) and selective serotonin reuptake inhibitors 
(SSRIs), which means that the total prevalence of psychoactive substances 
may have been higher than 5.5%.  
On the other hand, the collection procedure of oral fluid may have 
influenced the concentrations of the samples. The results from Chapter 5 
show that THC concentrations in oral fluid samples collected by spit tubes 
were on average 5.9 times higher than THC concentrations collected by the 
StatSure collection device. These findings imply that the applied equivalent 
cutoff concentrations, which is based on oral fluid results that were collected 
by the Statsure collection device, may have been too low for the Dutch study, 
in which spitting tubes were used for oral fluid collection. Consequently, 
some of the drug positive oral fluid samples in the Dutch study may have 
erroneously been regarded as positive. 
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7.4. The prevalence of psychoactive substances in seriously 
injured drivers in the Netherlands 
Between March 2008 and April 2010 a study on the presence of alcohol and 
other drugs in injured drivers admitted to the emergency departments of 
three hospitals in the Netherlands was undertaken as part of the European 
DRUID project. Only drivers of personal cars or vans, aged more than 18 
years and with a Maximum Abbreviated Injury Scale (MAIS) ≥2 were 
included (Association for the Advancement of Automotive Medicine 
(AAAM), 2008). In total 187 samples were collected.  
Blood samples were taken using a 5 mL glass collection tube containing 
potassium oxalate and sodium fluoride and stored in solid carbon dioxide in 
the hospitals. After transportation to the Netherlands Forensic Institute (NFI) 
in The Hague, blood samples were stored at -20°C until analysis. 
 
In Chapter 4 the results of the Dutch and Belgian DRUID study on 
psychoactive substance use among injured drivers were compared. The 
results showed that in the Netherlands almost 35% of the seriously injured 
drivers was positive for one or more psychoactive substances. Alcohol was 
the most prevalent substance. About 28% of the injured drivers in the 
Netherlands tested positive for alcohol above the legal limit (0.5g/L) and 
approximately 18% of BACs was higher than 1.3 g/L.  
Compared with the prevalence of alcohol, the prevalence of licit and illicit 
drugs was relatively low among injured drivers. Single use of psychoactive 
substances other than alcohol was barely detected in the Dutch hospital 
survey, ranging from 0 to 1.1% per substance. The prevalence of drug-drug 
combinations among injured drivers was also found to be low with 0.5%, 
whereas the prevalence of alcohol-drug combinations was relatively higher 
(4.3%). 
A higher prevalence of alcohol and drugs in seriously injured drivers was 
found in Belgium compared to the Netherlands. Alcohol was the most 
prevalent finding in both studies. The distribution of blood alcohol 
concentrations in the Dutch and Belgian study was similar with very high 
blood alcohol concentrations in both and a similar median blood alcohol 
concentration (about 1.6 g/L).  
One notable finding is the low prevalence of THC and benzodiazepines in 
the Dutch injured driver population. Despite the high prevalence of THC 
found in the general driving population surprisingly almost no THC was 
found in the Dutch injured driver population. In addition no 
benzodiazepines were found in the Dutch injured drivers. This could be 
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expected since a low prevalence was found in the general driving population 
(Belgium had a prevalence of about five times higher than the Netherlands). 
For the other illicit drugs (amphetamines, cocaine and illicit opiates) and 
medicinal drugs (z-drugs and medicinal opioids) no large differences were 
observed. When looking for explanations for the differences in prevalence 
found above different aspects such as differences in alcohol enforcement 
between the countries, differences in age and gender distribution of the 
samples and differences in consumption patterns should be kept in mind. 
 
In a previous study among seriously injured drivers in the Netherlands the 
prevalence of drugs was much higher (Mathijssen and Houwing, 2005). 
Several reasons can be given for the lower share of psychoactive substances 
other than alcohol. First, differences could be explained by the difference in 
the biological matrix. In one third of the IMMORTAL cases, urine was 
analysed. Since substance use can be detected more easily in urine, the 
prevalence of the hospital study in IMMORTAL could have been 
overestimated. The median interval between accident and sampling was 1.35 
h. Some drugs with a short half-life, such as THC and cocaine, might have 
been used by more drivers than it was detected in the Dutch study. Some 
Dutch injured drivers were found positive for the metabolite THC-COOH. 
The presence of THC-COOH indicates past use of cannabis. When 
calculating the prevalence of THC and/or THC-COOH 1.6% of the Dutch 
drivers were found positive compared to the 0.5% drivers found positive for 
THC. These drivers would also have been detected when urine would have 
been used as a biological matrix. 
A second possible reason for the lower prevalence in the DRUID study is the 
smaller number of substances that was analysed. In the DRUID study the 
blood samples were only screened for a limited list of benzodiapines. It may 
be possible that drivers were using other benzodiazepines than those 
screened for within the DRUID project. 
Finally, given the small number of included subjects the 95% confidence 
intervals provide a more accurate prevalence. In the case of a prevalence of 
0.5% e.g. for THC or Z-drugs the 95% confidence interval was 0.0-2.9%. For 
substances that were not detected, such as single cocaine use or single illicit 
opiate use, the 95% confidence interval was still 0.0-2.0%. 
 
The results of the prevalence of psychoactive substances in traffic (Section 
7.3) and the prevalence among injured drivers (Section 7.4) can be used to 
estimate the relative risk of driving under the influence. By comparing the 
ratio of drug positive injured drivers with the ratio of drug positive drivers 
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among the general driving population odds ratio can be calculated. These 
odds ratios are discussed in Sections 7.6 and 7.7 of this thesis. 
7.5. The effect of the oral fluid collection device type on 
substance concentrations  
The repeatability of both the Statsure collection method and the ordinary spit 
tubes is low when applied among subjects who have consumed cannabis 
very recently. In comparison with the Belgian legal limit, results of the 
Statsure collection method are more in agreement with each other than 
results of the spit tubes. Furthermore, the results of Chapter 5 show that 
samples obtained by spitting had 1.7-5.9 times higher THC concentrations 
than samples from the Statsure collection method, depending on the choice 
of the upper limit of THC concentrations that were included for analysis.  
The results of this study have implications for the comparability of the 
results of the Dutch roadside survey with the other DRUID studies as was 
already mentioned in Section 7.3. Since the results of the roadside survey are 
also used as the control population in the Dutch case-control study that 
estimated the risk of driving under the influence of psychoactive substances, 
the Dutch odds ratios for psychoactive substances other than alcohol are 
probably underestimated. Unfortunately, the number of samples is too small 
to calculate an alternative equivalent cut-off, based on the same method that 
equivalent cut-offs have been calculated for the oral fluid samples that were 
gathered by the Statsure collection device. Therefore, no exact size of the 
effect of the oral fluid collection device on substance concentrations can be 
measured. 
The blood alcohol concentration (BAC) was not measured in oral fluid, but in 
breath. Therefore, this issue does not seem to concern the prevalence of 
alcohol directly. However, in theory it might be possible that due to the 
alternative higher cut-offs for drugs in the spitting samples, samples that 
were initially assigned to the group of drug-alcohol combinations might be 
reassigned to the single alcohol group. This would lead to a decrease of the 
share of drivers positive for drug-alcohol combination and an increase of the 
share of drivers positive for single-alcohol use. Therefore, higher cut-offs for 
drugs in spitting samples could indirectly affect the results for alcohol as 
well. 
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7.6. The effect of random and systematic errors on the odds 
ratios of case-control studies  
As discussed in Section 1.3, the results of case-control studies on the risk of 
driving under the influence of psychoactive substances show large variations 
between the calculated odds ratios. This problem is acknowledged in review 
studies and is often related to differences in study design and to the effect of 
random and systematic errors. Separating the effect of differences in study 
design from the effect of errors is difficult though, and only possible if 
studies are compared that have been conducted by using the same design.  
Within the European DRUID project six case-control studies have been 
conducted to study the injury risk of driving under the influence of 
psychoactive substances. Guidelines were prepared to stimulate that the 
outcomes of these case-control studies were comparable. As a result, these 
studies were conducted based on a more or less similar design. The main 
design difference was the biological matrix that was used for sampling body 
fluids. In Lithuania, only blood samples were collected, in Denmark and 
Finland, only oral fluid samples were collected, whereas in Belgium, Italy 
and the Netherlands a mixture of both blood and oral fluid samples was 
available. To be able to compare the results from these studies, equivalent 
cut-offs were determined for all included samples.  
To study the potential effect of errors on the results of the six DRUID case-
control studies on injury risk, a list of indicators for potential errors was 
needed. In this thesis the categorization of Kleinbaum et al. (1982) and 
Rothman (1986) is used, which is supported by Wacholder et al. (1992). Table 
7.3 provides an overview of this list of indicators. 
 
Chapter 6 showed the results of the assessment of potential bias in the six 
DRUID case-control studies on injury risk. It can be concluded that none of 
these studies was perfect. The most commonly observed errors were due to 
selection bias and to relatively small sample sizes and low cell counts for 
individual substances. 
By introducing guidelines and a protocol for conducting case-control studies, 
and by using equivalent cut-offs, the effect of information bias (see Table 7.3) 
is probably relatively limited. The effect of confounding remains uncertain 
though. Age, gender and time period, which are commonly used 
confounding variables, have been included in the statistical model to 
calculate odds ratios. However, there may be other variables, such as road 
conditions and density of traffic, that influence the risk of injury when 
driving under the influence. 
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Table 7.3. Indicators of potential survey errors. 
Type of error Type of bias Indicator  
Random error  
Sample size 
Low cell counts 
Systematic error 
Selection bias 
Geographic area covered by cases and 
controls 
Size of non-response 
Age and gender distribution of 




Sampling method cases and controls 
Analytical method 
Time between accident and sampling 
Confounding Confounding factors controlled for 
 
 
Future epidemiological studies that assess the risk of driving under the 
influence of psychoactive substances are recommended to include a pilot 
study with an assessment of potential bias. An a priori assessment of the 
potential effect of random and systematic errors would allow identification 
of the presence of potential limitations in the study design that could result 
in bias. However, it should be taken into account that the present list of 
potential indicators is not exhaustive since it is tailored to the DRUID case-
control studies.  
7.7. The best estimate of the relative risk of driving under 
the influence of psychoactive substances 
In an ideal scenario, one would compare the odds ratios from a number of 
studies to arrive at the best estimate of the relative risk of driving under the 
influence of psychoactive substances. These studies should meet the 
following two conditions: the selected studies should have comparable 
designs and their results should not be affected by random and systematic 
errors.  
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7.7.1. Comparable study designs 
Several issues concerning study designs should be taken into account when 
comparing different studies that assess the risk of driving under the influence.  
First, the use of different study types should be considered. Case-control 
designs differ from the designs of culpability and pharmaco-epidemiological 
studies. Therefore, the results of pharmaco-epidemiological case-control 
studies and culpability studies, which can be seen as nested case-control 
studies, cannot be compared with those of regular case-control studies. Not 
much information is available on the effect of assessing the risk of driving 
under the influence of psychoactive substances by different types of studies. 
However, in the literature three studies were found that compared the 
estimated risk of driving under the influence, calculated by two different 
study types.  
Ravera et al. (2012) compared the results of their case-control study and their 
culpability study and found that the results differed. None of the results of the 
culpability study showed a significant increase of risk for psychotropic 
medication use, while their case-control study did. They concluded that their 
results were in line with Hebert et al. (2007) who also found an increased risk 
of benzodiazepine use in their case-control study which was not supported by 
their culpability study. Both Ravera et al. and Hebert and al. concluded that 
the differences among the findings of their studies could be the result of 
differences between the study types. 
A third example of a study in which both the results of a case-control and a 
culpability are compared is a study by Brault et al. (2004). In this study, odds 
ratios for fatal injury were calculated for alcohol, cannabis, benzodiazepines 
and cocaine. The results of the culpability studies showed lower odds ratios 
for alcohol, cannabis and benzodiazepines than the case-control results. No 
sufficient data were available for calculating the culpability rate of cocaine. 
The authors stated that the results of the responsibility analysis were 
deceiving. The lower odds ratios might be due to the high level of 
responsibility for fatal crashes of the included killed drivers. For this reason 
no large differences were found in the culpability study for sober and 
substance positive drivers, leading to relatively low odds ratios of being 
responsible for the fatal crash. 
Based on the results above it might be concluded that the differences between 
odds ratios for culpability studies and case-control studies are partly based on 
differences in methodology. The results of the studies that combine a regular 
case-control study with one of the other study designs indicate that odds 
ratios that were calculated by case-control studies might in general be 
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somewhat higher than odds ratios that were calculated by other 
epidemiological study designs. 
A second relevant issue when comparing the results of epidemiological 
studies that assess the risk of driving under the influence is the presence of 
differences within a specific type of study design. Examples of such 
differences are the type of injuries included, the cut-off levels of psychoactive 
substances, the biological matrix, and the list of substances included. The 
biological matrix is a design item that needs special attention. In theory, the 
ideal method would be to collect blood samples from both the case and the 
control population. However, in practice it is more common to collect oral 
fluid samples from the control population, since this leads to a lower share of 
non-response, is less expensive and easier to collect than blood. A 
disadvantage of oral fluid is that substance concentrations in oral fluid are not 
comparable to those in blood. In general, substance concentrations are higher 
in oral fluid than in blood which makes it easier to detect drug positive 
drivers. The selection of the biological matrix will therefore be of influence for 
the detected prevalence of psychoactive substances in the study population. 
Within the DRUID project a practical solution was found by using equivalent 
cut-offs. Another type of biological matrix is urine, which was used in the 
Dutch IMMORTAL study (Mathijssen and Houwing, 2005). However, the 
detection window of psychoactive substances is much larger in urine than it is 
in blood or oral fluid, which makes it difficult to regard the presence of 
substance concentrations in urine as a marker for recent substance use. By 
using urine to collect information on drug use among the control population 
in case-control studies, the prevalence of substances in general traffic could be 
overestimated. Subsequently, this would lead to an underestimation of the 
relative risk.  
In 2005, guidelines for epidemiological studies were prepared by a special 
ICADTS-committee (Walsh et al., 2008). These guidelines included several 
recommendations among which the use of specific cut-offs for substances and 
the use of blood or oral fluid as matrix. In 2007, the DRUID project adopted 
these guidelines for their case-control studies, and additionally included so-
called equivalent cut-offs to correct for the differences in substance 
concentrations between blood and oral fluid.  
In six of the DRUID case-control studies research was conducted on the risk of 
serious injury, while four other studies assessed the risk of fatal injury. The 
focus of this PhD thesis is on the comparability of those six DRUID studies 
that estimated the risk of serious injury. By applying the ICADTS-guidelines 
in combination with the equivalent cut-offs, the first condition (having 
comparable study designs) for determining the best estimate for the risk of 
driving under the influence can be regarded as fulfilled. 
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7.7.2. Bias due to random and systematic errors 
After the selection of studies with comparable research designs, the second 
step to determine the best estimate of the relative risk of driving under the 
influence of psychoactive substances is to assess the potential bias due to 
random and systematic errors.  
As explained earlier, ideally, the best estimate of the relative risk of driving 
under the influence would be based on a number of case-control studies with 
a sufficient number of cases and controls to show significant odds ratios for 
those psychoactive substances that are expected to have only moderate 
elevated risks, e.g. cannabis. Furthermore, there should be no non-response in 
both the control and case-population, and participants of the control 
population should be selected at random from the same study base as the 
cases. In addition, it is of importance that substance use is determined in both 
the case and the control population by the same biological matrix, preferably 
blood. Finally, confounding factors have to be taken into consideration as 
much as possible. To this, at least the variables age, gender and time should be 
included in the statistical analysis.  
Unfortunately, none of the present studies that estimated the risk of driving 
under the influence of psychoactive substances have met these (ideal) 
standards. The odds ratios of the six DRUID studies showed large variation as 
was presented in Chapter 6. The results of the assessment of bias in Chapter 6 
support the assumption that results may indeed be biased. Therefore, the 
second condition for a good estimate of the relative risk caused by driving 
under the influence was not met. 
7.7.3. An alternative estimation 
Since the DRUID studies do seem to suffer from random and systematic 
errors, it is hard to provide a good estimate. If there would have been one 
flawless study among the DRUID studies, it could have served as a reference 
study. In this case the size of the bias might have been quantified. However, 
by comparing the results of the DRUID case-control studies with each other, 
at least the direction of some of the bias can be estimated (see Chapter 6). 
Table 7.4 presents an overview of the calculated odds ratios for the six studies. 
Cells that include odds ratios which are potentially underestimated are 
colored light grey, whereas odds ratios that are potentially overestimated 
have been colored dark grey. Furthermore, the results for countries in which 
there was a relatively large likelihood of bias due to a small sample size in 
either the case or control populations, are presented in bold italics.  
  
Table 7.4. Odds ratios indicating the relative risk of being seriously injured (MAIS ≥2) due to driving under the influence of psychoactive substances 
according to country, adjusted for age and gender, and 95% confidence intervals (adapted from Hels et al., 2011); cells with OR’s which are 
potentially underestimated are colored light grey and cells with OR’s which are potentially overestimated are colored dark grey; na = not possible to 
calculate due to low cell counts. Inf = infinity. 
Psychoactive substance Belgium Denmark Finland Italy Lithuania Netherlands All countries 
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na na 8.01 
5.34-12.01 
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Although for most countries the estimations of the direction of the effect of 
potential bias look quite straightforward, not all effects seem to be fully 
explained by errors. Several reasons for this can be thought of: for example, 
the potential size of bias might not be the same for each country and even for 
each substance. Since qualitative measurements are not available, this issue 
has not been taken into account in the table. Furthermore, for some odds 
ratios two or more effects could have influenced the outcome. It is difficult to 
estimate which type of bias would have had the most dominant effect, let us 
take the case of the odds ratio for cannabis that was calculated in the Dutch 
study. This odds ratio is probably biased due to variation between the 
included regions and the non-included regions of the roadside survey, due to 
the use of spitting tubes as sample collection method at the roadside, and to 
the relatively small number of hospital samples which were sampled in the 
hospital study. It is impossible to disentangle the relative contribution of 
each of these biases. 
A third reason for variety that seems unexplainable by the assessment of bias 
as studied in this thesis, might be the presence of confounding by 
unidentified factors such as road conditions, and density of traffic. 
 
In general, the overall odds ratios for all countries in the last column of Table 
7.4 seem to be as expected, taking into account the direction of bias in the 
national studies. The overall odds ratios for alcohol are in line with those in 
international literature (Hargutt et al., 2011), although it is always difficult to 
compare the results of the DRUID studies with other studies since these 
studies were in general based on other designs and suffer from random and 
systematic errors as well. 
For illicit and medicinal drugs the number of more or less comparable 
studies is small. The case-control studies from Haworth et al. (1997) and 
Blows (2004) that were reported in Chapter 1 have based the prevalence in 
the control population on self-reported use. The French case-control study by 
Mura et al. (2003) did not include non-injured car drivers as the control 
group, but patients from a hospital in possession of a driving license that 
were involved in a non-traffic accident. The Canadian case-control study 
from Brault et al. (2004) and the Dutch case-control study by Mathijssen and 
Houwing (2005) did use both urine and blood as biological matrix. Other 
design differences were present as well; but relative to the other case-control 
studies these two studies might be more comparable -or less incomparable- 
to the DRUID studies. 
A comparison of these latter two studies show that the overall odds ratios for 
illicit drugs are in line with each other. The Canadian case-control study by 
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Brault et al. (2004) found an odds ratio of 4.5 for cocaine and of 1.6 for THC 
after adjustment for gender, age and time period. The Dutch case-control 
study by Mathijssen and Houwing (2005) found an odds ratio of 1.29 for 
THC after adjustment for age, gender and time period and year and quarter 
of the year. For the other illicit substances the numbers were too small to 
calculate odds ratios. The designs from both the Dutch and the Canadian 
case-control study were not directly comparable to the ones of the DRUID 
study which makes it difficult to value the similarities between the odds 
ratios from these studies and the overall odds ratios from the DRUID studies. 
Therefore, similar results between these studies alone do not ensure that the 
studies were free of bias. 
The studies from Brault et al. and from Mathijssen and Houwing found odds 
ratios for benzodiazepines of respectively 3.9 and 3.48, whereas in the overall 
odds ratio of the DRUID studies was lower at 1.99. Of the six case-control 
studies on injury risk that were conducted in the DRUID project, most odds 
ratios for benzodiazepines were around 2. Only the Danish study had an 
odds ratio that was higher: 4.37, whereas the Italian and Lithuanian study 
were lower at 0.2 and 1.02, respectively. The results of the study from 
Mathijssen and Houwing showed an odds ratio of 6.89 for codeine. In the 
DRUID studies, the overall odds ratio for illicit opiates and opioids was 9.06. 
This overall odds ratio for medicinal opioids is considered to be high, since 
most of the results from the national studies showed odds ratios between 4 
and 6. Only in Italy the odds ratio was higher, at 11.16, and in Lithuania the 
number of positive samples was too small to calculate the odds ratio for illicit 
opiates and opioids. 
Taken all together, we consider that apart from the odds ratio for medicinal 
opioids, the overall odds ratios for psychoactive substances provide a better 
estimate of the relative risk of having an injury when driving a car after 
recent use of psychoactive substances than the odds ratios of each of the six 
national case-control studies. 
7.8. Drug driving legislation 
Within Europe, new drug driving legislation has been introduced in 
February 2012 in Norway (Vindenes et al., 2012). In the Netherlands new 
drug driving legislation is foreseen for 2013. These are the first countries that 
have used the results of the DRUID project in their drug driving legislation. 
The proposed Dutch legislation covers the five different types of substances: 
amphetamines (amphetamine, methamphetamine, MDA, MDMA and 
MDEA), cocaine, THC (cannabis), and GHB (Adviescommissie 
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Grenswaarden, 2010). For these substances impairment related per se limits 
for concentrations have been determined by a group of experts. These 
concentration limits indicate that once they are exceeded, the driving skills 
are affected in such a way that the driver can no longer be expected to drive 
safely. Furthermore, the proposed drug driving legislation obliges drivers to 
cooperate with an oral fluid screening test and with a test on psycho-motor 
functions. If a driver is suspected for drug-driving a blood sample will be 
taken to determine whether or not the legal limits were exceeded.  
The results of the research as reported in this thesis could be used to support 
new drug driving legislation in several ways. Three relevant considerations 
in the process of new drug driving legislation can be distinguished. 
The first moment of consideration is in the design phase when the choice has 
to be made between per-se legislation and legislation on impairment. These 
per-se limits can be based on three different types of limits: the lowest limit 
of quantitation or the lowest limits of detection, the lowest limit of 
impairment or the lowest limit of risk (Verstraete et al., 2011b).  
When introducing per-se legislation with impairment or risk related legal 
limits, a meta-analysis of existing literature and/or an expert panel is needed 
to determine specific cut-offs for substance concentrations. Both in Norway 
and The Netherlands a panel of experts was established to determine a list of 
the psychoactive substances that should be included in legislation and their 
concentration limits. The panel of experts can discuss findings from different 
studies and come to an agreement on legal limits. The results from these 
studies are generally based on both experimental and epidemiological 
studies. Experimental studies provide information on the level of 
impairment that is caused by psychoactive substance use. Experimental 
studies can also compare impairment of licit and illicit drugs with 
impairment of alcohol at given BAC levels. 
Epidemiological studies can provide information on the share of drivers that 
are driving under the influence of psychoactive substances or that are 
seriously injured or even killed while driving under the influence. 
Furthermore, the relative injury or crash risk can be estimated by means of 
epidemiological studies. Although the information from epidemiological 
studies is at present insufficient to calculate risk-related legal limits, valuable 
information can be derived from epidemiological studies to support and 
interpret the results from experimental studies (Adviescommissie 
Grenswaarden, 2010). So even when legal limits are based on experimental 
studies, the results of epidemiological studies are still of value. 
This thesis provides some guidelines to review the outcomes of specific 
epidemiological studies. It offers a list of indicators of potential bias and a list 
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of items per specific study type that can be used to compare study designs 
and validate their results. 
 
The second relevant issue concerns the list of individual psychoactive 
substances to be included in the drug driving legislation. The present list of 
psychoactive substances and their legal limits are not fixed. From time to 
time it would be necessary to update the supporting literature to see whether 
the new substances could be included or the legal limits of listed substances 
need to be changed. If epidemiological studies are needed for supporting the 
introduction of new or altered legal limits, the results of the research 
presented here can provide background information on how to design or 
evaluate these studies.  
 
And finally, the results of this thesis can be used to design evaluation studies 
of new drug driving legislation. Within the European DRUID project a cost-
benefit analysis was conducted to gain insight in the costs and benefits from 
increased drug driving enforcement by means of oral fluid screening devices 
(Veisten et al., 2011). The results of this study indicate that it is important to 
introduce drug-driving enforcement with special caution, due to the 
potential negative side effect on drink driving enforcement. Baring this in 
mind, it is recommended to monitor the effects of new drug driving 
legislation and its enforcement on traffic safety. This monitoring should 
preferably not only be focused on the use of illicit drugs in traffic but also on 
the use of alcohol in order to be able to detect potential negative side effects 
of drug driving enforcement on the use of alcohol in traffic.  
7.9. Synthesis 
The main objective of this thesis was to provide insight in how to arrive at 
the best estimate of the injury risk of driving under the influence of 
psychoactive substances. To this end, two conditions were formulated. First, 
studies are needed with a comparable study design, since variation in results 
can be caused by differences in study design. The second condition includes 
the absence of random and systematic errors in those studies that meet the 
first condition. 
 
Between 2007 and 2010, six case-control studies were conducted within the 
European research-project DRUID by means of similar study designs. 
Guidelines and study protocols were prepared for the DRUID case-control 
studies according to the ICADTS guidelines for epidemiological studies 
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(Walsh et al., 2008) to stimulate that the outcomes of these case-control 
studies were comparable. Furthermore, equivalent cut-offs were applied to 
adjust for differences between studies that used oral fluid as biological 
matrix and studies that used blood samples. Despite the high comparability 
of the study designs, the results still showed large variations between the 
calculated odds ratios.  
To get insight in the reason behind this variation, it was assessed in this 
thesis whether these differences could be caused by different kinds of 
random and systematic errors. The results showed that this variation in odds 
ratios could indeed be explained by the presence of random and systematic 
errors. Another finding was that the most common types of errors that were 
detected in the case-control studies under scrutiny were selection bias and 
lack of sufficient study power due to small sample size.  
Based on these results, it can be concluded that the presence of guidelines 
and protocols did not sufficiently solve the issue of incomparable odds 
ratios. The question is whether this issue is caused by flaws in the guidelines 
or by flaws in the compliance of researchers to the guidelines. 
The combination of the ICADTS guidelines and the equivalent cut-offs of the 
DRUID project may be seen as the state-of-the-art on attempts to conduct 
case-control studies that are comparable. However, it may be questioned 
whether it is possible for future studies to adapt this design. The compliance 
to these guidelines can be restricted by practical, legal, financial and ethical 
reasons. Furthermore, it also depends on the willingness of researchers to 
commit themselves to guidelines, that they might not always fully agree 
with. Finally, the need to answer specific research questions could cause 
deviation from the ICADTS and DRUID guidelines. For example, if a case-
control study is designed to compare its results with that of a previous 
national case-control study the design should be comparable to that of the 
previous study in order to be able to monitor any differences. 
 
One of the largest problems in the design of case-control studies is the 
biological matrix that is used for collecting data on substance use from the 
control population. In theory, collecting blood samples would be the most 
appropriate method, since it matches with the collection of blood from 
injured drivers (the case population). However, one of the major 
disadvantages of blood sampling is that it may lead to relatively high non-
response rates, since participants might not always be very eager to give 
blood. Therefore, in practice oral fluid samples are mainly collected. The 
substance concentrations in oral fluid differ from concentrations in blood and 
therefore equivalent cut-offs were used within the DRUID case-control 
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studies. The use of oral fluid sampling may be replaced in future studies by 
the Dried Blood Spot (DBS) method. This method could be a less expensive 
and more reliable method to calculate odds ratios, however, although the 
results for some psychoactive substances seem promising, no strong 
correlation exists at present between the THC concentrations in venous blood 
and in DBS. Researchers are still trying to find a solution for this and if the 
correlation for THC can be established, the DBS method might replace oral 
fluid sampling in future case-control studies. Until then, we recommend the 
use of equivalent cut-offs if oral fluid samples are collected from the control 
population. 
In order to avoid bias and confounding due to errors, future guidelines are 
recommended to more systematically include an overview of the sources of 
potential bias and instructions of how to avoid them. The ICADTS guidelines 
already contained some guidelines on how to avoid bias and increase the 
power and sensitivity of a study. However, they may not have been specific 
enough. One of the recommendations in the ICADTS guidelines was to 
conduct a power-study to estimate the number of samples that would be 
needed to reach a sufficient level of sensitivity. In the DRUID studies no a 
priori study was conducted to assess the number of cases and controls that 
would be necessary. It was expected that if all studies would include on 
average between 600-700 samples and 1,500-4,000 samples at the roadside, 
that this would be sufficient. The results of an a posteriori assessment of the 
necessary sample size to get sufficient power to get significant results for the 
odds ratios for THC, showed that at least 3,700 cases and 11,000 controls 
should have been included. These numbers are far too large for a single case-
control study in the DRUID project, but by combining all case-control studies 
these numbers would have been feasible. Unfortunately, the average number 
of included cases in the six DRUID case-control studies was 415 (with only 54 
cases in Finland and 188 in the Netherlands), adding up to a total of 2490 
cases.  
It can be questioned whether it is necessary to calculate significant odds 
ratios for all substances. For policy purposes it might be sufficient to 
calculate significant odds ratios only for the most prevalent substances that 
cause high risks. On the other hand, if the results are used to calculate risk 
related legal concentration limits for psychoactive substances, far more cases 
and controls will be needed. It should therefore be noted that the required 
number of samples varies with the specific research question.  
It is also stated in the guidelines that the non-response level should be 
minimized and that specific information should be gathered to get more 
insight in the likelihood of non-response bias. However, guidelines do not 
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describe when a non-response percentage is regarded as too high, or when 
non-response bias is regarded as being so large that the results should be 
questioned. Since case-control studies are very costly and time-consuming to 
conduct it might be recommendable for future studies to a-priori assess the 
potential level of bias due to study errors by comparing the study design 
with one of the previous study designs. If the likelihood of bias is large and 
no or insufficient possibilities are available to avoid this potential bias, then it 
might be necessary to reconsider to conduct the study. Therefore, a pilot 
study with an a-priori assessment on potential bias, based on the one that 
was used in this thesis, could serve as a go-no go test for conducting future 
case-control studies that calculate the risk of driving under the influence of 
psychoactive substances. 
By increasing the comparability of study designs and by decreasing the 
potential errors of case-control studies a good estimate of the risk of driving 
under the influence of psychoactive substances might be available in future. 
However, since case-control studies are rarely conducted, it probably will 
take many years before a study is conducted and published that can serve as 
a theoretically sound landmark study for estimating the risk of driving under 
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Driving under the influence is regarded to be one of the leading causes for 
fatal traffic crashes. In the past decades much research has been conducted to 
estimate the risk of driving under the influence of alcohol. However, studies 
that estimate the risk of driving under the influence of psychoactive 
substances other than alcohol are less common. Some researchers state that 
the optimal study design to study the risk of driving under the influence of 
psychoactive substances is by means of case-control studies. A case-control 
study is an epidemiological study design in which psychoactive substance 
use is compared between crash involved drivers and non-crash involved 
drivers from traffic. For both groups of drivers the odds of substance use is 
calculated. These odds are divided by each other to generate an odds ratio, 
which can be used as an estimate of relative risk. A major disadvantage of 
case-control studies is that they are expensive and time-consuming. 
Therefore they have not been commonly conducted.  
This thesis aims at contributing to the current knowledge on how to 
determine the best estimate of the injury risk of driving under the influence 
of psychoactive substances.  
Thereto, this thesis included the following research questions: 
• Which are the possible methods to estimate the risk of driving under 
the influence of psychoactive substances? 
• What is the most preferred case-control design in theory and which 
design is most commonly used in practice? 
• What is the prevalence of psychoactive substances in general traffic? 
• What is the prevalence of psychoactive substances among seriously 
injured drivers? 
• Is there any difference between substance concentrations collected by 
means of spitting tubes and by a commercial oral fluid collection device 
• What is the effect of random and systematic errors on the odds ratios of 
case-control studies? 
 
In Chapter 1 an overview is given of the basic principles of case-control 
studies. Only few case-control studies have been conducted to estimate the 
risk of driving under the influence of psychoactive substances. This is mainly 
because case-control studies are expensive and difficult to conduct. Apart 
from the low number of case-control studies in the field of driving under the 
influence, the results of case-control studies seem to vary. Therefore, in 2006, 
a consensus meeting was organized by the International Council on Alcohol, 
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Drugs and Traffic Safety (ICADTS) to develop standards for future research. 
Their recommendations for standardized research included legal/ethical 
issues, subject and study design issues and core data parameters. Within the 
European research project DRUID (DRiving Under the Influence of Drugs, 
Alcohol and Medicines), six case-control studies were conducted according 
to these guidelines to assess the relative risk of serious injury due to driving 
under the influence. Although the design of the DRUID case-control studies 
was more or less comparable, differences were in practice still present 
because of practical, ethical or legal limitations. In order to compare the 
outcome of these studies with each other and with previous studies, more 
insight was needed in the effects that study errors and differences in study 
design have on the outcomes of case-control studies.  
 
Chapter 2 discusses the results of a questionnaire survey on methodological 
aspects concerning study designs that was sent to researchers in the field of 
driving under the influence of psychoactive substances. Four types of study 
designs could be distinguished among the studies of the researchers that 
actually conducted studies to estimate the risk of driving under the 
influence: case-control studies, culpability studies, pharmaco-
epidemiological studies and experimental studies. The focus of this thesis is 
solely on case-control studies. The results of Chapter 2 showed considerable 
consensus among researchers that conducted case-control studies regarding 
their preferred study design in the hypothetical situation, that no financial, 
legal or practical limitations were present. However, in practice the 
previously mentioned types of limitations forced researchers to deviate from 
their preferred study design. The main difference between the preferred 
design in theory and the design that was most commonly applied in practice, 
was the biological matrix of body fluid sampling that was used to collect 
information on substance use from the control population. Whereas all 
respondents would include blood sampling in their theoretical preferred 
designs, in practice oral fluid was mainly sampled. Most commonly 
mentioned reasons for collecting oral fluid samples instead of blood were 
that the collection of blood would have increased the refusal rates, that it 
took too much time, that it was too costly, or that it was too difficult and not 
practical.  
The collection of oral fluid samples from the general driving population is 
relevant for the results of case-control studies, since it may have led to an 
overestimation of drug use in the control samples. In general, substance 
concentrations are higher in oral fluid than in blood, which makes it easier to 
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have drug positive screenings. Consequently, the odds ratios for 
psychoactive substances will be lower.  
 
As mentioned before, guidelines were prepared for the DRUID case-control 
studies to stimulate uniform study designs. Chapter 3 compares the results of 
the prevalence studies on psychoactive substance use among the general 
driving population both in the Netherlands and Belgium. The prevalence 
studies were used to provide the control samples for the Dutch and Belgian 
case-control studies. Blood and oral fluid samples were analysed for 23 
substances including ethanol (alcohol) by means of UPLC-MS/MS or GC-MS 
analysis. The results show that the observed prevalence of psychoactive 
substances varies largely between the Netherlands and Belgium: the 
prevalence of single alcohol (6.4%) and single medicinal drugs (3.0%) was 
much higher in Belgium than in the Netherlands (respectively 2.2% and 
0.6%), while the single illicit drugs were more common in Dutch traffic 
(2.2%) than in Belgian traffic (0.6%). Probable reasons for the differences are 
the higher level of alcohol enforcement in the Netherlands and non-response 
bias in the Belgian study (for illicit drugs in particular). Furthermore, cultural 
differences and differences in prescription policy could be of influence.  
 
In Chapter 4 the results of the Dutch and Belgian hospital study are 
compared. These hospital studies provided the cases for the Dutch and 
Belgian case-control studies. The results showed that in the Netherlands 
almost 35% of the seriously injured drivers was positive for one or more 
psychoactive substances. Alcohol was the most prevalent substance. About 
28% of the injured drivers in the Netherlands tested positive for alcohol 
above the legal limit of 0.5 g/L. The use of licit and illicit drugs was detected 
among 10% of the seriously injured drivers in the Dutch hospital survey. The 
prevalence of single drug use was 3%, another 3% of the cases consisted of 
drug-drug combinations , and the prevalence of alcohol-drug combinations 
was 4%. A higher prevalence of alcohol and drugs in seriously injured 
drivers was found in Belgium compared to the Netherlands: 47% of the 
seriously injured drivers was positive for one of more psychoactive 
substances. A total of 38% was positive for alcohol above the legal limit of 0.5 
g/L, around 6.5% was positive for single drug use, 2.5% was positive for 
drug-drug combinations, and 13% for the combination of alcohol and drugs. 
When looking for explanations for the differences in prevalence found above, 
different aspects such as differences in enforcement levels between the 
countries, differences in the age and gender distribution of the samples and 
differences in consumption patterns should be kept in mind. Furthermore, 
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the uncertainty of the data due to a small sample size in the Dutch hospital 
study could have been of influence.  
The results of the studies on the prevalence of psychoactive substances in 
traffic and the prevalence among injured drivers can be used to estimate the 
relative risk of driving under the influence. By comparing the ratio of drug 
positive injured drivers with the ratio of drug positive drivers among the 
general driving population odds ratios can be calculated. In five out of the six 
DRUID case-control studies on injury risk oral fluid samples were collected 
from the randomly selected drivers in general traffic. In the Netherlands oral 
fluid was collect by spitting tubes, whereas in the other four countries oral 
fluid was collected by means of a commercial non-acidic oral fluid collection 
device (Statsure Saliva samplerTM). 
 
Chapter 5 discusses the influence of both oral fluid sample collection 
methods on THC concentrations. The Statsure device had a better rate of 
agreement between two sequently collected oral fluid samples when 
compared to the spitting method. Above that, THC concentrations of 
samples collected by spit tubes were on average a factor 5.9 higher than the 
corresponding concentrations in samples collected by the Statsure device. In 
order to adjust for the use of oral fluid samples instead of blood samples in 
the roadside surveys, equivalent cut-offs were used in the DRUID case-
control studies. These equivalent cut-offs were based on the concentrations of 
the Stature devices. Therefore, the outcomes of this chapter indicate that 
differences in oral fluid collection method could have biased the results of 
the Dutch case-control study. 
 
Chapter 6 deals with the potential effect of random and systematic errors on 
the calculated odds ratios for the six DRUID case-control studies that 
estimated the injury risk of driving under the influence of psychoactive 
substances. The odds ratios calculated in these studies showed large 
variations, despite the use of guidelines for uniform study designs. The 
results in Chapter 6 indicate that differences between the odds ratios in the 
DRUID case-control studies may indeed be (partially) explained by random 
and systematic errors. Selection bias and random errors due to small sample 
sizes and cell counts were the most frequently observed errors in the six 
DRUID case-control studies. 
  
Chapter 7 discusses how to determine the best estimate of the injury risk of 
driving under the influence of psychoactive substances. Two requirements 
were formulated: First, studies are needed with a comparable study design, 
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since variation in results can be caused by differences in study design. 
Second, studies that meet the first requirement should be free of random and 
systematic errors. The six DRUID case-control studies that estimated the 
injury risk of driving under the influence of psychoactive substances met the 
first condition. However, the results of this thesis show that all six case-
control studies did seem to suffer from random and systematic errors.  
The guidelines of the DRUID case-control studies were based on the 
guidelines for epidemiological research as prepared by a special ICADTS-
committee. These guidelines should ensure comparable study designs in 
future research on impaired driving. The guidelines seemed not capable 
though to prevent random and systematic errors. Possible reasons for this are 
the level of detail of the guidelines that leaves too much room for 
interpretation, but also the compliance of researchers to the guidelines may 
be questioned. Conducting pilot studies that include an assessment on 
potential indicators of random and systematic errors may improve the 
quality of future case-control studies, and consequently providing better 
estimates of the injury risk of driving under the influence of psychoactive 
substances.  
 
All in all, the best estimate of the injury risk of driving under the influence of 
psychoactive substances cannot yet be provided. As a result of the DRUID 
project and the ICADTS guidelines, studies with comparable study designs 
are available. These studies could be used to provide a solid estimate of the 
risk of driving under the influence. However, each of these studies suffer 
from random and systematic errors, causing large variation between the 
odds ratios. Based on the assessment of indicators of potential bias we 
regard, for the moment, the overall results of the DRUID case-control studies 
as the best possible estimate for the relative risk on serious injury, with the 
exception of the overall odds ratio for medicinal opioids which seems to be 
somewhat overestimated. However, the future should learn whether this 





Rijden onder invloed wordt beschouwd als een van de belangrijkste 
oorzaken van dodelijke verkeersongevallen. In de afgelopen decennia is er 
veel onderzoek uitgevoerd naar het risico van rijden onder invloed van 
alcohol. Onderzoeken naar het risico van rijden onder invloed van andere 
psychoactieve stoffen dan alcohol komen echter minder vaak voor. Sommige 
onderzoekers beschouwen case-controlstudies als de beste manier om het 
risico van rijden onder invloed van psychoactieve stoffen te onderzoeken. 
Een case-controlstudie is een epidemiologisch type studie waarin het gebruik 
van psychoactieve stoffen door automobilisten die betrokken zijn bij 
ongevallen, wordt vergeleken met het gebruik door automobilisten die niet 
bij ongevallen zijn betrokken. Voor beide groepen automobilisten wordt de 
relatieve kans op drugsgebruik berekend. Deze twee relatieve kansen 
worden vervolgens op elkaar gedeeld waardoor er een zogenaamd ‘odds 
ratio’ ontstaat. Deze kan gebruikt worden als schatting van het relatieve 
risico. Een belangrijk nadeel van case-controlstudies is dat de uitvoering 
kostbaar en moeilijk is. Daarom zijn er niet veel van deze studies uitgevoerd. 
Het doel van dit proefschrift is om een bijdrage te leveren aan de huidige 
kennis om tot de beste schatting te komen van het risico op letsel als gevolg 
van rijden onder invloed van psychoactieve stoffen.  
Het proefschrift behandelt daartoe de volgende onderzoeksvragen 
• Wat zijn de verschillende manieren om een schatting te geven van het 
risico van rijden onder de invloed van psychoactieve stoffen? 
• Wat is in theorie de meest geprefereerde opzet van case-controlstudies 
en welke opzet wordt het meest in de praktijk uitgevoerd? 
• Wat is de prevalentie van psychoactieve stoffen in het verkeer? 
• Wat is de prevalentie van psychoactieve stoffen onder ernstig gewonde 
automobilisten? 
• Verschillen de concentraties van stoffen in speekselmonsters die 
verzameld zijn met behulp van spuugpotjes, van de concentraties in 
speekselmonsters die verzameld zijn met behulp van een commerciële 
speekselafname set? 
• Wat is het effect van willekeurige en systematische fouten op de odds 
ratio’s van case-controlstudies? 
 
Hoofdstuk 1 geeft een overzicht van de basisprincipes van case-control-
studies. Er zijn slechts weinig case-controlstudies uitgevoerd die een 
schatting geven van het risico van rijden onder invloed van psychoactieve 
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stoffen. De belangrijkste reden hiervoor is dat het uitvoeren van case-
controlstudies duur en moeilijk is. Naast het kleine aantal case-controlstudies 
dat is uitgevoerd, lijken de resultaten ook nog eens te variëren. Daarom is in 
2006 een bijeenkomst georganiseerd door de ‘International Council on 
Alcohol, Drugs and Traffic Safety (ICADTS) om wetenschappelijke 
standaarden te ontwikkelen voor toekomstig onderzoek. Hun aanbevelingen 
voor gestandaardiseerd onderzoek richtten zich op wettelijke en ethische 
aspecten, aspecten op het gebied van deelnemers en onderzoeksopzetten en 
op de basisgegevens die verzameld dienden te worden. Binnen het Europese 
onderzoeksproject DRUID (DRiving Under the Influence of Drugs, Alcohol 
and Medicines), zijn zes case-controlstudies volgens deze richtlijnen 
uitgevoerd om het risico op ernstig letsel te bepalen als gevolg van 
alcoholgebruik in het verkeer. Hoewel de onderzoeksopzet van de DRUID-
case-controlstudies min of meer vergelijkbaar was, waren er toch nog 
verschillen in de uitvoering vanwege praktische en ethische beperkingen, en 
beperkingen gerelateerd aan wettelijke regels. Om de resultaten van deze 
studies met elkaar en met eerder uitgevoerde studies te kunnen vergelijken, 
is meer inzicht nodig in de effecten van fouten en verschillen in 
onderzoeksopzet op de resultaten van case-controlstudies.  
 
In Hoofdstuk 2 worden de resultaten van een vragenlijst besproken. Deze 
vragenlijst was gericht op methodologische aspecten van onderzoeks-
opzetten en is naar personen gestuurd die onderzoek uitvoerden op het 
gebied van rijden onder invloed. De uitgevoerde studies konden verdeeld 
worden in vier verschillende typen: case-controlstudies, studies gericht op de 
schuldvraag, pharmaco-epidemiologische studies en experimentele studies. 
De focus van dit proefschrift ligt enkel op de case-controlstudies. De 
resultaten van Hoofdstuk 2 tonen aan dat er tussen onderzoekers die case-
controlstudies hebben uitgevoerd, aanzienlijke overeenstemming bestaat 
over de in hun ogen optimale onderzoeksopzet in een theoretische situatie 
waarin geen financiële, wettelijke of praktische beperkingen bestonden. In de 
praktijk bestaan deze beperkingen echter wel en uit de enquête blijkt dat ze 
ervoor zorgen dat onderzoekers van hun optimale design moeten afwijken. 
Het belangrijkste verschil tussen de optimale onderzoeksopzet in theorie en 
de uitgevoerde versie in de praktijk was de biologische matrix die is gebruikt 
voor het verzamelen van lichaamsstoffen van de zogenaamde ‘control’-
populatie. Waar in de theoretische situatie alle respondenten voor bloed-
afname kozen, werd in de praktijk meestal speeksel afgenomen. De meest 
genoemde redenen voor deze afwijking waren dat de afname van bloed tot 
meer weigeraars zou leiden, dat het te veel tijd kostte, dat het te duur was, en 
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dat het te moeilijk en niet praktisch was. De verzameling van speeksel-
monsters van verkeersdeelnemers is van belang voor de resultaten van case-
controlstudies, omdat het zou kunnen leiden tot een overschatting van het 
gebruik van drugs en geneesmiddelen. Over het algemeen zijn de 
concentraties van stoffen namelijk hoger in speeksel dan in bloed, waardoor 
men sneller positief zal testen. Als gevolg hiervan zullen bij speekselafname 
van de ‘controls’ de odds ratio’s voor psychoactieve stoffen lager uitvallen.  
 
Zoals eerder vermeld zijn er richtlijnen opgesteld voor de case-controlstudies 
binnen DRUID om de uniformiteit van de onderzoeksopzetten te stimuleren. 
Hoofdstuk 3 bevat een overzicht van de resultaten van de studies naar het 
gebruik van psychoactieve stoffen in het Nederlandse en Belgische verkeer. 
Deze prevalentiestudies zijn ook gebruikt voor de verzameling van 
deelnemers voor de steekproefpopulatie van de ‘controls’ in de Nederlandse 
en Belgische case-controlstudies. Door middel van UPLC-MS/MS en GC-MS 
analyse werden bloed- en speekselmonsters geanalyseerd op 23 stoffen 
waaronder ethanol (alcohol).  
De resultaten tonen dat er grote verschillen bestaan tussen de geobserveerde 
prevalentie van psychoactieve stoffen in Nederland en België. De prevalentie 
van enkelvoudig alcoholgebruik (6,4%) en het enkelvoudige gebruik van 
geneesmiddelen (3,0%) was veel hoger in België dan in Nederland 
(respectievelijk 2,2% en 0,6%), terwijl het enkelvoudig gebruik van drugs 
meer in het Nederlandse verkeer (2,2%) is aangetroffen dan in het Belgische 
(0,6%). Deze verschillen worden waarschijnlijk veroorzaakt door het hogere 
handhavingsniveau op het gebied van alcohol in Nederland en non-response 
bias in de Belgische studie (met name voor drugs). Verder kunnen ook 
culturele verschillen en verschillen in het beleid om medicijnen voor te 
schrijven een rol spelen. 
 
In Hoofdstuk 4 worden de resultaten van de Nederlandse en Belgische 
ziekenhuisstudies met elkaar vergeleken. Deze ziekenhuisstudies voorzagen 
de Nederlandse en Belgische case-controlstudies van de ‘cases’. De resultaten 
toonden dat in Nederland bijna 35% van de ernstig gewonde automobilisten 
positief was voor een of meerdere psychoactieve stoffen. Alcohol kwam het 
vaakst voor. Ongeveer 28% van de gewonde automobilisten in Nederland 
was positief voor alcohol boven de wettelijke limiet van 0.5 g/L. Drugs en 
geneesmiddelen zijn bij ongeveer 10% van de ernstig gewonde automobi-
listen aangetroffen. Hiervan was 3% enkelvoudig, 3% in combinatie met 
andere drugs of geneesmiddelen, en 4% in combinatie met alcohol.  
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In België was het aandeel psychoactieve stoffen onder gewonde automobi-
listen hoger dan in Nederland: ongeveer 47% van de ernstig gewonde 
bestuurders was positief voor één of meerdere stoffen. Hiervan was 38% 
positief voor alcohol boven de wettelijke limiet van 0,5 g/L, ongeveer 6,5% 
positief voor enkelvoudig drugsgebruik, 2,5% voor de combinatie met 
andere drugs of geneesmiddelen, en 13% was positief voor de combinatie 
alcohol en drugs/geneesmiddelen. Mogelijke verklaringen voor deze 
verschillen tussen Nederland en België zijn de verschillen in handhavings-
niveaus tussen de landen, verschillen in de leeftijdsopbouw van de steek-
proeven en verschillen in de consumptiepatronen. Daarnaast speelt vanwege 
de kleine steekproef ook de onzekerheid van de resultaten in de Nederlandse 
ziekenhuisstudie een mogelijke rol.  
De resultaten van de studies naar het gebruik van psychoactieve stoffen in 
het verkeer en onder gewonde automobilisten kunnen gebruikt worden om 
het relatieve risico van rijden onder invloed te bepalen. Door de ratio van 
gewonde automobilisten die positief zijn voor drugs te vergelijken met het 
percentage automobilisten in de verkeerspopulatie dat positief test voor 
drugs, kunnen odds ratio’s berekend worden. In vijf van de zes DRUID-case-
controlstudies zijn speekselmonsters verzameld van willekeurig geselec-
teerde bestuurders in het verkeer. In Nederland is speeksel verzameld door 
middel van spuugpotjes, terwijl in de overige vier landen speeksel is 
verzameld met behulp van een commerciële speekselafnameset die geen 
gebruik maakte van zuur voor het stimuleren van de aanmaak van speeksel 
(Statsure Saliva samplerTM). 
 
Hoofdstuk 5 bediscussieert de invloed van beide speekselafnamemethoden 
op de concentraties van THC in speeksel. De afnameset van Statsure vertoon-
de meer overeenkomsten tussen twee direct achter elkaar afgenomen 
speekselmonsters dan de monsters die door middel van spuugpotjes 
verzameld waren. Daarnaast waren de THC concentraties in monsters die 
afgenomen waren met de spuugpotjes gemiddeld een factor 5,9 hoger dan 
corresponderende monsterafnames met behulp van de Statsure. Om te 
corrigeren voor het gebruik van speekselmonsters in plaats van bloed-
monsters in de metingen langs de kant van de weg, zijn equivalente 
ondergrenzen in de DRUID-case-controlstudies gebruikt. Deze equivalente 
ondergrenzen zijn gebaseerd op de concentraties van de Statsure-afnamesets. 
De resultaten van deze studie wijzen er dus op dat verschillen in de 
afnamemethode mogelijk geleid hebben tot een afwijking in de resultaten 
van de Nederlandse case-controlstudie.  
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Hoofdstuk 6 bespreekt het mogelijke effect van willekeurige en systema-
tische fouten op de berekende odds ratio’s van de zes DRUID-case-
controlstudies die een schatting geven van het risico op ernstig letsel als 
gevolg van rijden onder invloed van psychoactieve stoffen. Ondanks het 
gebruik van richtlijnen voor uniforme studieopzetten, variëren de berekende 
odds ratio’s enorm. De resultaten van Hoofdstuk 6 wijzen erop dat deze 
verschillen inderdaad mogelijk (gedeeltelijk) verklaard kunnen worden door 
willekeurige en systematische fouten. Afwijkingen door selectie en 
willekeurige fouten door kleine steekproeven en lage celaantallen waren de 
meest geobserveerde fouten in de zes DRUID-case-controlstudies. 
 
Hoofdstuk 7 bespreekt hoe men de beste schatting kan geven van het risico 
op ernstig letsel als gevolg van rijden onder invloed van psychoactieve 
stoffen. Er zijn twee criteria geformuleerd: ten eerste zijn studies nodig met 
een vergelijkbaar studieopzet omdat de variatie in resultaten veroorzaakt 
kan worden door verschillen in de opzet van studies. Ten tweede dienen 
studies die aan het eerste criterium voldoen vrij te zijn van willekeurige en 
systematische fouten. De zes DRUID-case-controlstudies die een schatting 
geven van het risico op ernstig letsel als gevolg van rijden onder invloed van 
psychoactieve stoffen voldoen aan het eerste criterium. De resultaten van dit 
proefschrift tonen echter aan dat alle zes case-controlstudies te lijden hebben 
gehad onder willekeurige en systematische fouten.  
De richtlijnen voor de DRUID-case-controlstudies waren gebaseerd op 
richtlijnen voor epidemiologisch onderzoek die opgesteld zijn door een 
special ICADTS-comité. Deze richtlijnen zouden vergelijkbare onderzoeks-
opzetten moeten garanderen in toekomstig onderzoek naar rijden onder 
invloed. De richtlijnen lijken echter nog niet in staat om willekeurige en 
systematische fouten te voorkomen. Mogelijke redenen hiervoor zijn het 
detailniveau dat nog te veel ruimte voor interpretatie overlaat en de mate 
waarin onderzoekers zich aan deze richtlijnen houden. Het uitvoeren van 
voorstudies met daarin een analyse naar mogelijke indicatoren voor 
willekeurige en systematische fouten, zou de kwaliteit van toekomstige case-
controlstudies mogelijk kunnen verbeteren en daardoor een betere schatting 
kunnen leveren van het risico op letsel als gevolg van rijden onder invloed 
van psychoactieve stoffen.  
 
Al met al kan de beste schatting van het risico op ernstig letsel als gevolg van 
rijden onder invloed van psychoactieve stoffen nog niet gegeven worden. 
Dankzij het DRUID-project en de richtlijnen van ICADTS zijn er studies met 
vergelijkbare onderzoeksopzetten beschikbaar. Deze studies kunnen 
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gebruikt worden om een goede schatting te geven van het risico van rijden 
onder invloed. Deze studies hebben echter te maken met willekeurige en 
systematische fouten, waardoor er een grote variatie bestaat tussen de odds 
ratio’s. Op basis van de analyse van indicatoren van mogelijke afwijkingen, 
kunnen we op dit moment, het totaal van de resultaten van de DRUID-case-
controlstudies beschouwen als de best mogelijke schatting van het relatieve 
risico op ernstig letsel, met uitzondering van de odds ratio voor medicinale 
opioïden, die een beetje een overschatting lijkt te geven. De toekomst moet 
echter uitwijzen of deze best mogelijke schatting uiteindelijk ook 
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